quinazolines has been researched along with lapatinib in 1397 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 289 (20.69) | 29.6817 |
| 2010's | 1071 (76.66) | 24.3611 |
| 2020's | 37 (2.65) | 2.80 |
| Authors | Studies |
|---|---|
| Alligood, KJ; Keith, BR; Liu, LH; Ma, H; Mullin, RJ; Owens, G; Rusnak, DW; Spector, NL; Xia, W | 1 |
| Bonomi, P | 1 |
| Hochberg, FH; Kirsch, DG | 1 |
| Ho, P; Liu, LH; Spector, NL; Xia, W | 1 |
| Earp, HS; Kim, YS; McCall, W; Peletier, A; Sartor, CI; Zhou, H | 1 |
| Burris, HA | 1 |
| Alligood, KJ; Dickerson, SH; Ellis, B; Gilmer, TM; Hassell, A; Horne, E; Lackey, K; McDonald, OB; Pennisi, C; Rusnak, DW; Shewchuk, L; Truesdale, AT; Wood, ER; Yuan, D | 1 |
| Adams, VR; Anderson, EB; Bence, AK; Bowen, CJ; Davis, GA; DeSimone, PA; Doukas, MA; Halepota, MA; Hsieh, S; Koch, KM; Mangum, S; Smith, DA; Spector, NL; Stead, AG | 1 |
| Blackwell, K; Chen, S; Chu, I; Slingerland, J | 1 |
| Bacus, S; Blackwell, KL; Bremer, TM; Burris, H; Dees, EC; Dowlati, A; Ellis, MJ; Harris, J; Hurwitz, H; Koch, KM; Liu, L; Man, AK; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A; Xia, W | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE | 1 |
| Blackwell, KL; Burris, HA; Dees, EC; Dowlati, A; Ellis, MJ; Harris, JL; Hurwitz, HI; Jones, SF; Koch, KM; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A | 1 |
| Civiello, G; Janne, PA; Johnson, BE; Mukohara, T | 1 |
| Rabindran, SK | 1 |
| Baudson, NM; Gerard, CM; Liu, L; Ory, TL; Spector, NL; Xia, W | 1 |
| Waltz, E | 1 |
| Bai, F; Fouladi, M; Fraga, CH; Freeman, BB; Stewart, CF | 1 |
| Brattain, MG; Conway, AN; Hauser, J; Hu, YP; Humphrey, L; Li, S; Vinci, MA; Wang, J; Willson, JK; Zborowska, E; Zhou, Y | 1 |
| Dolder, CR; Nelson, MH | 1 |
| Berger, M; Finn, R; Gilmer, TM; Keith, BR; Konecny, GE; Mullin, RJ; Pegram, MD; Podratz, KC; Rahmeh, M; Rusnak, DW; Slamon, DJ; Spehar, G; Untch, M; Venkatesan, N; Yang, G | 1 |
| Bacus, S; Bisi, J; Carrick, K; Dush, M; Graham, KM; Hardwicke, MA; Liao, Q; Liu, L; Spector, NL; Strum, J; Treece, AL; Westlund, RE; Xia, W; Zhao, S | 1 |
| Brose, MS; Flaherty, KT | 1 |
| Bacus, S; Harris, J; Hegde, P; Hill, J; Husain, I; Liu, L; Lyass, L; Paulazzo, G; Spector, NL; Strum, J; Trusk, P; Xia, W | 1 |
| Lackey, KE | 1 |
| Laurie, SA; Licitra, L | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Carter, M; Cockerill, GS; Dickerson, S; Gauthier, CA; Guo, Y; Lackey, KE; Mook, RA; Petrov, KG; Rusnak, DW; Walker, AL; Wood, ER; Zhang, YM | 1 |
| Hampton, T | 1 |
| Johnston, SR; Leary, A | 1 |
| McNeil, C | 1 |
| Budman, DR; Calabro, A; Diasio, R; Soong, R; Tai, J | 1 |
| Bankhead, C | 1 |
| Ebi, H; Kawada, K; Kojima, Y; Minami, H; Mukai, H; Murakami, K; Sato, T; Shimokata, K; Tahara, M | 1 |
| Boggess, KA; Dees, EC; Dorflinger, LJ; Graham, M; Harris, J; Humes, E; Kelly, H; O'Neil, BH; Spector, NL | 1 |
| Albanell, J | 1 |
| Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S | 1 |
| Muss, HB | 1 |
| Berger, M; Lipton, A; Planas-Silva, MD; Viallet, J; Witkoski, A; Witters, LM | 1 |
| Aglietta, M; Montemurro, F; Valabrega, G | 2 |
| Bacus, S; Husain, I; Liu, L; Pry, K; Saini, S; Spector, NL; Spohn, J; Stein, SH; Westlund, R; Xia, W | 1 |
| Du, Y; Esteva, FJ; Nahta, R; Yuan, LX | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Tuma, RS | 1 |
| Marais, R; Niculescu-Duvaz, D; Springer, C; Whittaker, S | 1 |
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Goss, PE; Moy, B | 2 |
| Bartsch, R; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Arteaga, CL; Hinow, P; Wang, SE; Webb, GF | 1 |
| Sonpavde, G | 1 |
| Healy, B | 1 |
| Burstein, HJ; Lin, NU; Mayer, EL | 1 |
| Anido, J; Arribas, J; Baselga, J; Cortes, J; Di Cosimo, S; Guzman, M; Matias-Guiu, X; Ocaña, A; Ramon y Cajal, S; Rojo, F; Scaltriti, M | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Hatake, K; Ito, Y; Sugihara, T; Takahashi, S; Tokudome, N | 1 |
| Alligood, K; Bertiaux, M; Gagnon, R; Gilmer, TM; Hegde, PS; Rusnak, D; Strum, J | 1 |
| Awada, A; Cardoso, F; de Azambuja, E; Dinh, P; Gil, T; Piccart-Gebhart, M; Widakowich, C | 1 |
| Engel, RH; Kaklamani, VG | 1 |
| Burtness, B | 1 |
| Bilancia, D; Dinota, A; Germano, D; Manzione, L; Romano, R; Rosati, G | 1 |
| Goss, P; Kar, S; Kirkpatrick, P; Moy, B | 1 |
| Alligood, KJ; Arenas-Elliott, C; Degenhardt, Y; Gilmer, TM; Haws, TF; Hudson-Curtis, BL; Martin, AM; Mullin, RJ; Rudolph, SK; Rusnak, DW; Spehar, GM | 1 |
| Cohen, EE; Ratain, MJ | 1 |
| Amar, S; Moreno-Aspitia, A; Perez, EA | 1 |
| Boyce, SH; Gay, RE; Gay, S; Huber, LC; Ink, BS; Künzler, P; Michel, BA | 1 |
| Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL | 1 |
| Cameron, D | 1 |
| Hatake, K | 1 |
| Arya, N; Chu, QS; Curtright, J; de Bono, J; Fleming, RA; Ho, PT; Koch, KM; Pandite, L; Rowinsky, EK; Schwartz, G; Smith, DA; Versola, MJ | 1 |
| Chan, S; Dhadda, AS; Mukherjee, A; Shehata, M | 1 |
| Agulnik, M; Brown, S; Chen, EX; Cohen, EW; Cohen, RB; Dancey, JE; Daneshmand, M; Hayes, DN; Ho, J; Hotte, SJ; Laurie, S; Lorimer, I; Pond, GR; Siu, LL; Tsao, MS; Vokes, EE; Winquist, E | 1 |
| Boughey, JC; Brandt, KR; Degnim, AC; Dy, GK; Goetz, MP; Ingle, JN; Perez, EA; Pruthi, S; Reynolds, CA; Schomberg, PJ | 1 |
| Becze, E | 1 |
| Boyle, SN; Koleske, AJ | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Andersson, M; Nielsen, DL | 1 |
| Dhillon, S; Wagstaff, AJ | 1 |
| Abraham, J; Higa, GM | 1 |
| Pal, SK; Pegram, M | 1 |
| Berveiller, P; Goffinet, F; Goldwasser, F; Mir, O; Pons, G; Ropert, S; Treluyer, JM | 1 |
| Eniu, A | 1 |
| Peckham, C | 1 |
| Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F | 1 |
| Lewis, LD | 1 |
| Beelen, AP; Ho, PT; Koch, KM; Roychowdhury, DF | 1 |
| Messori, A | 1 |
| Huang, SM; Lesko, L; Pazdur, R; Rahman, A; Wang, Y | 1 |
| Trippoli, S | 1 |
| Dowlati, A; Halmos, B; Kern, JA; Kluge, A; Nethery, D | 1 |
| Geyer, CE; Harkins, B | 1 |
| Frankel, C | 1 |
| Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E | 1 |
| Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P | 1 |
| Alligood, K; Cable, L; Carter, HL; Gallagher, KT; Gilmer, TM; Rusnak, D; Shewchuk, L; Spehar, G; Truesdale, AT; Woldu, E; Wood, ER | 1 |
| Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
| Castellino, S; Harmon, KA; Humphreys, JE; John-Williams, LS; Koch, KM; O'Mara, MJ; Olson, KL; Polli, JW; Serabjit-Singh, CJ | 1 |
| Doyle, DM; Miller, KD | 1 |
| Blackwell, KL; Burstein, HJ; Forster, J; Franco, S; Rubin, S; Salazar, VM; Stein, S; Storniolo, AM | 1 |
| Brunet, J; Colomer, R; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| Giordano, S; Petrelli, A | 1 |
| Heinemann, V; Rack, B; Salat, C; Schindlbeck, C; Sommer, H; Walther, J | 1 |
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Banjade, S; Bornmann, WG; Bose, R; Choi, SH; Cole, PA; Leahy, DJ; Lemmon, MA; Pal, A; Qiu, C; Sathyamurthy, A; Tarrant, MK | 1 |
| Dering, J; Fejzo, MS; Finn, R; Ginther, C; Jiang, SW; Konecny, GE; Podratz, KC; Rahmeh, M; Slamon, DJ; Toft, D; Venkatesan, N; Yang, G | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, SH; Kim, TY; Oh, DY | 1 |
| Sledge, GW | 1 |
| Blumenfeld, M; Farrar, W; Landon, MB; Pant, S; Shapiro, CL | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Geyer, CE; Greenberg, L; Ulhoa-Cintra, A | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
| Cardoso, F; de Azambuja, E; Dolci, S; Meirsman, L; Piccart-Gebhart, M; Straehle, C; Vantongelen, K | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Mukesh, M; Murray, P | 1 |
| Kopper, L | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Cheng, J; Gilmer, T; Greshock, J; Lee, K; Martin, AM; Rusnak, D; Weber, BL; Wooster, R; Zaks, T | 1 |
| Boukouvala, S; Calkins, K; Cutler, RE; Fong, R; Funke, R; Gendreau, SB; Gerritsen, ME; Heuer, TS; Kim, YD; Lamb, P; Matthews, DJ; Miller, N; Trowe, T; Vysotskaia, V; Woolfrey, JR; Yang, JP | 1 |
| Bullitt, E; Burstein, HJ; Carey, LA; Come, SE; Crawford, A; Ewend, M; Gelman, R; Harris, GJ; Henson, JW; Hochberg, F; Kasparian, E; Kirsch, DG; Li, X; Lin, NU; Liu, MC; Van den Abbeele, AD; Winer, EP; Younger, J | 1 |
| Chamness, GC; Chang, JC; Gutierrez, C; Hilsenbeck, SG; Huang, J; Lewis, MT; Li, X; Osborne, CK; Pavlick, A; Rosen, J; Wong, H; Wu, MF; Zhang, X | 1 |
| Ang, PC; Arbushites, MC; Aziz, Z; Berger, MS; Casey, MA; Chavez, MA; Chow, LW; Doval, DC; Franco, SX; Gomez, HL; Nag, S; Ng, C; Sledge, GW; Stein, SH | 1 |
| Seruga, B; Tannock, IF | 1 |
| Krop, IE; Winer, EP | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Audhuy, B; El-Hariry, I; Gardner, JP; Gore, M; Harper, P; Hawkins, R; Machiels, JP; Pétavy, F; Ravaud, A; Rolland, F; Schöffski, P; von der Maase, H; Zantl, N | 1 |
| Nanda, R | 1 |
| Schmidt, C | 1 |
| Ito, Y; Miura, H | 1 |
| Hirte, HW; Hotte, SJ | 1 |
| Arya, N; Burris, HA; Fleming, RA; Ho, PT; Jones, SF; Koch, KM; Lebowitz, PF; Loftiss, J; Overmoyer, B; Pandite, L; Paul, E; Peacock, NW; Pegram, MD; Silverman, P; Storniolo, AM | 1 |
| Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F | 1 |
| Heinemann, V; Stemmler, HJ | 1 |
| Byrne, J; Ewer, MS; Koehler, M; Perez, EA; Preston, AJ; Rappold, E | 1 |
| Nahleh, ZA | 1 |
| Dent, P; Emad, L; Fisher, PB; Grant, S; Hagan, MP; Martin, AP; Miller, A; Mitchell, C; Park, MA; Rahmani, M; Walker, T; Yacoub, A | 1 |
| Arya, N; Burris, HA; Fleming, RA; Gadgeel, S; Jones, SF; Koch, KM; Loftiss, J; LoRusso, PM; Pandite, L; Weber, BL | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| Avizienyte, E; Garner, AP; Ward, RA | 1 |
| Elstner, E; Emde, A; Eucker, J; Kühnl, A; Liu, H; Planas-Silva, MD; Possinger, K; Rosche, M; Schulz, CO; Zang, C | 1 |
| Cameron, DA; Stein, S | 1 |
| Benusiglio, PR | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Conte, P; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F | 1 |
| Huober, J; Spirig, C; Thürlimann, B | 1 |
| Ena, L; Ena, P; Fadda, GM; Farris, A; Santeufemia, DA | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Bartholomeusz, C; Bornmann, WG; Esteva, FJ; Hortobagyi, GN; Pal, A; Ueno, NT; Yamasaki, F; Zhang, D | 1 |
| Benowitz, S | 1 |
| Bronder, JL; Feigenbaum, L; Gril, B; Herring, JM; Liewehr, DJ; Merino, MJ; Palmieri, D; Rubin, SD; Steeg, PS; Steinberg, SM; Vega-Valle, E | 1 |
| Paoletti, P | 1 |
| Agulnik, M; Wang, LX | 1 |
| Alvarez, RD; Barnes, MN; Estes, JM; Kimball, KJ; Kirby, TO; Koch, KM; Matei, DE; Numnum, TM; Zamboni, WC | 1 |
| Azim, H; Azim, HA | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Antonacopoulou, A; Floratou, K; Giannopoulou, E; Kalofonos, HP; Papavassiliou, AG | 1 |
| Paul, B; Thompson, J; Trovato, JA | 1 |
| Bang, YJ; Hur, HS; Im, SA; Kang, S; Kim, HP; Kim, JH; Kim, JW; Kim, TY; Lee, DS; Oh, DY; Yoon, YK | 1 |
| Spector, N | 1 |
| Perez, EA | 1 |
| Toi, M | 1 |
| Goodin, S; Medina, PJ | 1 |
| Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H | 1 |
| Halterman, PA | 1 |
| Ambudkar, SV; Ashby, CR; Chen, LM; Chen, ZS; Dai, CL; Fu, LW; Huang, Y; Liang, YJ; Liu, DG; Robey, RW; Shi, CJ; Su, XD; Tiwari, AK; Wang, SR; Wu, CP | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Belkacémi, Y; Kuten, A | 1 |
| Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R | 1 |
| Glantz, M; Melisko, ME; Rugo, HS | 1 |
| Camara, O; Egbe, A; Hammer, U; Hoeffken, K; Jörke, C; Pachmann, K; Rabenstein, C; Runnebaum, IB | 1 |
| Benz, CC; Neve, RM; Park, JW; Szollosi, J | 1 |
| Aglietta, M; Botti, G; Bottini, A; Clavarezza, M; Danese, S; dei Tos, AP; del Curto, B; Di Bonito, M; Di Palma, S; Donadio, M; Durando, A; Jacomuzzi, ME; Kulka, J; Montemurro, F; Redana, S; Sanna, G; Sapino, A; Valabrega, G; Viale, G | 1 |
| Ma, CD; Shen, KW; Shen, ZZ | 1 |
| Arbushites, MC; Aziz, Z; Bines, J; Dering, J; Di Leo, A; Finn, RS; Gomez, HL; Guerrera, SF; Koehler, M; Oliva, C; Press, MF; Stein, SH; Williams, LS; Zvirbule, Z | 1 |
| Chen, FL; Spector, NL; Xia, W | 1 |
| Baselga, J; Beijersbergen, RL; Bernards, R; Eichhorn, PJ; Gili, M; Guzman, M; Nijkamp, W; Scaltriti, M; Seoane, J; Serra, V; Valero, V | 1 |
| Le, QT; Raben, D | 1 |
| de Azambuja, E; Dinh, P; Piccart-Gebhart, M; Snoj, N; Tomasello, G | 1 |
| Arbushites, M; Cameron, D; Danenberg, K; Di Leo, A; Finn, RS; Gagnon, R; Gasparyan, A; Geyer, CE; Guzman, R; Koehler, MT; Ma, Y; Martin, AM; Oliva, C; Press, MF; Santiago, A; Stein, S; Villalobos, IE; Williams, L | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Anania, FA; Knight, BB; Merlin, D; O'Regan, RM; Saxena, NK; Sharma, D; Taliaferro-Smith, L | 1 |
| Fukuoka, M; Kanezaki, M; Kawada, K; Kurata, T; Minami, H; Minamide, Y; Mukai, H; Mukaiyama, A; Nakagawa, K; Nogami, T; Sasaki, Y; Uejima, H | 1 |
| Castellino, S; Chism, JP; Demby, VE; John-Williams, LS; Olson, KL; Otto, V; Polli, JW; Woodard, SM; Yeager, RL | 1 |
| Arribas, J; Baselga, J; Guzman, M; Jimenez, J; Landolfi, S; Parra, JL; Pedersen, K; Ramon y Cajal, S; Scaltriti, M; Smith, DJ; Verma, C | 1 |
| Ciccarese, M; Lorusso, V | 1 |
| Belyayeva, Y; Gkouvi, A; Gregoriou, S; Katsambas, A; Larios, G; Rigopoulos, D | 1 |
| Carrasco-Pancorbo, A; Fernandez-Gutierrez, A; Garcia-Villalba, R; Menendez, JA; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A | 1 |
| Azambuja, E; Cardoso, F; Dolci, S; Ignatiadis, M; Meirsman, L; Piccart-Gebhart, MJ; Sotiriou, C; Straehle, C; Vantongelen, K | 1 |
| Caferro, TR; Dickerson, SH; Donaldson, KH; Gaul, MD; Goetz, AS; McDonald, OB; Mullin, RJ; Petrov, KG; Rheault, TR; Rusnak, DW; Shewchuk, LM; Spehar, GM; Truesdale, AT; Uehling, DE; Vanderwall, DE; Wood, ER | 1 |
| Fricker, J | 1 |
| Hay, JW; Le, QA | 1 |
| Brown, PH; Gilmer, TM; Hill, JL; Hilsenbeck, SG; Kim, HT; Li, Y; Osborne, CK; Sexton, KR; Shen, Q; Strecker, TE; Wang, C; Zhang, Y | 1 |
| Amonkar, MM; Cameron, D; Cella, D; Geyer, CE; Segreti, A; Stein, S; Walker, M; Zhou, X | 1 |
| Belani, CP; Dancey, J; Gandara, DR; Gandour-Edwards, R; Iqbal, S; Kindler, HL; Lenz, HJ; Longmate, J; Lurje, G; Mack, PC; Ramanathan, RK; Singh, DA; Tanaka, M; Yen, Y | 1 |
| Bourhis, J; D'Ambrosio, C; Deutsch, E; El-Hariry, IA; Harrington, KJ; Holford, CS; Lusinchi, A; Matthews, J; Nutting, CM; Pandeshwara, JS; Rosine, D; Tanay, M; Turner, SJ | 1 |
| Chen, G; Liu, BR; Xie, L | 1 |
| Arbushites, MC; Blackwell, KL; Burstein, HJ; Forster, JK; Maltzman, JD; Pegram, MD; Rubin, SD; Schwartzberg, LS; Stein, SH; Tan-Chiu, E | 1 |
| Beelen, AP; Cohen, RB; Koch, KM; Lewis, LD; Lewis, NL; Mackay, K; Reddy, NJ; Stead, A; Whitehead, B | 1 |
| Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D | 1 |
| Ali-Osman, F; Bigner, D; Buolamwini, J; Friedman, H; Haystead, T; Okamura, T; Singh, S | 1 |
| Amir, E; Freedman, O; Seruga, B; Tannock, I | 1 |
| Galsky, MD; Hassani, H; Hutson, TE; Sonpavde, G; Vocila, L; Von Hoff, DD; Zaks, T | 1 |
| Albano, L; Campaner, S; Castiglioni, F; Delia, D; Fontanella, E; Gasparini, P; Magnifico, A; Menard, S; Sozzi, G; Tagliabue, E | 1 |
| Casalini, P; Croce, CM; Di Leva, G; Iorio, MV; Ménard, S; Merlo, A; Piovan, C; Tagliabue, E; Triulzi, T | 1 |
| Griffiths, TR; Kriajevska, M; Manson, MM; McHugh, LA; Mejlvang, J; Mellon, JK; Sayan, AE; Sun, Y; Tulchinsky, E | 1 |
| Agulnik, M; Chen, EX; Cohen, EE; Cohen, RB; Dancey, J; Hayes, DN; Ho, J; Hotte, S; Laurie, S; Pond, GR; Siu, LL; Tsao, MS; Vidal, L; Winquist, E | 1 |
| Pikó, B | 2 |
| Rowan, K | 1 |
| Ross, JS | 2 |
| Hortobagyi, GN; Pusztai, L; Ravdin, PM; Ross, JS; Slodkowska, EA; Symmans, WF | 1 |
| McArthur, H | 1 |
| Arya, N; Beelen, A; Bowen, CJ; Herendeen, JM; Koch, KM; Smith, DA | 1 |
| Cohen, EE; Cooper, JB | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Awada, A; Bachelot, T; Blackwell, K; DeSilvio, M; Johnston, S; Kaufman, B; Salazar, V; Spector, N; Trudeau, M; Westlund, R; Zaks, T | 1 |
| Beuzeboc, P; De Groot, MR; El-Hariry, IA; Grimm, MO; Machiels, JP; Parikh, R; Pétavy, F; Richel, DJ; Treiber, U; Wülfing, C | 1 |
| Elzawawy, A | 1 |
| Bedard, PL; de Azambuja, E; Piccart-Gebhart, M; Suter, T | 1 |
| Holmes, D | 1 |
| Abbara, C; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Gonin, P; Noël-Hudson, MS; Thomas-Bourgneuf, L | 1 |
| Guo, Z; Zhao, H | 1 |
| Abad, M; Esparís-Ogando, A; Montero, JC; Ocaña, A; Ortiz-Ruiz, MJ; Pandiella, A | 1 |
| Arteaga, CL; Boimel, PJ; Coniglio, SJ; Hynes, NE; Kedrin, D; Segall, JE; Wyckoff, J | 1 |
| Cameron, DA; Hall, PS; Hanby, A | 1 |
| Castañeda, CA; Gomez, HL | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Belanger, K; Easaw, J; Eisenhauer, E; Forsyth, P; Kamel-Reid, S; Mason, W; McIntosh, L; Schaiquevich, P; Stewart, C; Thiessen, B; Tsao, M | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Belvin, M; Eastham-Anderson, J; Friedman, LS; Gunter, B; Haverty, PM; Hoeflich, KP; Lee-Hoeflich, ST; Lewin-Koh, N; Murray, LJ; Sliwkowski, MX; Truong, T; Yao, E; Zhou, W | 1 |
| Coombes, RC; Filipovic, A; Francis, RE; Gojis, O; Guest, SK; Hartman, J; Krol, J; Lam, EW; McGovern, UB; Myatt, SS; Palmieri, C; Peck, B; Peston, D; Shousha, S; Sicinski, P; Wang, J; Yu, Q | 1 |
| Boronina, T; Cole, PA; Cole, RN; Kavran, JM; Leahy, DJ; Longo, PA; Qiu, C; Tarrant, MK | 1 |
| Obajimi, O | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, JW; Kim, TY; Lee, JH; Oh, DY; Park, J; Yoon, YK | 1 |
| Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM | 1 |
| Carol, H; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Phelps, D; Reynolds, CP; Schaiquevich, P; Smith, MA; Stewart, C; Wu, J | 1 |
| del Barco, S; Martín-Castillo, B; Menéndez, JA; Oliveras-Ferraros, C; Vázquez-Martín, A | 1 |
| Tannock, IF | 1 |
| Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R | 1 |
| Jo Chien, A; Rugo, HS | 1 |
| Oestreicher, N | 1 |
| Carpenter, G; Liao, HJ | 1 |
| Argyriou, AA; Dimitrakopoulos, F; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Koutras, AK | 1 |
| Arbushites, M; Dering, J; Di Leo, A; Finn, RS; Koehler, M; Oliva, C; Press, MF; Williams, LS | 1 |
| Cathomas, R; von Moos, R | 1 |
| Azim, H; Azim, HA; Escudier, B | 1 |
| Azim, HA | 2 |
| Bravo Marques, JM | 1 |
| Chang, Y; Chesebrough, J; Coats, S; Coffman, KT; Fazenbaker, CA; Gooya, J; Jackson, D; Jallal, B; Leow, CC; Weng, D | 1 |
| Annan, R; Gilmer, TM; Greger, J; Greshock, J; Halsey, W; Liu, L; Liu, Y; Martin, AM; Sathe, GM; Shi, H | 1 |
| Bissell, MJ; Gray, JW; Lo, AT; Park, CC; Weigelt, B | 1 |
| Chen, LM; Chien, AJ; Dubey, S; Fong, L; Huang, Y; Hylton, NM; Illi, JA; Jahan, TM; Kashani-Sabet, M; Ko, AH; Koch, KM; Korn, WM; Moasser, MM; Rosenberg, JE; Ryan, CJ; Small, EJ; Yeh, BM | 1 |
| Agrawal, NS; Cronin, JC; Cruz, P; Lin, JC; Prickett, TD; Rosenberg, SA; Samuels, Y; Wei, X; Wunderlich, JR; Yates, KE | 1 |
| Chen, X; Chen, ZS; Fu, LW; Hopper-Borge, E; Kuang, YH; Lee, JW; Shen, T; Sodani, K; Tiwari, AK | 1 |
| Amir, E; Ocaña, A | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Balint, C; Bekaii-Saab, T; Campbell, A; Chen, H; Culler, K; Dai, Z; Dancey, J; Eng, C; Grever, M; Heerema, N; Lee, RM; Markowitz, J; O'Neil, B; Papp, A; Prescott, N; Sadee, W; Villalona-Calero, M; Wei, L; Zalupski, M | 1 |
| Collins, D; Hill, AD; Young, L | 1 |
| Commo, F; Dessen, P; Kroemer, G; Lacroix, L; Lazar, V; Olaussen, KA; Raza, SQ; Richon, C; Soria, JC; Tailler, M; Vitale, I | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Hede, K | 1 |
| Baselga, J; Cortes, J | 1 |
| Dieras, V; Florance, A; Gomez, HL; Johnston, S; Kennedy, MJ; Lichinitser, M; Maltzman, J; Manikhas, A; O'Rourke, L; Oliva, C; Pegram, M; Pippen, J; Pivot, X; Press, MF; Romieu, G; Sadeghi, S; Stein, S | 1 |
| Beard, C; Kasparian, E; Lin, NU; Morganstern, DE | 1 |
| Frampton, JE | 1 |
| Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D | 1 |
| Dent, P; Grant, S; Martin, AP; Mitchell, C; Nephew, KP; Rahmani, M | 1 |
| Arya, N; Burris, HA; Fleming, RA; Jones, SF; Koch, KM; Pandite, L; Smith, DA; Spector, N; Taylor, CW; Versola, MJ; Wilding, G | 1 |
| Allen, KE; Aogi, K; Arai, T; Ellis, CE; Fujiwara, Y; Gagnon, RC; Ito, Y; Iwata, H; Katsura, K; Nakamura, S; Rai, Y; Sasaki, Y; Taguchi, T; Takashima, S; Toi, M; Tokuda, Y; Wakamatsu, T; Watanabe, J | 1 |
| Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
| Camp, JT; Kimple, RJ; Sambade, MJ; Sartor, CI; Shields, JM | 1 |
| Clynes, M; McMahon, G; O'Connor, R; Roche, S | 1 |
| Amalfitano, A; Barry, WT; Chen, W; Clay, TM; Devi, GR; Hartman, Z; Hobeika, AC; Jiang, H; Lei, G; Lyerly, HK; Morse, MA; Osada, T; Peplinski, S; Ren, XR; Spector, N; Wei, J; Xia, W | 1 |
| Arbushites, M; Di Leo, A; Finn, RS; Gagnon, R; Koehler, M; Press, MF | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A | 1 |
| Cheon, S; Cho, H; Espina, V; Havaleshko, DM; Lee, JK; Liotta, LA; Owens, CR; Petricoin, EF; Smith, SC; Theodorescu, D; Wulfkuhle, JD | 1 |
| Akita, H | 1 |
| Guarneri, V | 1 |
| Amaravadi, R | 1 |
| Wicha, MS | 1 |
| Schwartz, J | 1 |
| Amano, R; Hirakawa, K; Kawajiri, H; Komoto, M; Nakata, B; Nishii, T; Shinto, O; Yamada, N; Yashiro, M | 1 |
| Carter, CA; Giaccone, G; Kelly, RJ | 1 |
| D'Alessio, A; De Luca, A; Gallo, M; Lamura, L; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM | 1 |
| Bedard, PL; de Azambuja, E; Devriendt, D; Lossignol, D; Piccart-Gebhart, MJ; Tomasello, G | 1 |
| Akhavan, D; Bensinger, SJ; Cloughesy, TF; Dang, J; DeAngelis, LM; Guo, D; Hock, MB; Horvath, S; Huang, TT; Iwanami, A; Kofman, AA; Kuga, D; Kuhn, JG; Lin, KY; Mehta, MP; Mellinghoff, IK; Mischel, PS; Prados, MD; Prins, RM; Robins, HI; Soto, H; Vinters, HV; Watson, AD; Wen, PY; Yong, WH; Zhu, S | 1 |
| Esteva, FJ; Hortobagyi, GN; Hung, MC; Yu, D | 1 |
| Gutteridge, E; Robertson, JF | 1 |
| Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
| Chin, JL; Dancey, JE; Gregg, R; Hedley, D; Hotte, SJ; Hudes, GR; Moore, MJ; Pham, NA; Sridhar, SS; Trachtenberg, J; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Schneider-Merck, T; Trepel, M | 1 |
| Ansaldi, F; Bagnasco, L; Ballestrero, A; Cea, M; Cirmena, G; Garuti, A; Grillo, V; Icardi, G; Moran, E; Nencioni, A; Parodi, S; Patrone, F; Rocco, I; Soncini, D; Zoppoli, G | 1 |
| Amonkar, MM; Aziz, Z; Bines, J; Di Leo, A; Gomez, HL; Sherrill, B; Wu, Y; Zvirbule, Z | 1 |
| Amir, E; Clemons, M; Freedman, O; Ocaña, A; Seruga, B | 1 |
| Baerman, KM; Calvo, BF; Cox, AD; Kimple, RJ; Sartor, CI; Shields, JM; Tepper, JE; Vaseva, AV | 1 |
| Iwata, K; Yamashita, T | 1 |
| Kolesar, JM; Tevaarwerk, AJ | 1 |
| Baselga, J; Bischoff, J; Blackwell, KL; Burstein, HJ; Casey, M; Ellis, C; Koehler, M; O'Shaughnessy, J; Rugo, H; Sledge, G; Storniolo, AM; Vukelja, S | 1 |
| Bacus, S; Chen, FL; Husain, I; Koch, KM; Liu, L; Liu, Z; Moseley, MA; Spector, NL; Thompson, JW; Xia, W; Zhao, S | 1 |
| Ballestrero, A; Cea, M; Garuti, A; Moran, E; Nencioni, A; Passalacqua, M; Patrone, F; Pistoia, V; Raffaghello, L; Soncini, D; Zoppoli, G | 1 |
| Brandes, AA; Degli Esposti, R; Franceschi, E; Tosoni, A | 1 |
| Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L | 1 |
| Anderton, J; Barlaam, B; Beck, S; Callis, R; Davenport, S; Grosios, K; Hickinson, DM; Klinowska, T; Marshall, G; Mills, E; Ogilvie, D; Smith, P; Speake, G; Trigwell, C; Vincent, J; Wilkinson, RW | 1 |
| Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS | 1 |
| Ferraz, MB; Puga, ME; Riera, R; Soárez, PC | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Anghel, A; Ayala, R; Desai, AJ; Fejzo, MS; Finn, RS; Hecht, JR; Luo, T; Safran, B; Slamon, DJ; Wainberg, ZA | 1 |
| Detre, S; Dowsett, M; Drury, S; Johnston, SR; Leary, AF; Lykkesfeldt, AE; Martin, LA; Pancholi, S | 1 |
| Arteaga, CL; Mayer, IA | 1 |
| Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A | 1 |
| Jørgensen, JT | 1 |
| Barok, M; Hemmilä, P; Ilvesaro, J; Isola, J; Köninki, K; Pitkänen, J; Staff, S; Tanner, M | 1 |
| Flores, LM; Hemler, ME; Krop, IE; Li, Q; Xu, F; Yang, XH; Zhou, P | 1 |
| Abujamra, AL; Cornelio, DB; Roesler, R; Schwartsmann, G | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Toth, G; Tsukuda, M | 1 |
| Arranz, EE; Auñón, PZ; Barón, MG; Marín, AP; Sánchez, AR | 1 |
| Balsari, A; Campiglio, M; Pupa, SM; Tagliabue, E | 1 |
| Amonkar, MM; Bachelot, T; Johnston, S; Kaufman, B; Salazar, V; Sherrill, B; Viens, P; Wu, Y | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| Chow, LW; Ong, EY; Tse, LA; Yip, AY | 1 |
| Byrne, AT; Crown, J; Gallagher, WM; McGee, S; O'Connor, AE; O'Donovan, N | 1 |
| Cheng, Y; Hait, WN; Li, H; Niu, T; Ren, X; Yang, J | 1 |
| Vitry, AI | 1 |
| Altundag, K; Arslan, C; Dizdar, O | 2 |
| Frankel, C; Palmieri, FM | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Ahuja, D; Amin, DN; Blair, JA; Hann, B; Koch, KM; McMahon, M; Moasser, MM; Sergina, N; Shokat, KM; Wang, D | 1 |
| Mukai, H | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Ulivi, P; Zoli, W | 1 |
| Dickler, MN | 1 |
| Hyun, SA; Kim, EJ; Kim, KS; Lee, HA; Park, SG | 1 |
| Angelini, PD; Arribas, J; Aura, C; Baselga, J; Cameron, D; Chandarlapaty, S; Ellis, C; Gagnon, R; Geyer, C; Gomez, H; Guzman, M; Jimenez, J; Koehler, M; Parra, JL; Prudkin, L; Rosen, N; Sánchez, G; Scaltriti, M | 1 |
| Fukuoka, M; Kiniwa, M; Nakagawa, K; Okamoto, I; Takezawa, K; Tanizaki, J; Tsukioka, S; Uchida, J | 1 |
| Camp, JT; Kimple, RJ; Livasy, CA; Peters, E; Sambade, MJ; Sartor, CI; Shields, JM | 1 |
| Calvo, A; Catena, R; Collantes, M; Diaz, R; Díaz-González, JA; Manrique, I; Nguewa, PA; Parrondo, R; Peñuelas, I; Perez-Stable, C; Redrado, M | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, C; Hudis, C; Lin, N; Morris, P; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Fornier, M; Murphy, CG | 1 |
| Rastogi, P | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| Arboleda, J; Browne, BC; Chow, L; Crown, J; Duffy, MJ; Ginther, C; O'Brien, NA; O'Donovan, N; Slamon, DJ; Wang, Y | 1 |
| Cristofanilli, M | 1 |
| Allen, JC; Ammoun, S; Chiriboga, L; Cunliffe, CH; Giancotti, FG; Hanemann, CO; Karajannis, MA; Zagzag, D | 1 |
| Boussen, H; Cristofanilli, M; DeSilvio, M; Salazar, V; Spector, N; Zaks, T | 1 |
| Cunningham, D; Okines, AF | 1 |
| Chan, A; Gril, B; Kim, SB; Kurebayashi, J; Liu, L; Lu, YS; Moon, H; Vogel, C | 1 |
| Pownall, M | 1 |
| Abrahámová, J; Bacanu, F; Brincat, S; Brize, A; Cesas, A; Cufer, T; Dank, M; Duchnowska, R; Eniu, A; Jassem, J; Kahán, Z; Matos, E; Padrik, P; Plāte, S; Pokker, H; Purkalne, G; Steger, GG; Timcheva, C; Tzekova, V; Vyzula, R; Zielinski, CC | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Chan, AT; Cheng, SH; Ho, K; Lau, CP; Lei, KI; Lui, VW; Mok, TS; Ng, MH; Tsang, CM; Tsao, SW | 1 |
| Balbi, A; Ballestrero, A; Castagnino, N; Montagna, R; Moran, E; Nencioni, A; Parodi, S; Pesenti, R; Soncini, D; Tortolina, L | 1 |
| Bono, P; Joensuu, H | 1 |
| Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ | 1 |
| Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S | 1 |
| Almenara, JA; Campbell, DJ; Dewitt, JL; Oyesanya, RA; Sirica, AE; Zhang, Z | 1 |
| Curran, MP | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hilfrich, J; Kreienberg, R; Loibl, S; Nekljudova, V; Solbach, C; Strumberg, D; Untch, M; von Minckwitz, G | 1 |
| Chan, EC; Ho, HK; Nelson, SD; New, LS; Oh, JW; Teng, WC; Wahlin, MD | 1 |
| Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| Fujita, KA; Kubota, H; Kuroda, S; Ozaki, Y; Toyoshima, Y; Uda, S | 1 |
| André, F; Bachelot, T; Campone, M; Juin, P | 1 |
| Crown, J; Duffy, MJ; O'Donovan, N | 1 |
| Luo, J; Ma, C; Niu, X; Shao, Z; Shen, K | 1 |
| Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Gilbertson, RJ; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A | 1 |
| Junttila, TT; Li, G; Parsons, K; Phillips, GL; Sliwkowski, MX | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ | 1 |
| Kaklamani, V; Moreira, C | 1 |
| Cameron, D; Casey, M; Geyer, CE; Imwalle, B; Newstat, B; Oliva, C | 1 |
| Burandt, E; Sauter, G | 1 |
| Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B | 2 |
| Moulder, SL | 1 |
| Awada, A; Azim, HA; Metzger Filho, O; Saini, KS | 1 |
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
| Mukohara, T | 1 |
| Arai, H; Nishimura, Y; Yamaki, M | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
| Anderson, T; Fleming, M; Galsky, MD; Mahoney, JM; Midwinter, D; Nagarwala, Y; Neubauer, M; Vocila, L; Von Hoff, DD; Zaks, TZ | 1 |
| Baas, J; Bloemendal, HJ; Boven, E; de Graaf, H; Hop, WC; Kroep, JR; Linn, SC; Mandjes, IA; Nortier, JW; Schröder, CP; Smit, WM; van den Bosch, J; Vermeulen, GJ | 1 |
| Egerton, N | 1 |
| Ghazaly, E; Joel, S; Kitromilidou, C; McGrowder, EH; Perry, J; Powles, T | 1 |
| Bang, YJ; Cha, Y; Ham, HS; Han, SW; Im, SA; Im, YH; Kim, HP; Kim, TY; Lee, KS; Oh, DY; Park, IH; Park, JW; Rhee, J; Ro, J | 1 |
| Emde, A; Köstler, WJ; Yarden, Y | 1 |
| Uehara, Y | 1 |
| Brunner, C; Hubalek, M; Marth, C; Matthä, K | 1 |
| Keane, MP; Kelly, E; McDonnell, TJ; Mhurchu, EN; Sukor, S; Tryfonopoulos, D | 1 |
| Singer, CF | 1 |
| Baer, T; Beckers, T; Ciossek, T; Eichhorn, E; Mahboobi, S; Maier, T; Pongratz, H; Sellmer, A; Winkler, M | 1 |
| Baek, JM; Boulbes, D; Esteva, FJ; Gomez-Cabello, D; Hawke, DH; Hortobagyi, GN; Hung, MC; Jin, Q; Lee, MH; Wang, YN; Yeung, SC; Yuan, LX | 1 |
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Abbey, R; DeSilvio, M; Dobrovolskaya, N; Jagiello-Gruszfeld, A; Manikhas, A; Pienkowski, T; Ridderheim, M; Tjulandin, S | 1 |
| Bailey, TA; Band, H; Band, V; Clubb, RJ; Duan, L; Natarajan, A; Nyong, AM; Ortega-Cava, C; Raja, SM; Reddi, AL; Williams, SH; Zhao, X | 1 |
| Gelmon, KA; MacFarlane, RJ | 1 |
| Bannykh, S; Cooper, O; Fukuoka, H; Melmed, S; Mizutani, J; Ren, SG; Tong, Y | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Catalano, G; Ciardiello, F; De Vita, F; Giuliani, F; Orditura, M; Silvestris, N | 1 |
| Barbieri, E; Conte, P; Dieci, MV; Guarneri, V; Piacentini, F | 1 |
| Chiuri, VE; De Laurentiis, M; Giampaglia, M; Lorusso, V; Silvestris, N; Tinelli, A | 1 |
| Arteaga, C; Chakrabarty, A; Chamness, GC; Chang, JC; Dave, B; Gutierrez, MC; Hilsenbeck, SG; Huang, J; Migliaccio, I; Narasanna, A; Osborne, CK; Rimawi, M; Schiff, R; Wong, H; Wu, MF | 1 |
| Clay, TM; Devi, G; Hartman, ZC; Hobeika, A; Lyerly, HK; Morse, MA; Osada, T | 1 |
| Arpino, G; Gutierrez, C; Hilsenbeck, SG; Huang, C; Massarweh, S; Migliaccio, I; Osborne, CK; Rimawi, MF; Schiff, R; Soliz, R; Wang, YC; Ward, R; Wiechmann, LS; Wu, MF | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Aglietta, M; Capellero, S; Cavalloni, G; Gammaitoni, L; Giordano, S; Migliardi, G; Milani, A; Moggio, A; Montemurro, F; Pecchioni, C; Peraldo-Neia, C; Petrelli, A; Sapino, A; Valabrega, G; Zaccarello, G | 1 |
| de Weger, RA; Moelans, CB; van Diest, PJ | 1 |
| De Keulenaer, GW; Doggen, K; Lemmens, K | 1 |
| Argyriou, AA; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Petsas, T; Tsiata, E; Zolota, V | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Collins, DJ; del Campo, JM; DeSouza, NM; Diaz de Corcuera, I; El-Hariry, IA; Harrington, K; Koh, DM; Leach, MO; Orton, MR; Parera, M; Schmid, VJ; Whitcher, B | 1 |
| Choudhury, A; Fujii, H; Inoue, M; Izawa, S; Kawaguchi, Y; Kiessling, R; Kono, K; Kono, T; Maruyama, T; Mimura, K; Mizukami, Y; Shiba, S; Watanabe, M | 1 |
| Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V | 1 |
| Ito, Y | 2 |
| Bing, N; Briley, LP; Budde, LR; Cardon, LR; Cox, CJ; King, KS; Mooser, VE; Preston, AJ; Spraggs, CF; Stein, SH; Whittaker, JC | 1 |
| Abramson, V; Arteaga, CL | 1 |
| Anderson, A; Gilmer, TM; Greger, J; Liu, L; Liu, Y; Martin, AM; Peterson, J; Shi, H | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Azria, D; Bascoul-Mollevi, C; Bazin, H; Chardès, T; Crapez, E; Gaborit, N; Larbouret, C; Mathis, G; Pèlegrin, A; Peyrusson, F; Poul, MA; Vallaghe, J | 1 |
| Bouchalova, K; Cizkova, M; Cwiertka, K; Friedecky, D; Hajduch, M; Trojanec, R | 1 |
| Durbin, JE; Koromilas, AE; Muller, WJ; Raven, JF; Tremblay, ML; Wang, S; Williams, V | 1 |
| Morioka, T; Niikura, N; Okamura, T; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B | 1 |
| Arteaga, CL; Balko, JM; Bates, M; Chakrabarty, A; Dua, R; Ghosh, R; González-Angulo, AM; Kostler, WJ; Leitzel, K; Lipton, A; Liu, S; Mills, GB; Mukherjee, A; Narasanna, A; Penuel, E; Pidaparthi, S; Sperinde, J; Wang, SE; Winslow, J | 1 |
| Katano, M; Morisaki, T; Nakafusa, Y; Nakashima, Y; Onishi, H; Yokohata, K | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T | 1 |
| Brachtel, E; Chiba, N; Edelman, EJ; Hayashida, T; Maheswaran, S; Moriyama, H; Ramaswamy, S; Shimada, T; Tajima, K; Takahashi, F; Takahashi, M | 1 |
| Addeo, R; Caraglia, M | 1 |
| Bethke, K; Cianfrocca, M; Gordon, J; Gradishar, W; Hansen, N; Jeruss, JS; Jovanovic, B; Kaklamani, VG; Khan, SA; Lacouture, M; Meservey, C; Parimi, V; Rosen, S; Scholtens, D; Siziopikou, K; Uthe, R; Von Roenn, J; Wayne, J | 1 |
| Chan, EC; Hanson, KL; Nelson, SD; New, LS; Takakusa, H; Wahlin, MD; Zhao, C | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, CT; Dickler, M; Fleisher, M; Hudis, CA; Lehman, R; Lin, N; McArthur, HL; Morris, PG; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Arao, T; Azuma, K; Fujisaka, Y; Kaneda, H; Kurata, T; Nakagawa, K; Nishio, K; Okamoto, I; Sakai, K; Satoh, T; Takeda, M; Tsurutani, J; Watatani, M | 1 |
| Arteaga, CL; Chakrabarty, A; Chang, J; Cook, RS; Dave, B; Garrett, JT; Granja-Ingram, ND; Manning, HC; McKinely, E; Olivares, MG; Pao, W; Rinehart, C; Sánchez, V | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Armstrong, AJ; Crane, JM; George, DJ; Godley, PA; Grigson, G; Kim, WY; Moore, DT; Morris, K; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, CP; Whang, YE | 1 |
| Barco, SD; Brunet, J; Cufí, S; Lopez-Bonet, E; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Sauri-Nadal, T; Torres-Garcia, VZ; Vazquez-Martin, A | 1 |
| Amonkar, MM; Baselga, J; Blackwell, KL; Burstein, HJ; Ellis, C; O'Shaughnessy, J; Sherrill, BH; Wu, Y | 1 |
| Blanke, CD; Danenberg, KD; Fenoglio-Preiser, CM; Goldman, B; Iqbal, S; Lenz, HJ; Shibata, SI; Zhang, W | 1 |
| Twombly, R | 1 |
| Abraham, J; Efstratiadis, A; Giles, FG; Keller, C; Kilcoyne, A; LeGallo, RD; Malempati, S; McCleish, AT; Nelon, LD; Nishijo, K; Nowak, BM; Prajapati, SI; Rubin, BP; Schaffer, BS; Taniguchi, E | 1 |
| Ali, SM; Carney, W; Gagnon, R; Leitzel, K; Lipton, A; Maltzman, J; Martin, AM; Platek, G; Steplewski, K; Westlund, R | 1 |
| El-Khoueiry, A; Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Russell, J; Wilson, PM | 1 |
| Dao-Pick, T; DeFazio-Eli, L; Goodman, L; Parry, G; Strommen, K; Winslow, J | 1 |
| Ho, PC; Lo, YH; Wang, SC; Zhao, H | 1 |
| Fumita, S; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Tanizaki, J | 1 |
| Callahan, R; Hurvitz, S | 1 |
| Jia, F; Radhakrishnan, R; Shih, AJ; Telesco, SE | 1 |
| Barok, M; Isola, J; Köninki, K; Tanner, M | 1 |
| Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL | 1 |
| Berille, J; Bonneterre, J; Brain, E; Dieras, V; Isambert, N; Lokiec, F; Rezai, K; Roche, H; Urien, S | 1 |
| Hatake, K; Ito, Y; Iwase, T | 1 |
| Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY | 1 |
| Burstein, HJ; DiPiro, PJ; Krop, IE; Lin, NU; Najita, JS; Olson, EM; Winer, EP | 1 |
| Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA | 1 |
| Brasseur, L; Cvitkovic, F; Gutierrez, M; Le Scodan, R; Lyazidi, S | 1 |
| Di Gion, P; Doroshyenko, O; Fuhr, U; Scheffler, M; Wolf, J | 1 |
| Chang, Y; Chen, S; Feng, J; Li, X; Wang, Z; Wen, A | 1 |
| Borštnar, S; Cwiertka, K; Das Gupta, A; Greil, R; Koza, I; Linn, M; Marcou, Y; Petráková, K; Pikiel, J; Steger, GG; Wojtukiewicz, MZ | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sophie, S; Zanetti, A | 1 |
| Korman, DB | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K | 1 |
| Antonelli, A; Borsari, V; Carpi, A; Fallahi, P; Ferrari, P; Fini, M; Miccoli, P; Nicolini, A | 1 |
| Chefrour, M; Ciccolini, J; Denden, A; Fischel, JL; Formento, P; Giacometti, S; Iliadis, A; Milano, G; Renée, N | 1 |
| Kawaguchi, H; Koga, C; Nakamura, Y; Nishimura, S; Ohno, S; Tanaka, K; Yamaguchi, H; Yoshiyama, T | 1 |
| Kalofonos, H; Koutras, A; Labropoulou-Karatza, C; Makatsoris, T; Onyenadum, A; Peroukides, S; Tsamandas, A | 1 |
| Dicker, DT; Dolloff, NG; El-Deiry, WS; Hart, LS; Humphreys, R; Mayes, PA | 1 |
| Ahmad, ZK; Brown, CM; Cueva, RA; Doherty, JK; Ryan, AF | 1 |
| Cognetti, F; Di Benedetto, A; Fabi, A; Ferretti, G; Metro, G; Mottolese, M; Papaldo, P; Russillo, M | 1 |
| Bacus, SS; Blackwell, KL; Clay, TM; Hartman, ZC; He, J; Liu, L; Liu, Z; Lyerly, HK; Mao, Y; Osada, T; Petricoin, EF; Spector, NL; Wulfkuhle, JD; Xia, W; Yang, XY; Zhao, S; Zong, R | 1 |
| Amala, K; Bhujanga Rao, AK; Gondi, CS; Gorantla, B; Jogi, KV; Junnarkar, A; Myneni, PC; Naidu, MU; Rao, JS; Venkat Ramana, G | 1 |
| Guo, H; Hu, X; Jia, Z; Shao, Z; Sun, S; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Okamura, T; Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Bonanni, B; Decensi, A; Dotti, MC; Galimberti, V; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Luini, A; Macis, D; Pala, O; Pruneri, G; Puntoni, M; Serrano, D; Veronesi, P; Viale, G | 1 |
| Adams, A; Dolan, R; Graham, TR; Liu, T; Lobo, C; O'Regan, RM; Sun, SY; Taliaferro-Smith, LD; Tighiouart, M; Yacoub, R; Yang, L | 1 |
| Alvarez, RH; Cristofanilli, M; De Giorgi, U; De Laurentiis, M; De Placido, S; Giordano, A; Giuliano, M; Handy, BC; Hess, KR; Hortobagyi, GN; Jackson, S; Mego, M; Reuben, JM; Ueno, NT; Valero, V | 1 |
| Amonkar, MM; Browning, D; Cameron, D; Delea, TE; Karnon, J; Sofrygin, O; Tappenden, P; Walker, MD | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Davidson, NE | 1 |
| Fowler, MB; Telli, ML; Witteles, RM | 1 |
| Danko, J; Horton, K; Kostyal, D; Lanning, C; Shay, T; Welt, RS; Welt, S | 1 |
| Chew, HK; Christensen, S; Davies, AM; Gandour-Edwards, R; Gitlitz, B; Linden, H; Mack, PC; Solis, LJ; Somlo, G; Yang, X | 1 |
| Bubley, GJ; Carducci, M; Chen, YH; Dipaola, R; Huang, W; Kolesar, J; Liu, G; Pins, M; Stein, M; Wilding, G | 1 |
| Breindl, S; Brockhoff, G; Buchholz, S; Diermeier-Daucher, S; Ortmann, O | 1 |
| Bode, AM; Carper, A; Cho, YY; Ericson, ME; Grubbs, CJ; Langfald, A; Li, J; Lubet, RA | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Biswas-Baldwin, N; Bourhis, J; Carracedo, C; Compton, N; Cupissol, D; De Raucourt, D; Del Campo, JM; Downie, L; El-Hariry, I; Harrington, KJ; Hitt, R; Lokanatha, D; Maroudias, N; Midwinter, D; Nutting, CM; Sebastian, P; Temam, S | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| Albain, KS; Clementz, AG; Meeke, K; Miele, L; Osipo, C; Pandya, K; Roberts, J; Rogowski, A | 1 |
| Brosens, JJ; Chan, KY; Chen, J; Cheung, YN; Feltes, A; Gomes, AR; Ho, KK; Karadedou, CT; Khoo, US; Lam, EW; Petkovic, M; Tsang, JW; Wong, SY; Zwolinska, AK | 1 |
| Fujii, H; Inoue, A; Inoue, M; Inoue, S; Izawa, S; Kawaguchi, Y; Kono, K; Maruyama, T; Mimura, K; Nogata, H; Shiba, S; Watanabe, M | 1 |
| Cortes, J; Roché, H | 1 |
| Crane, K | 1 |
| Bissell, MJ; Hilsenbeck, SG; Huang, C; Osborne, CK; Park, CC; Rimawi, MF; Schiff, R; Shou, J; Wang, YC; Ward, R | 1 |
| Conzelmann, H; Kleiman, LB; Lauffenburger, DA; Maiwald, T; Sorger, PK | 1 |
| Chen, C; D'Andrea, G; Drullinsky, P; Feigin, K; Gajria, D; Gonzalez, J; Hudis, CA; Lake, D; Norton, L; Patil, S; Theodoulou, M; Traina, TA | 1 |
| Bao, Y; Chang, CJ; Hortobagyi, GN; Hsu, JL; Hung, MC; Lang, JY; Meric-Bernstam, F; Wang, Q; Woodward, WA; Xie, X; Yamaguchi, H; Yu, D | 1 |
| Albini, A; Anzà, C; Baravelli, M; Bucci, EO; Cammarota, R; Cesana, E; Donatelli, F; Noonan, DM | 1 |
| Jehn, C; Kunc, K; Lüftner, D; Possinger, K; Seidel, J | 1 |
| Liebmann, C; Weisheit, S | 1 |
| Borts, DJ; Bowers, GD; Castellino, S; Koch, K; MacLauchlin, C; O'Mara, M | 1 |
| Bignon, YJ; Cayre, A; El Guerrab, A; Nemlin, CC; Penault-Llorca, F; Rossignol, F; Vigier, F; Zegrour, R | 1 |
| Dasanu, CA; Kaur, A | 1 |
| Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| Castellino, S; Gril, B; Hua, E; Lockman, J; Lockman, PR; Mittapalli, RK; Palmieri, D; Polli, JW; Rubin, SD; Rudraraju, V; Samala, R; Smith, QR; Steeg, PS; Taskar, KS; Thorsheim, HR | 1 |
| Awada, A; Bozovic-Spasojevic, I; Saliba, W | 1 |
| Constantinidou, A; Smith, I | 1 |
| Azim, HA; de Azambuja, E; Loi, S; Metzger-Filho, O; Piccart, M; Saini, KS; Sotiriou, C | 1 |
| Anees, M; Dolznig, H; El-Gazzar, A; Grunt, TW; Holcmann, M; Horak, P; Horvat, R; Krainer, M; Pils, D; Savarese-Brenner, B; Schemper, M; Schöfer, C; Sibilia, M; Vanhara, P; Wittinger, M; Zeillinger, R | 1 |
| Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM | 1 |
| DeMichele, A; Hirsh, RL | 1 |
| Bisagni, G; Clavarezza, M; Cognetti, F; Crivellari, D; Fabi, A; Ferzi, A; Foglietta, J; Gamucci, T; Gori, S; Metro, G; Montemurro, F; Silva, RR; Spazzapan, S; Stocchi, L; Torrisi, E | 1 |
| Bianchini, G; Gianni, L | 1 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Arnold, SL; Gayle, SS; Nahta, R; O'Regan, RM | 1 |
| Bartosch, N; Duyster, J; Engh, RA; Kancha, RK; Peschel, C; von Bubnoff, N | 1 |
| Aoki, Y; Fujii, T; Hada, K; Ishii, N; Kondoh, O; Mio, T; Miura, T; Nakanishi, Y; Nakano, K; Ono, N; Saitoh, R; Sakata, K; Sato, S; Suda, A; Tachibana, Y; Tsukuda, T; Yamazaki, T | 1 |
| Bassano, C; Centritto, F; Flora, M; Fratelli, M; Garattini, E; Gardini, G; Guarnaccia, V; Paroni, G; Terao, M; Ubezio, P; Zanetti, A | 1 |
| Akhavan, D; Amzajerdi, AN; Babic, I; Chakravarti, A; Cloughesy, TF; Dang, J; Deangelis, LM; Dejesus, J; Gini, B; Guo, D; Hong, C; Huang, TT; Iwanami, A; James, CD; Kuga, D; Lisiero, DD; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nathanson, D; Prados, MD; Prins, RM; Reinitz, F; Robins, HI; Soto, H; Tanaka, K; Tontonoz, P; Wen, PY; Youssef, M; Zhu, S | 1 |
| Bode, AM; D'Alessio, A; De Luca, A; Dong, Z; Ericson, ME; Grubbs, C; Li, J; Lubet, RA; Normanno, N; Zhu, F | 1 |
| Garden, BC; Lacouture, ME; Wu, S | 1 |
| Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Kerem, M; Pasali, H; Pasaoglu, H; Uner, A; Yılmaz, G | 1 |
| Bellomo, C; Leporatti, S; Lorusso, V; Lvov, YM; Maffia, M; Rinaldi, R; Tinelli, A; Vergara, D; Vergaro, V; Zhang, X | 1 |
| Cole, PA; Head, S; Kim, K; Leahy, DJ; Longo, PA; Tarrant, MK; Wang, Z | 1 |
| Botero, MF; Chamness, GC; Fu, X; Gillihan, R; Guo, J; Healy, NA; Hilsenbeck, SG; Morrison, G; Osborne, CK; Phillips, GL; Rimawi, MF; Schiff, R; Wang, YC; Ward, RM | 1 |
| Arteaga, CL; Gianni, L; Osborne, CK; Perez, EA; Puglisi, F; Sliwkowski, MX | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N | 1 |
| Baergen, RN; Boeck, M; Christos, P; Chuang, E; Cigler, T; Cobham, MV; Donovan, D; Jain, S; Lam, C; Lane, ME; Mittal, V; Moore, A; O'Loughlin, J; Rafii, S; Schneider, S; Swistel, A; Vahdat, LT; Ward, MM; Wiener, N | 1 |
| Andersen, JB; Avital, I; Barbour, A; Blechacz, BR; Conner, EA; Factor, VM; Gillen, MC; Komuta, M; Roberts, LR; Roskams, T; Spee, B; Thorgeirsson, SS | 1 |
| Arbushites, MC; Chien, AJ; Dickler, MN; Franco, SX; Glencer, A; Hudis, C; Lahiri, S; Nulsen, B; Park, JW; Rugo, HS; Scott, J; Stopeck, AT | 1 |
| Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Chen, YC; Chen, YJ; Huang, HL; Huang, YC; Pan, Hy; Shih, SP; Yang, KC | 1 |
| Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Tang, Y | 1 |
| Ji, Y; Lu, Y; Mills, GB; Müller, P; Nieto-Barajas, LE | 1 |
| Burns, SS; Bush, ML; Chang, LS; Davletova, S; Jacob, A; Oblinger, J; Welling, DB | 1 |
| Lee, SH | 1 |
| Chen, CT; Christensen, JG; Gao, S; Kim, H; Liska, D; Weiser, MR | 1 |
| Chudenko, VA; Dashian, GA; Filatova, LV; Gershanovich, ML; Latipova, DKh; Luk'ianchikova, VS; Paltuev, RM; Semiglazov, VV; Semiglazova, TIu | 1 |
| Afonso, N; de Mello, RA; de Vasconcelos, A; Pereira, D; Pousa, I; Ribeiro, RA; Rodrigues, H | 1 |
| Bonneterre, J; Brain, E; Cottura, E; Dalenc, F; Diéras, V; Fumoleau, P; Isambert, N; Jimenez, M; Lokiec, F; Mahier-Aït Oukhatar, C; Mefti-Lacheraf, F; Rezai, K; Tresca, P; Vanlemmens, L | 1 |
| Chia, SK | 1 |
| Bischoff, J; Blohmer, JU; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kreienberg, R; Kühn, T; Loibl, S; Nekljudova, V; Rezai, M; Strumberg, D; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Carli, P; Crivellari, D; Di Lauro, V; Dolcetti, R; Lamaj, E; Miolo, G; Quitadamo, D; Spada, A; Spazzapan, S; Turchet, E; Veronesi, A | 1 |
| Aktan, G; Aura, C; Baselga, J; Bradbury, I; Chang, TW; Coccia-Portugal, M; de Azambuja, E; Di Cosimo, S; Dinh, P; Domont, J; Eidtmann, H; Fauria, K; Gelber, RD; Goldhirsch, A; Gómez, H; Horváth, Z; Kunz, G; Lerzo, G; Palacova, M; Piccart-Gebhart, M; Probachai, V; Pusztai, L; Semiglazov, V; Sohn, JH; Tseng, LM; Untch, M; Van Dooren, V | 1 |
| Deng, BG; Gao, ZT; Guo, XF; Wang, H; Zhong, GS; Zhu, XF | 1 |
| Awada, A; Bozovic-Spasojevic, I; Chow, L | 1 |
| Blackwell, K; Broadwater, G; Castro, H; Chen, W; Clay, TM; Hamilton, E; Hobeika, AC; Lehmann, F; Lyerly, HK; Morse, MA; Osada, T; Ren, XR; Spector, N; Wei, J | 1 |
| Evens, A; Osborne, CK | 1 |
| Huang, Y; Rizzo, RC | 1 |
| Dollery, CT; Hunt, CM; Parham, LR; Spraggs, CF | 1 |
| Bareford, MD; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Poklepovic, A | 1 |
| Biller, BM; Tritos, NA | 1 |
| Chan, A; Chan, EC; Chanthawong, S; Ho, HK; Saetaew, M; Teo, YL; Yap, YS | 1 |
| Aktolga, S; Blair, EA; Bozeman, J; Cohen, EE; Dancey, JE; Davis, DW; de Souza, JA; Khattri, A; Kozloff, MF; Kunnavakkam, R; Lingen, MW; Nattam, S; Seiwert, TY; Stenson, KM; Vokes, EE; Wong, SJ; Zhang, Y | 1 |
| Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY | 1 |
| Hirata, H; Inoue, K; Kida, H; Kijima, T; Kohmo, S; Kumanogoh, A; Minami, T; Nagatomo, I; Otani, Y; Suzuki, M; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Loibl, S; Untch, M; Von Minckwitz, G | 1 |
| Aura, C; Baselga, J; Calvo, MT; García-García, C; Grueso, J; Guzmán, M; Ibrahim, YH; Jessen, K; Liu, Y; Pérez, J; Rommel, C; Scaltriti, M; Serra, V; Tabernero, J | 1 |
| Jelovac, D; Wolff, AC | 1 |
| Fujita, KA; Kakuda, H; Kuroda, S; Toyoshima, Y; Uda, S | 1 |
| Bosch-Barrera, J; Brunet, J; Cufí, S; De Llorens, R; Martin-Castillo, B; Massaguer Vall-Llovera, A; Menendez, JA; Oliveras-Ferraros, C; Queralt, B; Salip, DC; Vazquez-Martin, A | 1 |
| Azria, D; Bascoul-Mollevi, C; Campigna, E; Chardès, T; Coelho, M; Gaborit, N; Larbouret, C; Mach, JP; Pèlegrin, A; Robert, B | 1 |
| Bekaii-Saab, T; O'Neil, B; Peck, J; Villalona Calero, M; Wei, L; Zalupski, M | 1 |
| Deng, BG; Guo, XF; Zhong, GS; Zhu, XF | 1 |
| Bigot, L; Boige, V; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Goéré, D; Gonin, P; Marion, S; Noël-Hudson, MS; Polrot, M | 1 |
| Battelli, N; Bessi, S; Biganzoli, L; Buyse, M; Coombes, CR; Di Leo, A; Di Marsico, R; Gianni, L; Gori, S; Masci, G; Minisini, AM; Pestrin, M; Puglisi, F; Ravaioli, A; Stebbing, J; Tondini, C | 1 |
| Beijnen, JH; Guchelaar, HJ; Opdam, FL; Schellens, JH | 1 |
| Artioli, F; Bagnalasta, M; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; D'Amico, R; Frassoldati, A; Generali, DG; Giardina, G; Guarneri, V; Marini, L; Musolino, A; Orlando, L; Piacentini, F; Ravaioli, A; Sarti, S; Serra, P; Untch, M | 1 |
| Aiba, S; Fujimura, T; Haga, T; Hashimoto, A; Hidaka, T; Mizuashi, M; Onami, K; Watabe, A | 1 |
| Chan, EC; Chua, TB; Ho, HK; Nelson, SD; New, LS; Yap, CW | 1 |
| He, XM; Li, Y; Zhang, LY | 1 |
| Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY | 1 |
| Arkhipov, A; Dror, RO; Eastwood, MP; Jumper, J; Kim, ET; Kuriyan, J; Shan, Y; Shaw, DE; Zhang, X | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Buechner, SA; Erne, P; Joshi, MB; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| André, F; Bachelot, T; Campone, M; Frenel, JS; Juin, P | 1 |
| Giuliano, M; Schiff, R; Trivedi, MV | 1 |
| Han, J; Kil, WH; Kim, S; Lee, JE; Nam, SJ; Shin, I | 1 |
| Batra, SK; Chen, AC; Creighton, CJ; Gutierrez, MC; Huang, C; Lopez-Tarruella, S; Massarweh, S; Migliaccio, I; Osborne, CK; Rimawi, M; Schiff, R; Wang, YC | 1 |
| Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M | 1 |
| D'Alessio, G; De Lorenzo, C; Fedele, C; Malara, AE; Riccio, G | 1 |
| Arpino, G; De Angelis, C; Minisini, AM; Puglisi, F | 1 |
| Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L | 1 |
| Aktan, G; Baselga, J; Bischoff, J; Blackwell, KL; Burstein, HJ; Ellis, C; Florance, A; O'Shaughnessy, J; Rugo, HS; Sledge, G; Storniolo, AM; Vukelja, S | 1 |
| Dixon, JM; Symmans, WF; Verrill, M; Wilson, V | 1 |
| Ma, F; Westlund, KN; Zhang, L | 1 |
| Aherne, ST; Clynes, M; Crown, J; Doolan, P; Madden, SF; O'Connor, R; O'Neill, F | 2 |
| Kołodziejczyk, P; Kulig, J; Kulig, P; Legutko, J | 1 |
| Criscitiello, C; de Azambuja, E; de Castro, G; Diaz, M; La Gerche, A; Metzger-Filho, O; Piccart-Gebhart, MJ; Saini, KS | 1 |
| Altundag, K; Dogan, E; Ozer, N; Ozisik, Y; Petekkaya, I; Yorgun, H | 1 |
| Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Amir, E; Bouganim, N; Clemons, M; Fralick, M; Hilton, JF | 1 |
| Anderson, L; Britten, CD; Christensen, JG; Cohen, DJ; Conklin, D; Desai, AJ; Finn, RS; Ginther, C; Kalous, O; O'Brien, NA; Slamon, DJ; Taylor, I | 1 |
| Burton, L; Chan, E; Fridlyand, J; Koeppen, H; Li, J; Lin, E; Merchant, M; Moffat, J; Neve, R; Peng, J; Penuel, E; Ribas, A; Settleman, J; Sosman, J; Sutherlin, DP; Wang, Y; Wilson, TR; Yan, Y | 1 |
| Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E | 1 |
| Ramfidis, VS; Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Locasale, JW | 1 |
| Alici, S; Arslan, UY; Bilici, M; Boruban, C; Buyukberber, S; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Mert, AG; Ozkan, M; Suner, A; Tarhan, MO; Unal, OU; Urakci, Z; Yaman, S; Yildiz, R | 1 |
| Rudà, R; Soffietti, R; Trevisan, E | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Chung, JS; Im, YH; Kim, S; Kim, TY; Moon, H; Park, S; Rha, SY; Ro, J; Santillana, S | 1 |
| Bezler, M; Hengstler, JG; Ullrich, A | 1 |
| Boehm, A; Diet, A; Dietz, A; Mozet, C; Reiche, A; Schrader, C; Wichmann, G | 1 |
| Allen, JC; Ballas, MS; Brown, K; Goldberg, JD; Golfinos, JG; Hagiwara, M; Hochman, T; Karajannis, MA; Koch, KM; Legault, G; Nusbaum, AO; Roland, JT | 1 |
| Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J | 1 |
| Komurov, K; Moss, TJ; Muller, M; Nagrath, D; Ram, PT; Seviour, EG; Tseng, JT; Yang, L | 1 |
| Lind, P; Mauri, D; Nearchou, A; Valachis, A | 1 |
| Bernhard, JC; Gross-Goupil, M; Ravaud, A | 1 |
| Abulafia, O; Fischer, EG; Godwin, AK; Gray, H; Hanjani, P; Lankes, HA; Leslie, KK; Rose, PG; Schilder, RJ; Sill, MW; Tewari, K; Walker, JL | 1 |
| Bissell, MJ; Furuta, S; Kenny, PA; Lee, SY; Lenburg, ME; Meier, R; Xu, R | 1 |
| Lim, E; Lin, NU | 1 |
| Dorssers, LC; Foekens, JA; Godinho, MF; Look, MP; Petricoin, EF; Sieuwerts, AM; Sleijfer, S; van Agthoven, T; Wulfkuhle, JD | 1 |
| Bischoff, J; Eidtmann, H; Fasching, PA; Fehm, T; Hauschild, M; Huober, J; Issa-Nummer, Y; Karn, T; Khandan, F; Liedtke, C; Loibl, S; Mau, C; Meinhold-Heerlein, I; Müller, V; Rack, B; Schem, C; Schmatloch, S; Untch, M; von Minckwitz, G; Witzel, I; Zu Eulenburg, C | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Finnie, JW; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM | 1 |
| Bedja, D; Belmonte, F; Gabrielson, K; Guo, X; Kang, B; Pin, S; Sysa-Shah, P; Tsuchiya, N; Xu, Y | 1 |
| Cornelio, GH; Devi, BC; Khorprasert, C; Kim, SB; Kim, TY; Kobayashi, M; Landis, SH; Lee, SC; Moon, H; Park, YH; Ro, J; Sohn, JH; Sutandyo, N; Wong, DW; Yap, YS; Yeoh, EM | 1 |
| Hasinoff, BB; Patel, D; Wu, X | 1 |
| Deng, X; Erfani, SF; Hemler, ME; Hoff, J; Jin, H; Kaetzel, DM; Li, Q; Novak, M; Rabinovitz, I; Sharma, C; Sonnenberg, A; Stipp, CS; Yang, H; Yang, XH; Yi, Y; Zhou, P | 1 |
| Choowongkomon, K; Gleeson, MP; Songtawee, N | 1 |
| Jain, A; Ryan, PD; Seiden, MV | 1 |
| Imami, K; Imamura, H; Ishihama, Y; Sugiyama, N; Taniguchi, M; Toi, M; Tomita, M; Ueno, T; Wakabayashi, M | 1 |
| Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G | 1 |
| Cardoso, F; Sousa, B | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, H; Tang, Y | 1 |
| Andry, G; Awada, A; Bogaerts, J; El-Hariry, I; Fortpied, C; Lacombe, D; Lalami, Y; Langendijk, JA; Liberatoscioli, C; Specenier, PM; Vermorken, JB | 1 |
| Booth, L; Chen, CS; Cruickshanks, N; Dent, P; Grant, S; Ridder, T | 1 |
| Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M | 1 |
| Bartlett, J; Bogaerts, J; Bonnefoi, H; Cameron, D; Debled, M; Fiche, M; Fournier, M; Koch, KM; Marreaud, S; Nobahar, M; Pierga, JY; Zaman, K; Zimmer, A | 1 |
| Brouwers, AH; de Vries, EG; Lub-de Hooge, MN; Oude Munnink, TH; Schröder, CP; Timmer-Bosscha, H; Vedelaar, SR | 1 |
| Carey, LA; Chiu, WM; Dees, EC; Halle, JS; Horton, JK; Ivanova, A; Kimple, RJ; Lawrence, JA; Livasy, CA; Ollila, DW; Sartor, CI; Shields, JM | 1 |
| Drebin, JA; Pippin, JA; Singla, S | 1 |
| Fujiwara, Y; Ito, Y; Iwata, H; Katsura, K; Narabayashi, M; Saji, S; Sasaki, Y; Usami, S | 1 |
| Bozovic-Spasojevic, I; de Azambuja, E; Zardavas, D | 1 |
| Albano, L; Balsari, A; Borrelli, S; Fabris, S; Magnifico, A; Mantovani, R; Neri, A; Ripamonti, F; Rossini, A; Tagliabue, E | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M | 1 |
| Lin, NU; Vaz-Luis, I; Winer, EP | 1 |
| Adam, J; Doss, S; Robertson, J | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Bell, R; Khasraw, M | 1 |
| Arumugham, T; de Jonge, MJ; Hamberg, P; Hodge, J; Hurwitz, HI; Pandite, LN; Savage, S; Suttle, AB; Verweij, J | 1 |
| Cao, S; Gao, H; Jiang, X; Pang, Z; Xi, Z; Yang, Z; Zhang, S | 1 |
| Ager, E; Chung, E; Duyverman, AM; Eichler, AF; Engelman, JA; Farrar, CT; Fukumura, D; Goel, S; Hiddingh, L; Huang, Y; Incio, J; Jain, RK; Kamoun, W; Kodack, DP; Lussiez, A; Mahmood, S; Snuderl, M; Song, Y; Tannous, BA; Yamashita, H | 1 |
| Cooper, T; Nowsheen, S; Stanley, JA; Yang, ES | 1 |
| Clynes, M; Corkery, B; Crown, J; Kennedy, S; Larkin, A; O'Donovan, N; O'Driscoll, L; Walsh, N | 1 |
| Hoe, N; Iorns, E; Jegg, AM; Landgraf, R; Liu, X; Pegram, MD; Singh, S; Ward, TM; Zhou, J | 1 |
| Barrick, B; Fraga, G; Matthys, B | 1 |
| Bartsch, R; Preusser, M | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Bang, YJ; Elvin, P; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, A; Nam, HJ; Oh, DY; Song, SH; Yoon, YK | 1 |
| Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M | 1 |
| Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A | 1 |
| Fujita, Y; Goto, M; Hamaoka, A; Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Shouji, M; Taguchi, T; Umeda, Y | 1 |
| Cheng, T; Ge, Z; Li, R; Qiao, K; Zhang, L; Zhang, X | 1 |
| Fujii, H; Inoue, A; Inoue, M; Izawa, S; Kawaguchi, Y; Kono, K; Maruyama, T; Mimura, K; Shiba, S; Shiraishi, K; Watanabe, M | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Isıkdogan, A; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Andreu, X; Baena, C; Bronchud, MH; Castillo, S; Escriva de Romaní, S; Esquius, J; Fernández, A; Julia, JC; Mourelo, S; Murillo, J; Romero, R | 1 |
| Ashraf, SQ; Bodmer, WF; Mortensen, NJ; Nicholls, AM; Ntouroupi, TG; Wilding, JL | 1 |
| Aronson, AB; Bose, R; Ding, L; Ellis, MJ; Goel, N; Kavuri, SM; Koboldt, DC; Li, S; Ma, CX; Mardis, ER; Monsey, J; Searleman, AC; Shen, D; Shen, W | 1 |
| Bosserman, L; DeSilvio, ML; Hagan, MK; Hart, L; Mahoney, JM; Nagarwala, Y; Richards, P; Salleh, MN; Waterhouse, DM; Yardley, DA | 1 |
| Arteaga, CL; Cook, RS; Garrett, JT; Kuba, MG; Sutton, CR | 1 |
| Guo, Q; Ma, C; Song, X; Wang, X; Wei, L; Zuo, W | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Aboagye, EO; Contractor, KB; Coombes, RC; El-Bahrawy, M; Elsheikh, SE; Hadjiminas, DJ; Horimoto, Y; Lam, EW; Mansi, JL; Marconell, MH; Miller, ML; Palmieri, C; Reise, JA; Shaw, JA; Shousha, S; Stebbing, J; Tat, T; Walker, RA | 1 |
| Lønning, PE | 1 |
| Aktan, G; Boyle, F; Buzdar, AU; Chavarri-Guerra, Y; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Kaufmann, M; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Williams, LS | 1 |
| Alvarez, RH; Blackwell, KL; Cristofanilli, M; Gladkov, O; Gomez, HL; Johnston, SR; Manikhas, A; Ranganathan, S; Redhu, S; Rubin, SD; Safina, S; Shao, Z; Trudeau, ME | 1 |
| Berrier, A; Biswas-Baldwin, N; Compton, N; de Mendoza, FH; El-Hariry, I; Fayette, J; Franklin, N; Harrington, K; Housset, M; Kumar, R; Lau, M; Legenne, P; Mehanna, H; Remenar, E; Robinson, M | 1 |
| Amano, S; Enomoto, K; Fujisaki, S; Hara, Y; Hirano, T; Maeda, T; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Harada, T; Itamochi, H; Kato, M; Kigawa, J; Kudoh, A; Naniwa, J; Nishimura, M; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N | 1 |
| Nieder, C | 1 |
| Basavalingaiah, A; Madhusudhan, N; Revannasiddaiah, S; Susheela, SP | 1 |
| Bachelot, T; Campone, M; Cropet, C; Diéras, V; Jimenez, M | 1 |
| Durante, M; Gómez, H; Goodman, V; Johnston, SR; Pandite, L; Richie, M; Slamon, D; Stemmer, SM | 1 |
| Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D | 1 |
| Casanovas, O; Castillo-Ávila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Graupera, M; Hernández-Losa, J; Juliachs, M; Pandiella, A; Piulats, JM; Teixidó, C; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Cho, N; Hayashi, M; Yomo, S | 1 |
| Damodaran, S; Olson, EM | 1 |
| Bristow, RG; Groselj, B; Kerr, M; Kiltie, AE; Knowles, MA; Phillips, RM; Qiao, B; Teo, MT | 1 |
| Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
| Gustafson, DL; Hudachek, SF | 2 |
| Bastida, CC; Falchook, GS; Janku, F; Kurzrock, R; Stewart, DJ; Tsao, AS | 1 |
| Brünner, N; Deng, X; Fogh, L; Jensen, V; Lademann, U; Schrohl, AS; Stenvang, J; Yang, H | 1 |
| Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R | 1 |
| Inoue, K | 1 |
| Chen, WS; Chen, YJ; Hsia, TC; Hsu, SC; Huang, CY; Huang, TC; Huang, WC; Hung, MC; Tsai, SL; Tu, CY; Wei, YL; Yeh, MH; Yen, CJ; Yu, MC; Yu, YL | 1 |
| Majem, M; Pallarès, C | 1 |
| Aktan, G; Baselga, J; Bines, J; Boyle, F; Bradbury, I; de Azambuja, E; Dooren, VV; Jackisch, C; Lang, I; Metzger-Filho, O; Perez, EA; Piccart-Gebhart, M; Pritchard, KI; Saini, KS; Simon, SD; Smith, I; Untch, M; Wolff, AC; Xu, B | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
| Kalous, J; Mlynarcikova, A; Nagyova, E; Nemcova, L; Scsukova, S | 1 |
| Chi, SN; Forsyth, P; Jayanthan, A; Lun, X; Narendran, A; Obaid, H; Ruan, Y; Singh, A; Smith, A; Strother, D | 1 |
| Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L | 1 |
| Selam, M | 1 |
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Barbara, JE; Buckley, DB; Kazmi, F; Parkinson, A | 1 |
| Contini, A; Erne, P; Ferri, N; Frachet, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| Abagyan, R; Behera, R; Katiyar, S; Kufareva, I; Mensa-Wilmot, K; Ogata, Y; Pollastri, M; Thomas, SM | 1 |
| Guillen-Ponce, C; Molina-Garrido, MJ; Mora-Rufete, A | 1 |
| Adair, SJ; Bauer, TW; Borgman, CA; Chopivsky, ME; Cowan, CR; Gilmer, TM; Lindberg, JM; Lowrey, BT; Newhook, TE; Parsons, JT; Stelow, EB; Stokes, JB; Walters, DM | 1 |
| Hattori, S; Kage, M; Kan, H; Kawahara, A; Kuwano, M; Murakami, Y; Ono, M; Shibata, T; Ureshino, H; Watari, K | 1 |
| Cao, S; Chen, C; Gao, H; Jiang, X; Pan, S; Pang, Z; Xi, Z; Yang, Z; Zhang, Q | 1 |
| Antoniani, B; Botti, C; Ciccarese, M; Cognetti, F; Di Benedetto, A; Ercolani, C; Fabi, A; Ferretti, G; Gori, S; Malaguti, P; Marino, M; Merola, R; Mottolese, M; Nisticò, C; Papaldo, P; Sperduti, I; Vici, P | 1 |
| Ashworth, A; Chong, I; Cunningham, D; Lambros, M; Lord, CJ; Mackay, A; Meijer, T; Reis-Filho, JS; Shiu, KK; Wetterskog, D | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Colon-Otero, G; Dakhil, S; Dueck, AC; Franco, S; Ghanem-Cañete, I; Jenkins, RB; Johnson, D; Kahanic, S; McCullough, AE; Moreno-Aspitia, A; Northfelt, D; Palmieri, FM; Patel, T; Perez, EA; Rodeheffer, R; Tenner, KS | 1 |
| Kümler, I; Larsen, PB; Nielsen, DL | 1 |
| Clarke, PA; Pearl, LH; Polier, S; Prodromou, C; Samant, RS; Workman, P | 1 |
| Arpornwirat, W; Chen, G; DeSilvio, ML; Gomez, H; Guan, Z; Jiang, Z; Leung, WL; Lorvidhaya, V; Makhson, A; Newstat, B; Oliva, C; Russo, MW; Shen, Z; Tong, Z; Wang, L; Xu, B; Yang, J | 1 |
| Buss, MC; Castellino, RC; Gayle, SS; Nahta, R | 1 |
| Bean, GR; Chan, PM; Cheng, EH; Chodosh, LA; Dong, Y; Ganesan, YT; Hsieh, JJ; Huang, Y; Liu, H; Takeda, S; Zambetti, GP | 1 |
| Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH | 1 |
| Abel, EV; Amaravadi, RK; Aplin, AE; Basile, KJ; Ertel, A; Fortina, P; Karakousis, GC; Kugel, CH; Le, K; Lee, JB; Schuchter, LM; Witkiewicz, AK; Xu, W; Xu, X | 1 |
| Hunt, CM; Spraggs, CF; Xu, CF | 1 |
| Bozzi, F; Casale, A; Casali, PG; Conca, E; Crippa, F; Gronchi, A; Lo Vullo, S; Mariani, L; Marrari, A; Messina, A; Morosi, C; Negri, T; Palassini, E; Palmerini, E; Pilotti, S; Stacchiotti, S; Tamborini, E | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Boku, N | 1 |
| Agbor-tarh, D; Azim, HA; Baselga, J; Bradbury, I; Criscitiello, C; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Piccart, M; Rubio, IT | 1 |
| Chang, JC; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Mayer, IA; Nanda, R; Osborne, CK; Pavlick, AC; Rimawi, MF; Rodriguez, AA; Schiff, R; Wang, T | 1 |
| Aglietta, M; Milani, A; Montemurro, F; Sangiolo, D; Valabrega, G | 1 |
| Ahmed, S; Ammannagari, N; Bravin, EN; Patel, A | 1 |
| Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C | 1 |
| Arihiro, K; Awai, K; Date, S; Hirokawa, Y; Iida, M; Kakizawa, H; Kitamura, S; Nakamura, Y; Tatsugami, F; Yamasaki, W | 1 |
| Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Fan, YX; Johnson, GR; Marino, MP; Ou, W; Reiser, J; Shen, Y; Wong, KK; Wong, L; Wu, WJ | 1 |
| Mitrasinovic, PM | 1 |
| Lind, P; Nearchou, A; Polyzos, NP; Valachis, A | 1 |
| Arteaga, CL; Balko, JM; Cheng, H; Cook, RS; Kuba, MG; Owens, P; Perou, CM; Pfefferle, AD; Rexer, BN; Sánchez, V; Young, CD; Zhao, JJ | 1 |
| Kaniwa, N; Saito, Y | 1 |
| Accolla, ML; Castelli, F; Celia, C; Ferrari, M; Fresta, M; Grattoni, A; Paolino, D; Sarpietro, MG | 1 |
| Dewhirst, MW; Geradts, J; Henao, R; Kim, J; Kim, WJ; Kornbluth, S; Kurokawa, M; Liu, L; Lucas, JE; Matsuura, K; Ran, X; Ribar, TJ; Spector, NL; Wang, S; Xia, W | 1 |
| Avery, M; Coombes, RC; Di Leo, A; Frampton, AE; Krell, J; Payne, R; Pestrin, M; Reise, J; Stebbing, J; Woodley, L | 1 |
| Aldrich, AJ; Allensworth, JL; Devi, GR; Ingram, SM; Sexton, JZ; Smith, GR; Williams, KP | 1 |
| Ellis, CE; Fujii, H; Gagnon, RC; Iwata, H; Katsura, K; Masuda, N; Mukai, H; Nakamura, S; Nishimura, Y | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Goldstein, LA; Han, J; Hou, W; Lu, C; Rabinowich, H; Stolz, DB; Watkins, SC | 1 |
| Iyengar, NM; Morris, PG | 1 |
| Chalfant, CE; Garcia-Vargas, A; Park, MA; West, NW | 1 |
| Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X | 1 |
| Cameron, D; Krop, I; Piccart, M; Zardavas, D | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| Chang, JC; Osborne, CK; Parma, J; Pavlick, A; Rimawi, M; Schiff, R; Trivedi, MV | 1 |
| Brown, C; De Souza, P; Fox, P; Gebski, V; Hudson, M; Lee, CK; Lord, S | 1 |
| Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W | 1 |
| Ariad, S; Geffen, DB; Geva, S; Lazarev, I | 1 |
| Chen, S; Feng, D; Han, T; Jiang, R; Liu, X; Ma, Y; Qiao, H; Wei, Y; Wu, L; Zhang, J; Zhang, S; Zhang, Y; Zhu, X | 1 |
| Albanell, J; Dalmases, A; Rojo, F; Rovira, A | 1 |
| Lou, L; Quan, H; Wang, L; Wang, Q; Xie, C; Zhao, J | 1 |
| Gradishar, WJ | 1 |
| Azria, D; Braccini, AL; Ferrero, JM; Jacot, W; Romieu, G; Thezenas, S | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Geyer, JR; Gilbertson, RJ; Goldman, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Daschil, N; Datta, S; Doppler, W; Hannesdóttir, L; Koller, JB; Müller-Holzner, E; Parajuli, N; Philipp, S; Sexl, V; Stoitzner, P; Tripp, CH; Tymoszuk, P; Villunger, A; Wasmer, MH; Wiegers, GJ | 1 |
| Bastida, CC; Falchook, GS; Kurzrock, R; Lippman, SM | 1 |
| Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T | 1 |
| Bang, YJ; Han, SW; Hwang, D; Im, SA; Jeong, EG; Kim, HP; Kim, TY; Lee, MY; Song, SH | 1 |
| Piccart, M | 1 |
| Burris, HA; Crown, J; DeSilvio, M; Diéras, V; Espie, M; Kennedy, MJ; Koch, KM; Kothari, D; Lau, MR; Marty, M; Tresca, P | 1 |
| Guan, X; Gustafsson, JÅ; Strom, A; Tang, L; Wang, Y | 1 |
| Bessonov, AA; Bozhok, AA; Manikhas, AG; Nikolaev, KS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR | 1 |
| Baselga, J; Jin, C; Kharbanda, A; Kharbanda, S; Kufe, D; Panchamoorthy, G; Raina, D; Rajabi, H; Scaltriti, M; Uchida, Y | 1 |
| Aldape, KD; Ding, Z; Guo, H; Huang, S; Huang, WC; Lowery, FJ; Sahin, AA; Steeg, PS; Wang, H; Yu, D; Zhang, C; Zhang, L; Zhang, S | 1 |
| Andrianifahanana, M; Becker, J; Edens, M; Gupta, SK; Leof, EB; Maidl, E; Rahimi, RA; Repellin, CE; Wilkes, MC; Wittenberger, J; Yin, X | 1 |
| Arteaga, CL; Bialucha, CU; Collins, SD; Defazio-Eli, L; Ettenberg, SA; Garrett, JT; Kurupi, R; Sheng, Q; Sutton, CR; Wallweber, J | 1 |
| Boddapati, S; Gray, JW; Iacovides, DC; Johnson, AB; Korkola, J; Wang, N | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Komoto, M; Murata, A; Nakata, B | 1 |
| Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B | 2 |
| Du, JY; Kirouac, DC; Lahdenranta, J; McDonagh, CF; Nielsen, UB; Onsum, MD; Overland, R; Pace, E; Paragas, V; Yarar, D | 1 |
| Furuya, T; Ito, Y; Kodera, Y; Kondo, E; Murakami, H; Nakanishi, H; Oshima, Y; Tanaka, H | 1 |
| Arribas, J; Baselga, J; Caratù, G; De Mattos-Arruda, L; Felip, E; Grueso, J; Hernández-Losa, J; Nuciforo, P; Parra, JL; Prudkin, L; Puente, XS; Scaltriti, M; Seoane, J; Serra, V; Silberschmidt, D; Vivancos, A | 1 |
| Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K | 1 |
| Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C | 1 |
| Basaran, G; Benekli, M; Cetin, B; Eralp, Y; Isikdogan, A; Karaca, H; Kucukoner, M; Onur, H; Ozkan, M; Saip, P; Sen, F; Un, O | 1 |
| Ambudkar, SV; Cheng, HW; Hsiao, SH; Huang, YH; Li, YQ; Luo, SY; Sim, HM; Tuo, WC; Wu, CP | 1 |
| Barker, HE; Chang, J; Cox, TR; Erler, JT; Martens, JW; Nicolau, MM; Wetterskog, D | 1 |
| Abdulkarim, B; Bhatnagar, P; Graham, K; Lesniak, D; Sabri, S; Suresh, M; Xu, Y | 1 |
| Fu, Y; He, Q; Lin, G; Lou, J; Ma, J; Wu, Y; Yang, B; Zheng, L; Zhu, H | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Awada, A; Buttice, A; Cardoso, F; D'Hondt, V; de Azambuja, E; Devriendt, D; Gil, T; Lalami, Y; Lebrun, F; Lemort, M; Moulin, C; Paesmans, M; Piccart-Gebhart, M; Rossari, J; Sotiriou, C; Zardavas, D | 1 |
| Adak, S; Landgraf, R; Macdonald-Obermann, JL; Pike, LJ; Piwnica-Worms, D | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S | 1 |
| Abbruzzi, A; Chen, C; Come, SE; Dang, CT; Hudis, CA; Iyengar, NM; Lehman, R; Lin, N; Morris, PG; Moy, B; Norton, L; Oeffinger, KC; Patil, S; Steingart, R; Winer, EP | 1 |
| Bacus, S; Cheng, Q; Gallagher, RI; Gwin, WR; Liu, L; Lyerly, HK; Osada, T; Petricoin, EF; Spector, NL; Wulfkuhle, JD; Xia, W; Yang, X; Zhao, S | 1 |
| Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A | 1 |
| Becker, MN; Copland, JA; Kreinest, PA; Marlow, LA; Vonroemeling, CA; Williams, CR; Wu, KJ | 1 |
| Christensen, SD; Chung, V; Gadgeel, SM; Hoering, A; Kingsbury, L; Kurzrock, R; Lew, DL; LoRusso, P; Smith, DC; Synold, TW | 1 |
| Aura, CM; Azim, HA; Baselga, J; Bavington, M; Cure, H; de Azambuja, E; Di Cosimo, S; Domont, J; Eidtmann, H; Ellis, C; Ferro, A; Gamez, C; Gebhart, G; Ignatiadis, M; Maetens, M; Piccart-Gebhart, M; Rothé, F; Rouas, G; Sotiriou, C; Toral-Peña, JC; Vuylsteke, P | 1 |
| Cho, SY; Choi, J; Hwang, JJ; Jang, SJ; Kim, CS; Lee, G; Lee, JH; Lee, SW; Lim, C; Seo, J; Song, JY | 1 |
| Aglietta, M; Baselga, J; Donadio, M; Galván, P; Montemurro, F; Peraldo-Neia, C; Prat, A; Rossi, V; Sapino, A; Scaltriti, M; Sperinde, J; Valabrega, G | 1 |
| Kümler, I; Nielsen, DL; Tuxen, MK | 1 |
| Hoving, S; Russell, NS; Seemann, I; Song, JY; Stewart, FA; te Poele, JA | 1 |
| Bhosle, J; Hartley, JA; Hochhauser, D; Kiakos, K; Makris, A; Porter, AC; Wu, J | 1 |
| Aktan, G; Baselga, J; Coccia-Portugal, MA; Cortés, M; Cure, H; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Fauria, K; Flamen, P; Gámez, C; Garcia, C; Gebhart, G; Holmes, E; Kim, SB; Piccart, M; Robles, J; Van Dooren, V; Vuylsteke, P | 1 |
| Johnston, SR | 1 |
| Atkins, JN; Azar, CA; Baez-Diaz, L; Bandos, H; Bear, HD; Brufsky, AM; Costantino, JP; Farrar, WB; Fehrenbacher, L; Geyer, CE; Mamounas, EP; Margolese, RG; Paik, S; Rastogi, P; Robidoux, A; Sarwar, S; Shibata, HR; Swain, SM; Tang, G; Wolmark, N | 1 |
| Araki, M; Ariki, S; Hasegawa, Y; Ikeda, Y; Kuroki, Y; Nishitani, C; Tajiri, M; Takahashi, M; Takamiya, R; Taniguchi, N; Wada, Y; Yamaguchi, Y | 1 |
| Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ | 1 |
| Gyõrffy, B; Mihály, Z | 1 |
| Sato, Y; Takakura, N; Yashiro, M | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Fan, C; Guo, Z; Li, Y; Lin, D; Yang, S; Yang, Y; Zhang, L; Zhao, S; Zhu, J | 1 |
| Laoui, D; Van Ginderachter, JA; Van Overmeire, E | 1 |
| Bai, YZ; Chen, L; Kou, DQ; Li, R; Li, XR; Wang, JD; Wang, QS | 1 |
| Candon, D; Crown, J; Healy, J | 1 |
| Barroso-Sousa, R; de Melo Gagliato, D; Mano, MS; Santana, IA; Testa, L | 1 |
| Chough, C; Joung, M; Kim, ES; Lim, JW; Maeng, HJ; Shim, CK; Shim, WS | 1 |
| Akça, Z; Büyükçelik, A; Erden, A; Mutlu, H | 1 |
| Cecil, DL; Disis, ML; Gad, E; Herendeen, DR; Lai, VP; Lubet, RA; O'Meara, MM; Park, KH; Treuting, PM | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Bastida, CC; Falchook, GS; Jiang, Y; Kurzrock, R; Moulder, SL; Wheler, JJ | 1 |
| Gao, S; Liu, ZL; Long, XH; Luo, QF; Peng, AF; Wen, HC; Zhang, GM; Zhang, L; Zhou, RP; Zhou, Y | 1 |
| Mehta, A; Tripathy, D | 1 |
| Li, J; LoRusso, P; Wiegand, R; Wu, J | 1 |
| Hardy, KD; Nelson, SD; Papageorgiou, I; Rettie, AE; Unadkat, JD; Wahlin, MD | 1 |
| Fuentes, G; Pereira, M; Verma, CS | 1 |
| Bellon, JR; Come, SE; Eichler, AF; Eisenberg, E; Freedman, RA; Gelman, RS; Harris, GJ; Henderson, MA; Ligibel, JA; Lin, NU; Macdonald, SM; Mahadevan, A; Mayer, EL; Moy, B; Ramakrishna, N; Storniolo, AM; Winer, EP; Younger, J | 1 |
| Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF | 1 |
| Bode, AM; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Normanno, N | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S | 1 |
| Althaus, B; Diéras, V; Fang, L; Guardino, E; Hurvitz, SA; Lalla, D; Miles, D; Sohn, JH; Welslau, M | 1 |
| Fujii, H; Izawa, S; Kiessling, R; Kono, K; Kua, LF; Mimura, K; Mueller, A; Seliger, B; Shiraishi, K; So, J; Yong, WP | 1 |
| Bundred, NJ; Clarke, RB; Farnie, G; Johnson, RL; Williams, KE | 1 |
| Agbor-Tarh, D; Aktas, B; Azim, HA; Baselga, J; Bradbury, I; de Azambuja, E; Di Cosimo, S; Dinh, P; Dreosti, L; Eidtmann, H; Greger, JG; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Piccart, M; Smith, I; Vuylsteke, P | 1 |
| Brady, SW; Seok, D; Wang, H; Yu, D; Zhang, J | 1 |
| Fan, Y; Li, HH; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
| Cho, BK; Han, SW; Kang, MJ; Kim, HP; Kim, TY; Lee, YY; Yi, EC | 1 |
| Galichet, A; Müller, EJ; Rüegg, S; Sayar, BS; Schmidt, E; Sibilia, M; Siffert, M; Suter, MM | 1 |
| Bannykh, S; Ben-Shlomo, A; Bonert, V; Carmichael, J; Cook-Wiens, G; Cooper, O; Lim, S; Mamelak, A | 1 |
| Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G | 1 |
| Anderson, T; Blum, JL; Danso, M; Espina, V; Florance, A; Holmes, FA; Krekow, L; Liotta, LA; Mahoney, J; McIntyre, KJ; Nagarwala, YM; O'Shaughnessy, JA; Osborne, CR; Pippen, J | 1 |
| Bhujanga Rao, AK; Jyothiprasad, R; Nanubolu, JB; Ravikumar, K; Sridhar, B | 1 |
| Bailey, ST; Bowman, T; Brown, M; Choi, YJ; Debajit, KB; Foley, KM; Iglehart, JD; Kochupurakkal, B; Maulik, G; Miron, A; Miron, PL; Rodig, SJ; Tian, R | 1 |
| Arya, N; Botbyl, J; Cartee, L; Chu, QS; Devriese, LA; Koch, KM; Ma, WW; Matthys, GM; Mergui-Roelvink, M; Orford, KW; Robidoux, A; Schellens, JH; Stephenson, JJ | 1 |
| Miller, TW | 1 |
| Agboto, VK; Koumangoye, RB; Nangami, GN; Ochieng, J; Sakwe, AM; Thompson, PD | 1 |
| Bozzi, F; Conca, E; Dagrada, G; Gronchi, A; Manenti, G; Messina, A; Panizza, P; Pierotti, MA; Pilotti, S; Stacchiotti, S; Tamborini, E | 1 |
| Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Wang, Y; Wei, Y | 1 |
| Fu, W; Gao, X; Li, H; Tan, W; Wu, H; Xu, Q | 1 |
| Calvani, N; Ciccarese, M; Cinieri, S; Fedele, P; Forcignanò, RC; Lorusso, V; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F | 1 |
| Andrighetto, S; Chen, B; Dell'orto, P; Dueck, AC; Gelber, RD; Jackisch, C; Jenkins, RB; McCullough, AE; Perez, EA; Piccart-Gebhart, MJ; Reinholz, MM; Russo, L; Untch, M; Viale, G | 1 |
| Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Du, C; Huang, Y; Li, F; Mahato, RI; Wang, H | 1 |
| Bian, L; Du, G; Guo, YF; Jiang, ZF; Li, W; Song, ST; Wang, T; Wu, SK; Zhang, HQ; Zhang, SH | 1 |
| Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Xi, Z; Zhang, Q | 1 |
| Baselga, J; Chandarlapaty, S; de Stanchina, E; Huang, X; Jiang, X; Liu, N; Monian, P; Qin, AC; Rodrik-Outmezguine, V; Rosen, N; Schneider, C; Toy, W; Will, M; Yao, Z | 1 |
| Eroglu, Z; Somlo, G; Tagawa, T | 1 |
| Tolaney, S | 1 |
| Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN | 1 |
| Alba, E; Albanell, J; Barnadas, A; Burgués, O; Caballero, R; Calvo, L; Cámara, MC; Carrasco, E; de la Haba, J; Lluch, A; Porras, I; Ramos, M; Rojo, F; Sánchez-Rovira, P; Tibau, A | 1 |
| Ando, Y; Araki, K; Inada-Inoue, M; Ishida, H; Kawada, K; Mitsuma, A; Mizuno, K; Nagamatsu, K; Nagashima, F; Sasaki, Y; Sawaki, M; Sunakawa, Y; Takekura, A; Yamashita, K; Yokoyama, T | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Al-Awar, R; Aman, A; Chung, PE; Deng, T; Egan, SE; Jiang, Z; Joseph, B; Ketela, T; Liu, JC; Moffat, J; Rottapel, R; Schachter, NF; Uehling, D; Zacksenhaus, E | 1 |
| Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q | 1 |
| Arteaga, CL; Bi, X; Guo, M; Mahadevan-Jansen, A; Rexer, B | 1 |
| Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Downing, SR; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ | 1 |
| Gavine, P; Gu, Y; Liu, C; Liu, YJ; Lv, J; Ni, X; Qian, J; Qian, Z; Shen, D; Su, X; Sun, Y; Xu, Y; Yin, X; Zhan, P; Zhang, J; Zhang, T | 1 |
| Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF | 1 |
| Şendur, MA; Uncu, D; Zengin, N | 1 |
| Beyer, WF; Gooden, D; Liu, L; Soderblom, EJ; Spector, NL; Toone, EJ; Walder, H; Xia, W; Zhao, S | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E | 1 |
| Breslin, S; Corcoran, C; Crown, J; Ghobrial, IM; Gogarty, M; O'Driscoll, L; Rani, S | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| An, Z; Dunne, LW; Fan, X; Huang, Z; Meng, W; Zhang, N; Zhang, Q | 1 |
| Axelrod, MJ; Conaway, MR; Gioeli, DG; Gordon, V; Jameson, MJ; Leimgruber, SS; Mendez, RE; Sharlow, ER; Weber, MJ | 1 |
| Cardinali, B; Crinò, L; Del Mastro, L; Foglietta, J; Gori, S; Inno, A; Lunardi, G | 1 |
| Croft, SL; Sanderson, L; Yardley, V | 1 |
| Cañamares-Orbis, I; Cortijo-Cascajares, S; Ferrari-Piquero, JM; García-Muñoz, C; Goyache-Goñi, MP | 1 |
| Brady, SW; Chang, CC; Chang, J; Ellis, K; Esteva, FJ; Landis, MD; Muller, WJ; Priya, P; Sahin, O; Wang, H; Wang, Q; Wong, ST; Yu, D; Zhang, Q; Zhu, R | 1 |
| Cardon, LR; Cox, CJ; Curran, J; Ejlertsen, B; Finkelstein, DM; Goss, PE; McDonnell, SK; Parham, LR; Rappold, E; Schaid, DJ; Spraggs, CF | 1 |
| Awasthi, S; Hamburger, AW | 1 |
| Chen, CH; Chen, WS; Chen, YJ; Hsia, TC; Hsu, KW; Hsu, MH; Huang, WC; Liu, LC; Tu, CY; Wei, YL; Yeh, MH; Yu, MC | 1 |
| Auerback, G; Chien, AJ; Goga, A; Khanafshar, E; Koch, KM; Melisko, ME; Moasser, MM; Munster, PN; Ordovas, K; Park, JW; Rugo, HS | 1 |
| Cao, KI; Kirova, YM | 1 |
| Inoue, T; Iyoda, T; Uetsuka, Y; Yamamoto, W | 1 |
| Hayashi, M; Hironaka, H; Morita, N; Orita, M | 1 |
| Arima, Y; Hosonaga, M; Kohno, N; Saya, H; Sugihara, E | 1 |
| Nolting, M; Schneider-Merck, T; Trepel, M | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Altun, A; Altun, GG; Babacan, N; Bahceci, A; Kacan, SB; Kacan, T; Sarac, B; Seker, MM | 1 |
| Chang, TC; Chao, A; Chao, AS; Chou, HH; Hsueh, S; Huang, HJ; Lai, CH; Lee, YS; Lin, CY; Wang, TH; Wu, TI | 1 |
| Chen, M; Hu, L; Yang, X; Zhang, Q | 1 |
| Chen, J; Dokmanovic, M; Hirsch, DS; Shen, Y; Wu, WJ; Wu, Y | 1 |
| Fabi, A; Mottolese, M; Segatto, O | 1 |
| Baumann, C; Gusenbauer, S; Kéri, G; Őrfi, L; Pénzes, K; Szabadkai, I; Torka, R; Ullrich, A | 1 |
| Bang, YJ; Chung, HC; Chung, IJ; Doi, T; Feng, JF; Kobayashi, M; Li, J; Miwa, H; Mukaiyama, A; Ohtsu, A; Omuro, Y; Qin, SK; Satoh, T; Sun, GP; Tsuji, A; Wang, JW; Xu, JM; Xu, RH; Yeh, KH | 1 |
| Moasser, MM | 1 |
| Ardern-Holmes, S; de Souza, P; Lim, SH; McCowage, G | 1 |
| Bianco, R; D'Amato, C; D'Amato, V; Damiano, V; De Placido, S; Formisano, L; Iommelli, F; Marciano, R; Nappi, L; Parsons, SJ; Raimondo, L; Rosa, R; Scorziello, A; Troncone, G; Veneziani, B | 1 |
| Gao, HL; He, Q; Ruan, SB; Zhang, L; Zhang, QY; Zhang, S | 1 |
| Boehm, JS; Hahn, WC; Izzo, F; Kim, SY; Luo, L; Moody, SE; Schinzel, AC; Singh, S; Strickland, MR; Thomas, SR; Wang, ZC | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Bartholomeusz, C; Hortobagyi, GN; Humphries, J; Lee, J; Mansour, O; Ordentlich, P; Ueno, NT | 1 |
| Balduzzi, S; D'Amico, R; Guarneri, V; Mantarro, S; Moja, L; Pistotti, V; Tagliabue, L | 1 |
| Abdel-Rahman, O; Fouad, M | 3 |
| Chen, YJ; Chi, CW; Huang, HL; Su, WC | 1 |
| Browne, BC; Clynes, M; Conlon, NT; Crown, J; Dowling, P; Henry, M; McDermott, MS; Meleady, P; O'Brien, NA; O'Donovan, N; Slamon, DJ | 1 |
| Akar, E; Kilickap, S; Mutlu, H; Tural, D | 1 |
| Clozel, T; de Martino, M; Elemento, O; Klatte, T; Krzywinski, M; Rieken, M; Rouprêt, M; Shariat, SF; Xylinas, E; Zhuang, D | 1 |
| Chang, J; Fang, Q; Geng, R; Ji, D; Li, J; Liu, L; Liu, R; Wang, C; Wang, J; Wu, Z; Xiong, L; Zhang, Z; Zhu, D | 1 |
| Hao, Y; Huang, H; Lang, K; Menzin, J; Paly, VF; Sasane, M | 1 |
| Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ | 1 |
| Balansky, R; Camoirano, A; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; Izzotti, A; La Maestra, S; Longobardi, M; Micale, RT; Steele, VE | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM; Wignall, A | 1 |
| Davis, M; Eldridge, S; Furniss, M; Guo, L; Hamre, J; Mussio, J | 1 |
| DeSilvio, M; Ellis, C; Guan, Z; Jiang, Z; Leigh, M; Russo, M; Shen, Z; Tong, Z; Xu, B; Yang, J | 1 |
| Awada, A; Bogaerts, J; Brain, E; Cardoso, F; Fumoleau, P; Hayward, L; Koch, KM; Lokiec, F; Marréaud, S; Rezai, K; Werutsky, G | 1 |
| Ambartsumian, N; Andersen, SH; Brix, DM; Bundgaard Clemmensen, K; Jäättelä, M; Kallunki, T; Rafn, B | 1 |
| Bang, YJ; Cha, Y; Han, SW; Han, W; Im, SA; Kim, TY; Noh, DY; Oh, DY; Park, IA; Seol, H | 1 |
| Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK | 1 |
| Fasching, PA; Gade, S; Loibl, S; Lübbe, K; Mau, C; Müller, V; Pantel, K; Schem, C; Schwarzenbach, H; Schwedler, K; Steinbach, B; Untch, M; von Minckwitz, G | 1 |
| Chen, YF; Fu, LW; Hu, YP; Huang, ZC; Ma, SL; Wang, F; Wang, XK | 1 |
| Brunton, VG; Byron, A; Creedon, H; Hayward, L; Klinowska, T; Main, J | 1 |
| Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W | 1 |
| Joensuu, H | 1 |
| Azim, HA; Barrios, CH; Baselga, J; Boyle, F; de Azambuja, E; Di Cosimo, S; Dreosti, L; Eidtmann, H; Eniu, A; Gelber, RD; Gorbunova, V; Holmes, AP; Holmes, E; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Kuemmel, S; Lang, I; Perez, EA; Piccart-Gebhart, M; Smith, I; Swaby, RF; Tavartkiladze, N; Untch, M; Vuylsteke, P; Xu, B | 1 |
| He, J; Li, YS; Wei, X; Yu, FF; Zhang, TY; Zhang, X; Zhang, XJ | 1 |
| Calvo, I; Estévez, LG; Fernández-Abad, M; García, E; Herrero, M; Hidalgo, M; Lopez Ríos, F; Marcos, M; Márquez, C; Miró, C; Perea, S; Suarez-Gauthier, A | 1 |
| Annunziato, S; Benedicenti, F; Brasca, S; Calabria, A; Gallina, P; Montini, E; Naldini, L; Ranzani, M | 1 |
| Andre, F; Denkert, C; Dohnal, K; Dykgers, A; Eidtmann, H; Fasching, PA; Gade, S; Guo, S; Heinrichs, C; Huober, J; Khandan, F; Lehmann, A; Lindner, JL; Loi, S; Loibl, S; Nekljudova, V; Paepke, S; Pfitzner, B; Rezai, M; Schneeweiss, A; Sinn, P; Sotiriou, C; Untch, M; von Minckwitz, G; Zahm, DM | 1 |
| Dranitsaris, G; Lacouture, ME | 1 |
| Muggia, F; Teplinsky, E | 1 |
| Ashrafian, H; Athanasiou, T; Hayashida, T; Jinno, H; Kitagawa, Y; Matsumoto, A; Murata, T; Nagayama, A; Okabayashi, K; Seki, T; Takahashi, M | 1 |
| Halmos, B; Hibshoosh, H; Jin, C; Li, G; Wang, X | 1 |
| Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z | 1 |
| Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S | 2 |
| Hamachi, I; Kioi, Y; Kiyonaka, S; Kuwata, K; Takaoka, Y; Tamura, T; Yamaura, K | 1 |
| Dagli, AF; Erman, F; Gundogdu, B; Isik, A; Karatas, A; Koca, SS; Ozgen, M; Sahin, K | 1 |
| Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B | 1 |
| Shawky, H; Tawfik, H | 1 |
| Borger, DR; Byron, VF; DiGloria, CM; Foster, R; Groeneweg, JW; Growdon, WB; Hernandez, SF; Kim, M; Lopez, H; Rueda, BR; Scialabba, V; Tambouret, R; Zhang, L | 1 |
| Asztalos, S; Bellis, AD; Bluver, D; Broadbelt, LJ; Dubbury, SJ; Jeruss, JS; Mui, MD; Peñalver Bernabé, B; Saez-Rodriguez, J; Shea, LD; Shin, S; Tonetti, DA; Weiss, MS | 1 |
| Fang, L; Gou, S; Lyu, A | 1 |
| Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y | 1 |
| Corcoran, C; O'Driscoll, L | 1 |
| Falchook, GS; Fu, S; Hong, DS; Huang, M; Janku, F; Jiang, Y; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Finigan, JH; Kern, JA; Mason, RJ; Mishra, R; Shatat, MA; Thaikoottathil, JV; Vasu, VT | 1 |
| Barry, WT; Blackwell, KL; Burstein, HJ; Chew, HK; Cirrincione, CT; Hudis, CA; Lake, DE; Ma, C; Tolaney, SM; Winer, EP | 1 |
| Hao, Y; Huang, H; Lang, K; Lin, I; Menzin, J; Rogerio, JW | 1 |
| Bass, AJ; Fox, C; Hong, SW; Hong, YS; Kim, J; Ma, Q; Pectasides, E; Peng, S; Stachler, MD; Thorner, AR; Van Hummelen, P; Wong, GS | 1 |
| Baron-Hay, S; Bauwens, A; Chan, A; Craft, P; de Boer, R; Kotasek, D; Redfern, A; Shannon, C; Townsend, A; Webb, S | 1 |
| Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M | 1 |
| Araki, T; Cooper, O; Fukuoka, H; Kano, M; Liu, X; Melmed, S; Tone, M; Tone, Y | 1 |
| A'Hern, R; Bliss, JM; Bundred, N; Coombes, G; Detre, S; Dowsett, M; Evans, A; Harper-Wynne, C; Haynes, BP; Hills, M; Johnston, SR; Leary, A; Sahoo, R; Smith, I | 1 |
| Cao, S; Jiang, X; Wang, F; Wang, Y; Wei, Y; Xiong, Y; Xu, S; Zhang, Q; Zhang, S; Zou, A | 1 |
| Arold, ST; Bartholomeusz, C; Blachno, KV; Boulbes, DR; Brady, SW; Chang, WC; Chauhan, GB; Deng, N; Esteva, FJ; Hsu, JM; Huang, TH; Hung, MC; Jin, Q; Ladbury, JE; Stone, S; Yu, D | 1 |
| Bańkowski, K; Gniazdowska, E; Koźmiński, P; Królicki, L; Łuniewski, W | 1 |
| Bessadóttir, M; Eccles, S; Gowan, S; Ogmundsdóttir, HM; Ögmundsdóttir, S; Skúladóttir, EÁ | 1 |
| Coussy, F; Cuvier, C; Espié, M; Giacchetti, S; Hocini, H; Teixeira, L | 1 |
| Cao, PR; Huang, W; Kong, YL; Wu, QD; Xu, JH; Ye, M; Zhang, M; Zheng, W | 1 |
| Bodmer, A; Bonnefoi, H; Brain, E; Cameron, D; Chakiba, C; Jacot, W; Jerusalem, G; Matos, E; Messina, CG; Moldovan, C; Petit, T; Quenel-Tueux, N; Saghatchian, M; Slaets, L; Tredan, O; Venat-Bouvet, L; Vuylsteke, P; Zaman, K | 1 |
| Agbor-Tarh, D; Arribas, J; Aura, C; Baselga, J; Bradbury, I; Campbell, C; Chenna, A; Cortes, J; de Azambuja, E; Eidtmann, H; Ellis, C; Harbeck, N; Jimenez, J; Nuciforo, P; Parra, JL; Piccart, M; Prudkin, L; Pusztai, L; Scaltriti, M; Serra, V; Sperinde, J; Winslow, J | 1 |
| Bertucci, F; Gonçalves, A; Monneur, A; Viens, P | 1 |
| Ali, SM; Chmielecki, J; Frampton, GM; Lipson, D; Miller, VA; Morosini, D; Palma, N; Palmer, GA; Ross, JS; Stephens, PJ; Wang, K; Yelensky, R | 1 |
| He, Z; Li, J; Li, X; Lin, B; Tang, X; Zhou, K | 1 |
| Dehghan Kelishady, P; Dorkoosh, FA; Kobarfard, F; Ravar, F; Saadat, E | 1 |
| Haskins, JW; Nguyen, DX; Stern, DF | 1 |
| Abt, MA; Hill, EG; Yeh, ES | 1 |
| Fujisawa, T; Hayashi, N; Honda, Y; Hozumi, Y; Ishida, M; Iwata, H; Kanbayashi, C; Kondo, N; Masuda, N; Matsui, A; Naito, Y; Nakamura, R; Niikura, N; Oshitanai, R; Saji, S; Takashima, S; Tsuneizumi, M; Watanabe, K; Yamauchi, H; Yasojima, H | 1 |
| Carr, A; Cremona, M; Elster, N; Eustace, AJ; Hennessy, BT; Morgan, C; O'Grady, A; Toomey, S | 1 |
| Patil, A; Sherbet, GV | 1 |
| Aleixo, SB; Arantes, H; Caleffi, M; Figueira, AC; Gutierrez, C; Nunes de Matos Neto, J; Osborne, CK; Reiriz, AB; Rimawi, MF; Rozas, AA; Solca, F; Souza, SC; Uttenreuther-Fischer, MM | 1 |
| Guan, X; Nie, W; Shao, J; Song, W; Wang, Y; Zhang, W; Zhu, A | 1 |
| Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W | 1 |
| Anderson, JC; Arafat, W; Bonner, JA; Denton, AJ; Dobelbower, MC; Dussaq, AM; Gilbert, AN; Minnich, DJ; Rohrbach, TD; Welaya, K; Willey, CD | 1 |
| Dittrich, C; Fridrik, MA; Gampenrieder, SP; Greil, R; Hufnagl, C; Lang, A; Mlineritsch, B; Petru, E; Pircher, M; Ressler, S; Rinnerthaler, G; Thaler, J; Ulmer, H; Weltermann, A | 1 |
| Aura, C; Baselga, J; Bernards, R; Bosma, AJ; de Azambuja, E; de la Peña, L; Díaz-Delgado, MC; Eidtmann, H; Ellis, C; Fumagalli, D; Harbeck, N; Holmes, E; Jimenez, J; Loi, S; Majewski, IJ; Mittempergher, L; Nuciforo, P; Piccart-Gebhart, M; Prudkin, L; Schultz, N; Sotiriou, C | 1 |
| Byrn, S; Chen, X; Lubach, JW; Nie, H; Song, Y; Yang, X | 1 |
| Clurman, BE; Faltermeier, CM; Mendelsohn, L; Porter, PL; Roberts, JM; Zhao, H | 1 |
| Osborne, CK; Rimawi, MF; Schiff, R | 1 |
| Buonanno, A; Canfield, K; Cook, RS; Hu, H; Kurokawa, M; Li, J; Liby, KT; Morrison, MM; Schiff, R; Ung, M; Vullhorst, D; Wells, W; Wilkins, OM; Williams, CR | 1 |
| Karakashev, SV; Reginato, MJ | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V | 1 |
| Chen, ZT; Xie, QC; Zhang, L; Zhu, B; Zhuo, WL | 1 |
| Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B | 1 |
| Wang, H; Yang, B; Zhang, H | 1 |
| Marchetti, D; Ngo, JA; Wetzel, MD; Zhang, L | 1 |
| Jiang, Z; Li, L; Pan, Z; Yang, Y; Yue, Z | 1 |
| Ahmed, S; Sami, A; Xiang, J | 1 |
| Chan, EC; Chan, JC; Hardy, KD; Ho, HK | 1 |
| Akpolat, N; Bulut, H; Demir, T; Kaya, MK; Turgut, B | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Franckena, M; Kraan, J; Sleijfer, S; van Doorn, L; van Meerten, E; Westermann, A; Wiemer, E | 1 |
| Bachelot, T; Bernard-Marty, C; Bonneterre, J; Conforti, R; Le Rhun, E; Taillibert, S | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Buffa, FM; Harris, AL; Kong, A; Leung, WY; Li, JL; Roxanis, I; Sheldon, H | 1 |
| Brady, SW; Tsai, MH; Yu, D; Zhang, J | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Jing, T; Pang, X; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zheng, X | 1 |
| Kaneko, T; Lau, MR; Lunec, J; Margetts, J; Novello, S; Nutt, J; Plummer, R; Ramlau, R; Reck, M; Scagliotti, GV; Thomas, M | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Bartsch, R; Bergen, ES; Berghoff, AS; Preusser, M; Rudas, M | 1 |
| Kim, EH; Kim, H; Lee, S; Park, Y; Suh, CO | 1 |
| Abdel-Rasoul, M; Friedman, S; Hicks, M; Layman, R; Lustberg, M; Macrae, ER; Mrozek, E; Querry, J; Ramaswamy, B; Shapiro, C; Wesolowski, R | 1 |
| Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L | 1 |
| Amonkar, M; Boyle, FM; Buzdar, AU; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Huang, Y; Kaneko, T; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Wang-Silvanto, J; Williams, LS | 1 |
| Aparicio, S; Boyle, FM; Chapman, JA; Coleman, RE; Connor, AP; Dent, S; Di Leo, A; Ellard, SL; Gelmon, KA; Huntsman, DG; Kaufman, B; Khasanov, R; Lemieux, J; Manikhas, A; Martin, M; Mukai, H; Nomikos, D; Nusch, A; Parulekar, WR; Pritchard, KI; Rizel, S; Santillana, SL; Schwartzberg, LS; Shepherd, LE; Tjulandin, S; Tonkin, K; Whelan, TJ | 1 |
| Agazie, YM; Ammer, AG; Creighton, CJ; Farrugia, MK; Lin, CC; McLaughlin, SL; Ruppert, JM; Salkeni, MA; Sharma, SB; Stoilov, P; Vanderbilt, DB | 1 |
| Brown, AS; Landgraf, R; Liu, W; Wilson, JN | 1 |
| Alloisio, M; Fatuzzo, G; Lorenzi, E; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA | 1 |
| Ameels, H; Aura, C; Baselga, J; de la Peña, L; Eidtmann, H; Ellis, C; Holmes, E; Jimenez, J; Martinez, P; Nuciforo, PG; Piccart-Gebhart, MJ; Prudkin, L; Scaltriti, M | 1 |
| Bouffet, E; DeWire, M; Fisher, P; Foreman, N; Fouladi, M; Gajjar, A; Gilbert, MR; Gilbertson, R; Goldman, S; Hawkins, C; Hwang, EI; Jacobs, C; Khakoo, Y; Liu, D; Rytting, M; Stewart, CF; Turner, DC; Wetmore, C; Yuan, Y | 1 |
| Angus, SP; Beltran, AS; Carey, LA; Chen, X; Collins, KA; Duncan, JS; Earp, HS; Gomez, SM; Granger, DA; Graves, LM; Jin, J; Johnson, GL; Kuan, PF; Miller, SM; Nakamura, K; Parker, JS; Reuther, RA; Sciaky, N; Stuhlmiller, TJ; Zawistowski, JS | 1 |
| Beraldi, E; Bishop, JL; Cordonnier, T; Gleave, ME; Kuruma, H; Nip, KM; Shiota, M; Takeuchi, A; Zoubeidi, A | 1 |
| Awasthi, S; Ezelle, H; Hamburger, AW; Hassel, BA | 1 |
| Abt, MA; Bruce, JS; Ghatnekar, GS; Grek, CL; Rhett, JM; Yeh, ES | 1 |
| Aburatani, H; Fukayama, M; Hoshino, H; Hosoya, Y; Ishikawa, S; Lefor, AK; Matsubara, D; Morishima, K; Niki, T; Saito, S; Sata, N; Ui, T; Yasuda, Y | 1 |
| Mazo, A; Pérez-Torras, S; Urtasun, N; Vidal-Pla, A | 1 |
| Matevossian, A; Resh, MD | 1 |
| Geng, P; Lin, F; Wang, S; Wu, C; Zhang, Q; Zhang, X; Zhou, Y; Zou, H | 1 |
| Amin, DN; Carmena, JM; Chang, YH; Gray, JW; Korkola, J; Moasser, MM; Tomlin, CJ | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Chang, JC; Colon-Otero, G; Dave, B; Patel, TA; Perez, EA; Rodriguez, AA | 1 |
| Bidard, FC; Cottu, P; Escalup, L; Lim, R; Mariani, P; Ng, CK; Norton, L; Pierga, JY; Piscuoglio, S; Reis-Filho, JS; Reyal, F; Sakr, RA; Servois, V; Sigal, B; Vincent-Salomon, A; Wang, L; Weigelt, B | 1 |
| Bolis, M; Fisher, JN; Fratelli, M; Garattini, E; Gianni, M; Goodall, GJ; Kurosaki, M; Lupi, M; Paroni, G; Terao, M; Tsykin, A; Zanetti, A | 1 |
| Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N | 1 |
| Bekki, K; Haarmann-Stemmann, T; Ito, T; Li, W; Matsumura, F; Sweeney, C; Vogel, CF; Vogel, H | 1 |
| Briley, LP; Cox, CJ; Dilthey, A; Iqbal, Z; King, KS; Li, L; McVean, G; Nelson, MR; Newcombe, PJ; Parham, LR; Shen, J; Slater, AJ; Spraggs, CF | 1 |
| Chamness, GC; Chang, JC; Contreras, A; De Angelis, C; Fu, X; Giuliano, M; Gray, JW; Gutierrez, C; Heiser, LM; Herrera, S; Hilsenbeck, SG; Hu, H; Lopez-Tarruella, S; Mao, S; Nardone, A; Osborne, CK; Pavlick, AC; Rimawi, MF; Schiff, R; Trivedi, MV; Wang, NJ; Wang, T; Wang, YC | 1 |
| Chen, Z; Dai, C; Fu, L; Huang, Z; Ma, S; To, K; Wang, F; Wu, X; Zhao, H | 1 |
| Chen, WD; Deng, R; Feng, GK; Ji, J; Jiao, L; Kong, PF; Li, X; Li, YT; Li, ZH; Qian, XJ; Wu, RY; Yu, Y; Zhu, XF | 1 |
| Chun, SY; Kim, S; Kwon, YS; Nam, KS | 2 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Arribas, J; Aura, C; Boehm, M; Burgues, O; Cortés, J; Deeds, J; Lluch, A; Marangoni, E; Martínez-Barriocanal, Á; Morancho, B; Mosher, R; Navarro Jiménez, A; Nuciforo, P; Peg, V; Rubio, IT; Schlegel, R; Tabernero, J; Vicario, R; Zacarias-Fluck, M; Zhang, J | 1 |
| Banno, E; Boku, N; De Velasco, MA; Fujita, Y; Mizukami, T; Nakajima, TE; Nishio, K; Sakai, K; Sogabe, S; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Agelaki, S; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kallergi, G; Kalykaki, A; Markomanolaki, H; Mavroudis, D; Papadaki, MA | 1 |
| Halstead-Nussloch, G; Irie, HY; Ito, K; Katsyv, I; Olcott, W; Park, SH | 1 |
| Ethier, SP; Soloff, AC; Williams, CB; Yeh, ES | 1 |
| Hagihara, K; Hirasawa, M; Izumi, T; Okudaira, N | 1 |
| Sardesai, SD; Storniolo, AM | 1 |
| Blancafort, A; Brugada, R; Campuzano, Ò; Carrión-Salip, D; Giró-Perafita, A; Gómez-Miragaya, J; González-Suárez, E; Massaguer, A; Oliveras, G; Palafox, M; Palomeras, S; Puig, T; Turrado, C | 1 |
| Al-Foheidi, M; Al-Rehaily, S; Darwish, T; Karim, SM; Mahrous, M; Mansour, M; Mokhtar, M; Rizvi, A; Zekri, J | 1 |
| Akhtar, S; Al-Khaldi, AT; Attur, S; Benter, IF; Chandrasekhar, B; Dhaunsi, GS; Sarkhou, F; Yousif, MH | 1 |
| Moser, A; Piwko, C; Pollex, E; Prady, C; Yunger, S | 1 |
| Aderhold, C; Erben, P; Faber, A; Hoermann, K; Hofheinz, RD; Schultz, JD; Umbreit, C; Weiss, C; Wenzel, A | 1 |
| Herman-Antosiewicz, A; Kaczyńska, A; Świerczyńska, J | 1 |
| Arteaga, CL; Barry, WT; Dees, EC; Falkson, CI; Guo, H; Hobday, TJ; Krop, IE; Lin, NU; Mayer, IA; Najita, JS; Nanda, R; Richardson, AL; Rimawi, MF; Ryabin, N; Van den Abbeele, AD; Winer, EP; Wolff, AC; Yap, JT | 1 |
| Huo, ZJ; Liu, K; Liu, P; Pang, B; Wang, SJ; Wang, ZQ; Zuo, WS | 1 |
| Budani, MC; Capone, E; D'Agostino, D; De Cola, A; De Laurenzi, V; Di Ilio, C; Ferracin, M; Lattanzio, R; Negrini, M; Piantelli, M; Sala, G; Stassi, G; Todaro, M; Turdo, A; Veronese, A; Volpe, S | 1 |
| Aura, C; Baselga, J; Bradbury, I; Campbell, C; de Azambuja, E; Denkert, C; Eidtmann, H; Ellis, CE; Loi, S; Michiels, S; Nucifero, P; Nuciforo, P; Piccart-Gebhart, MJ; Salgado, R; Savas, P; Sotiriou, C | 1 |
| Bayani, N; Billig, J; Collisson, EA; Cooper, B; Esch, A; Feiler, H; Gray, JW; Griffith, OL; Heiser, M; Hung, JL; Itani, S; Jakkula, L; Korkola, JE; Kuo, WL; Lu, Y; Mills, GB; Mukherjee, S; Oates, C; Spellman, PT; Thompson, W; Tomlin, C; Wang, NJ; Ziyad, S | 1 |
| Bandai, Y; Ijichi, M; Kusaka, K; Sakata, H; Shibasaki, M; Tanabe, A; Toda, T | 1 |
| Fu, S; George, GC; Henary, H; Hong, DS; Kurzrock, R; Mistry, R; Naing, A; Piha-Paul, S; Wheler, J; Zinner, R | 1 |
| Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Teknos, TN; Xie, X; Zhang, M | 1 |
| Casanova, C; Dazzi, C; Mazza, V; Verlicchi, A | 1 |
| Di Luca, A; Henry, M; Meleady, P; O'Connor, R | 1 |
| González, V; Hernández-García, S; Pandiella, A; Sanz, E | 1 |
| Bettelli, S; Bicciato, S; Bisagni, G; Cagossi, K; Conte, P; Crescenzo, R; Dieci, MV; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Maiorana, A; Musolino, A; Sarti, S; Tagliafico, E | 1 |
| Fouad, TM; Piccart, M; Zardavas, D | 1 |
| Edgerton, SM; He, Z; Huang, J; Liu, B; Lyu, H; Thor, AD | 1 |
| Briley, LP; Byrne, J; Goss, PE; King, KS; Parham, LR; Rappold, E; Spraggs, CF | 1 |
| Dorkoosh, FA; Kelishadi, PD; Ravar, F; Saadat, E | 1 |
| Airhart, S; Bult, C; Davis, RR; de Vere White, RW; Gandara, DR; Ghosh, PM; Gill, P; Keck, J; Lin, TY; Liu, E; Pan, CX; Tepper, CG; Zhang, H | 1 |
| Bianco, R; D'Amato, V; De Placido, S; Formisano, L; Giuliano, M; Raimondo, L; Rosa, R | 1 |
| Nishio, K; Sakai, K; Togashi, Y | 1 |
| Bertotti, A; Catalano, I; Leto, SM; Migliardi, G; Sassi, F; Throsby, M; Torri, V; Trusolino, L; Zanella, ER | 1 |
| Cao, L; Guan, X; Shen, Y; Shi, Y; Sun, Z; Zhang, W | 1 |
| Esteva, FJ; Teplinsky, E | 1 |
| Christgen, M; Dorssers, LC; Kreipe, H; Lehmann, U; Looijenga, LH; van Agthoven, T | 1 |
| Harbeck, N | 1 |
| LaBarge, MA; Lakins, J; Lin, CH; Park, C; Pelissier, FA; Weaver, VM; Zhang, H | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Alunni-Fabbroni, M; de Gregorio, N; Fehm, T; Friedl, TW; Hartkopf, A; Huober, J; Janni, W; Meier-Stiegen, F; Müller, V; Pantel, K; Rack, B; Schneeweiss, A; Schochter, F; Scholz, C; Schramm, A; Taran, FA; Trapp, E; Wallwiener, D | 1 |
| Choi, JD; Hwang, SG; Jang, CS; Kim, JK; Kim, SY; Kim, YR; Kwon, K; Lee, YS; Myeong, HS; Noh, YH; Park, TH; Ro, YT | 1 |
| Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN | 1 |
| Chen, S; Ding, L; Lai, X; Qiao, H; Wen, A; Ye, M; Yu, S; Zhang, J; Zhu, X | 1 |
| Bitterman, H; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A; Yerushalmi, R | 1 |
| He, Z; Li, G; Li, J; Lin, Y; Qiu, K; Wu, J; Zhu, J | 1 |
| Brain, E; Briggs, K; Caglevic, C; DeSilvio, M; Janni, W; Karaszewska, B; Mahood, K; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Arribas, J; Aura, C; Burrows, J; Cecchi, F; Cortes, J; Ferreres, JC; Garrido-Castro, A; Hembrough, T; Hoos, W; Jimenez, J; Nuciforo, P; Peg, V; Perez-Garcia, J; Scaltriti, M; Thyparambil, S; Vicario, R; Vilaro, M | 1 |
| Nakano, Y; Saita, T; Shin, M; Yamamoto, Y | 1 |
| Christenson, JL; Denny, EC; Kane, SE | 1 |
| Ahn, SE; Bae, DS; Cho, YJ; Choi, JJ; Choi, YL; Jung, K; Kim, BG; Kim, S; Lee, JW; Oh, DY; Oh, E; Park, WY; Song, JY; Song, S | 1 |
| Bodiga, S; Bodiga, VL; Thokala, S; Vemuri, PK | 1 |
| Ding, P; Guo, Q; Jiang, Z; Li, H; Sun, L; Tian, C; Wang, Z; Yuan, Z; Zhang, L; Zhao, Y | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Aprile, G; Bencardino, K; Ciardiello, F; Frau, B; Gambacorta, M; Garufi, C; Graiff, C; Grigioni, W; Labianca, R; Lauricella, C; Leone, F; Lonardi, S; Loupakis, F; Marsoni, S; Martino, C; Mosconi, S; Noe, J; Penaullt-Llorca, F; Pinto, C; Racca, P; Risio, M; Rugge, M; Sartore-Bianchi, A; Siena, S; Tonini, G; Truini, M; Valtorta, E; Veronese, S; Viale, G; Zagonel, V | 1 |
| Baselga, J; Chen, MF; Comen, EA; D'Andrea, GM; Dang, CT; Drullinsky, PR; Fornier, MN; Gajria, D; Goldfarb, SB; Hudis, CA; Iyengar, NM; Lacouture, ME; Lake, DE; Modi, S; Norton, L; Patil, S; Sugarman, SM; Theodoulou, M; Traina, TA; Troso-Sandoval, TA | 1 |
| Dang, CV; Gao, S; Gurung, B; Hua, X; Jin, G; Katona, BW; Kong, XC; Liao, J; Matkar, S; Muhammad, AB; Sharma, P; Wang, L | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Dai, W; He, B; Hu, H; Lin, Z; Wang, J; Wang, X; Zhang, H; Zhang, Q; Zhang, X | 1 |
| Cheow, H; De Silva, N; Fitzgerald, R; Ford, H; Godfrey, E; Hochhauser, D; Jobanputra, M; Lao-Sirieix, P; O'Donovan, M; Paterson, A; Qain, W; Schulz, L; Secrier, M | 1 |
| Diorio, C; Furrer, D; Jacob, S; Sanschagrin, F | 1 |
| Bonnefoi, H; Grellety, T; Italiano, A; Robert, J; Soubeyran, I | 1 |
| Krop, IE; Lin, NU; Liu, P; Roberts, TM; Spangle, JM; Von, T; Wang, Q; Winer, EP; Zhao, JJ | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Takai, N; Tanaka, Y | 1 |
| Gabrielson, A; He, AR; Hwang, JJ; Ley, L; Marshall, JL; Pishvaian, MJ; Weiner, LM; Wu, Z; Zhuang, T | 1 |
| Arteaga, CL; Bose, R; Button, B; Chu, D; Cidado, J; Cimino-Mathews, A; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Kavuri, SM; Konstantopoulos, K; Kyker-Snowman, K; Lauring, J; Manto, KM; Park, BH; Parsons, HA; Red Brewer, M; Rosen, DM; Wong, HY; Yankaskas, CL; Zabransky, DJ | 1 |
| Chen, YJ; Hsiao, YC; Huang, WC; Liu, JF; Tang, CH; Yeh, MH | 1 |
| Bianca, D; Caro, G; Fabbrocini, G; Panariello, L | 1 |
| Amin, DN; Gulizia, N; Moasser, MM; Ruiz-Saenz, A | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Ahmed, N; Amonkar, M; Biswas-Baldwin, N; Bourhis, J; D'Cruz, A; D'Onofrio, I; Dietzsch, S; Dubinsky, P; El-Hariry, I; Ellis, C; Farrell, J; Franklin, N; Harrington, K; Holeckova, P; Horvath, Z; Jain, M; Legenne, P; Manikhas, G; Mehanna, H; Netherway, T; Santillana, S; Sun, Y; Temam, S; Wang-Silvanto, J; Wissel, P | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Pang, X; Wan, X; Zhang, Q; Zhang, Z; Zheng, X | 1 |
| Jiang, M; Liu, TT; Shen, GF; Shi, JH; Wang, Q | 1 |
| Avisar, E; Bacus, S; Beitsch, P; Blackwell, K; Cartee, L; Gittelman, M; Glenn, K; Harris, J; Kimbrough, CL; Koch, KM; Robertson, FC; Smith, DA; Spector, NL | 1 |
| Goel, S; Winer, EP | 1 |
| Afonso, N; Alves, C; Andrade, S; Batel-Marques, F; Cardoso, F; Costa, L; Mendes, D; Passos-Coelho, JL | 1 |
| Eisenstein, M | 1 |
| Coarfa, C; Edwards, DP; Hilsenbeck, SG; Holdman, XB; Huang, S; Mo, Q; Pond, A; Rajapakshe, K; Rosen, JM; Welte, T; Zhang, X | 1 |
| Choi, J; Kim, A; Kim, C; Kim, J; Lee, J | 1 |
| Chen, JY; Chen, WS; Chen, YJ; Huang, WC; Yen, CJ | 1 |
| Bachelot, T; Barriere, J; Bono, P; Ciruelos, E; Cortés, J; Dieras, V; Espié, M; Hurvitz, S; Joensuu, H; Kellokumpu-Lehtinen, PL; Kim, SB; Le Rhun, E; Nabholtz, JM; Ould-Kaci, M; Piacentini, F; Ro, J; Roux, F; Schneeweiss, A; Sohn, JH; Taguchi, J | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M | 1 |
| Armour, A; Baselga, J; Boyle, F; de Azambuja, E; Di Cosimo, S; Diéras, V; Dinh, P; Dolci, S; Dueck, AC; Eidtmann, H; Gelber, RD; Goldhirsch, A; Gomez, H; Harbeck, N; Hillman, DW; Holmes, AP; Holmes, E; Huang, CS; Im, YH; Jackisch, C; Lang, I; McCullough, AE; McFadden, E; Perez, EA; Piccart-Gebhart, M; Pritchard, KI; Smith, I; Suter, T; Tjulandin, S; Tonghua, L; Untch, M; Viale, G; Wolff, AC; Xu, B; Zujewski, JA | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Edgerton, SM; He, Z; Liu, B; Lyu, H; Thor, AD; Wu, X; Yang, XH | 1 |
| Biernat, W; Czartoryska-Arłukowicz, B; Dębska-Szmich, S; Demlova, R; Duchnowska, R; Foszczyńska-Kłoda, M; Hajac, Ł; Jassem, J; Karczmarek-Borowska, B; Korski, K; Kowalczyk, A; Lang, I; Merdalska, M; Myśliwiec, P; Niwińska, A; Orlikowska, M; Radecka, B; Studziński, M; Wysocki, PJ; Żawrocki, A; Ziółkowska, B; Zuziak, D | 1 |
| Bissinger, R; Egler, J; Lang, F; Zierle, J | 1 |
| Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Jeong, H; Liu, Y; Zhang, N | 1 |
| Bekiranov, S; Capaldo, B; Conaway, MR; Gioeli, D; Mackey, AJ; Petricoin, EF; Roller, DG; Weber, MJ | 1 |
| Akgullu, C; Aksun, S; Bilgen, M; Boyacioglu, M; Demirci, B; Eryilmaz, U; Ilgenli, TF; Yalinkilinc, HS | 1 |
| Dang, C; Friedman, MD; Lacouture, M | 1 |
| Bian, L; Du, G; Guo, Y; Jiang, Z; Song, S; Wang, T; Xu, X; Zhang, S; Zhuo, J | 1 |
| Chen, X; Ding, L; Jin, L; Liang, GK; Wu, HH; Yao, ZT; Zhang, JQ | 1 |
| Byrn, S; Chen, X; Fang, K; Lubach, JW; Nie, H; Smith, D; Song, Y; Su, Z; Yang, X; Zemlyanov, D | 1 |
| Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI | 1 |
| Grunt, TW; Gschwantler-Kaulich, D; Kölbl, H; Muhr, D; Singer, CF; Wagner, R | 1 |
| Bell, D; Hanna, EY; Jiffar, TW; Kupferman, ME; Lee, J; Myers, JN; Pickering, C; Takahashi, Y | 1 |
| Le, QA | 1 |
| Cameron, D; Davies, L; de Souza, P; Di Leo, A; Ellis, C; Gebski, VJ; Geyer, C; Johnston, S; Lee, CK; Loi, S; Lord, SJ; Marschner, I; Press, MF; Simes, J | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Chen, KF; Chen, MH; Chen, YT; Chu, PY; Hsu, CC; Hsu, CJ; Hu, MH; Huang, CT; Lee, CH; Liu, CY; Shiau, CW; Tsai, WC; Tseng, LM; Wang, DS | 1 |
| Boyle, F; Buzdar, AU; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Horick, N; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Strasser-Weippl, K | 1 |
| Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
| Griggs, JJ; Hayes, DF; Henry, NL; Kidwell, KM; Merajver, SD; Murthy, P; Schott, AF; Smerage, JD; Van Poznak, CH; Wicha, MS | 1 |
| Balla, J; Brunton, VG; Byron, A; Canel, M; Creedon, H; Fraser, C; Gómez-Cuadrado, L; Klinowska, T; Le Bihan, T; MacLeod, KG; Serrels, B; Sims, AH; Tarnauskaitė, Ž; Tracey, N; Unciti-Broceta, A | 1 |
| Bartsch, R; Brodowicz, T; Knittelfelder, R; Kuhar, CG; Lang, I; Melichar, B; Petruzelka, L; Singer, CF; Thallinger, C; Zielinski, C | 1 |
| Harvey, R; Simpson, E; Squires, H; Stevens, J; Stevenson, M | 1 |
| Castro, DJ; Gray, JW; Gu, S; Hu, Z; Morry, J; Ngamcherdtrakul, W; Reda, MM; Yantasee, W | 1 |
| Aktaş, S; Başak, S; Başal, Y; Demirci, B; Eliyatkın, N; Ermişler, B; Eryılmaz, A; Günel, C; Kurt Ömürlü, İ; Sağıroğlu, M | 1 |
| Dermawan, JK; Gurova, KV; Hitomi, M; Lathia, JD; Purmal, AA; Rich, JN; Sandlesh, P; Silver, DJ; Sloan, AE; Stark, GR; Venere, M; Wu, Q | 1 |
| Chen, B; Hu, JL; Jing, T; Yu, Y; Zhang, XP; Zheng, YB | 1 |
| Cameron, MD; El-Gendy, Bel-D; Eno, MR | 1 |
| Barinoff, J; Buyse, M; Cameron, D; Cobleigh, M; Di Leo, A; Gasparini, G; Grun, D; Johnston, S; Kaufman, B; Marguet, S; Marty, M; Michiels, S; Nekljudova, V; Paluch-Shimon, S; Penault-Llorca, F; Piccart, M; Pugliano, L; Slamon, D; Vogel, C; von Minckwitz, G | 1 |
| Al-Aqtash, T; Albashaireh, D; Alkhatib, Y; Awdish, R | 1 |
| Mehra, R; Zibelman, M | 1 |
| Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A | 1 |
| de la Cruz Merino, L; Marcos Rodríguez, JA; Romero Carreño, E; Santana Martínez, S | 1 |
| Becker, C; Keul, M; Nguyen, HD; Öcal, S; Phan, T; Rauh, D; Simard, JR | 1 |
| Borger, D; Chisholm, S; Foster, R; Growdon, WB; Hernandez, SF; Rueda, BR | 1 |
| Bell, MC; Burkard, ME; Eickhoff, J; Flynn, C; Kolesar, JM; Liu, G; Rampurwala, M; Tevaarwerk, AJ; Wisinski, KB | 1 |
| Chen, W; Li, W; Liu, C; Wang, H; Wei, Q; Zhai, L; Zhang, J | 1 |
| Abt, MA; Phelps-Polirer, K; Smith, D; Yeh, ES | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Jiang, T; Jiang, X; Pang, X; Pang, Z; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zhao, J; Zheng, X | 1 |
| Agbor-Tarh, D; Azim, HA; Boyle, F; Bradbury, I; Campbell, C; de Azambuja, E; Dueck, AC; Gomez, H; Huang, Y; Jackisch, C; Lang, I; Perez, EA; Piccart, M; Pritchard, KI; Smith, I; Sonnenblick, A; Untch, M; Wolff, AC; Xu, B | 1 |
| Ajgal, Z; Alexandre, J; Arrondeau, J; Goldwasser, F; Huillard, O; Hulin, A; Lavaud, P; Rousseau, B | 1 |
| Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bertotti, A; Cassingena, A; Ciardiello, F; Comoglio, PM; Depetris, I; Ghezzi, S; Lauricella, C; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Palmeri, L; Racca, P; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Veronese, S; Zagonel, V | 1 |
| Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V | 1 |
| Alias, Z; Kabir, MZ; Mohamad, SB; Mukarram, AK; Tayyab, S | 1 |
| Arya, N; Bang, YJ; Beyer, J; Botbyl, J; Briley, LP; Cartee, L; Chu, Q; Chung, HC; Dar, MM; Koch, KM; Smith, DA; White, JH | 1 |
| Clavarezza, M; D'Amico, M; DeCensi, A; Gennari, A; Paleari, L; Provinciali, N; Puntoni, M | 1 |
| Herman-Antosiewicz, A; Kaczyńska, A | 1 |
| Allemand, DH; Charreau, EH; Cidlowski, JA; Cordo Russo, RI; Cortese, E; De Martino, M; Elizalde, PV; Guzmán, P; Huang, TH; Izzo, F; Mercogliano, MF; Oakley, RH; Pereyra, MG; Proietti, CJ; Rivas, MA; Roa, JC; Schillaci, R; Venturutti, L; Yankilevich, P | 1 |
| Baselga, J; Bernards, R; Bria, E; Conte, P; Denkert, C; Guarneri, V; Holmes, E; Loi, S; Loibl, S; Majewski, I; Nekljudova, V; Piccart, M; Schem, C; Sotiriou, C; Untch, M; von Minckwitz, G | 1 |
| Denkert, C; Diebold, K; Eidtmann, H; Fasching, PA; Glados, M; Habeck, JO; Heck, E; Holms, F; Ingold Heppner, B; Krabisch, P; Lederer, B; Loibl, S; Lorenz, P; Ober, A; Pfitzner, BM; Rezai, M; Schmitt, W; Solbach, C; Tesch, H; Untch, M; Zahm, DM | 1 |
| Bagley, S; Bauml, J; Cohen, RB; Hayes, DN; Hwang, WT; Langer, C; Olson, JG; Weiss, JM | 1 |
| Barni, S; Bisagni, G; Bogina, G; Duranti, S; Fabi, A; Fiorio, E; Foglietta, J; Gori, S; Inno, A; Leonardi, V; Lunardi, G; Marchetti, F; Montemurro, F; Pavese, I; Pellegrino, A; Rossi, V; Santini, D; Saracchini, S; Turazza, M; Vici, P; Zambelli, A | 1 |
| López-Tarruella, S; Martin, M | 1 |
| Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J | 1 |
| Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M | 1 |
| Li, G; Yang, B; Yang, N; Yang, YS; Zhu, HL | 1 |
| Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M | 1 |
| Feng, J; Ha, Q; Han, D; Han, X; Hua, W; Li, D; Li, J; Li, X; Liao, F; Liu, C | 1 |
| Davoodzadeh, H; Ebadi, A; Rahmani, H; Shahriary, A; Sheikhi, MA | 1 |
| Briner, C; Gladkov, O; Hsieh, RK; Kaneko, T; Koch, KM; LaBonte, MJ; Lee, WP; Lenz, HJ; Nagarwala, YM; Pishvaian, MJ; Rha, SY; Sakaeva, D; Urba, SG; Wilson, PM; Yang, D; Zhang, W | 1 |
| Bao, J; Li, J; Wang, H; Wu, C | 1 |
| Ambroggi, M; Ardizzoni, A; Bisagni, G; Boggiani, D; Cagossi, K; Conte, PF; Dieci, MV; Generali, DG; Gianni, L; Guarneri, V; Musolino, A; Naldi, N; Piacentini, F; Rimanti, A; Sarti, S; Sgargi, P; Zanoni, D | 1 |
| Hurvitz, S; Zhang, B | 1 |
| Bégin, LR; Bourque, G; Caron, M; Deblois, G; Giguère, V; Gravel, SP; Labbé, DP; Muller, WJ; Park, M; Savage, P; Smith, HW; St-Pierre, J; Tam, IS; Tremblay, ML | 1 |
| Adam, T; Bouchalová, K; Faber, E; Friedecký, D; Janečková, H; Mičová, K; Vrobel, I | 1 |
| Chen, S; Chen, X; Dou, K; Qiao, H; Wei, L; Zhang, J; Zhang, R | 1 |
| Chen, MC; Huang, CC; Huang, PH; Lee, YT; Lin, H; Wang, HY; Yue, CH | 1 |
| Gonzalez-Martin, A; Kim, SB; Krop, IE; Lysbet de Haas, S; Smitt, M; Wildiers, H; Yu, R | 1 |
| Chen, Y; Gibson, SB; Henson, ES; Ma, S | 1 |
| Clark, RN; Jackson, KD; Rettie, AE; Towles, JK; Uttamsingh, V; Wahlin, MD | 1 |
| Manole, S; Meyer, AS; Richards, EJ | 1 |
| Ariza, L; Atencia-Cibreiro, G; Bosch, A; Calvo, AC; Corfas, G; Esteban-Pérez, J; García-Redondo, A; Gregorio, D; Leiva, T; Mancuso, R; Martínez-Muriana, A; Morell, M; Navarro, X; Osta, R | 1 |
| Amici, A; Andreani, C; Bartolacci, C; Belletti, B; Elexpuru Zabaleta, M; Galeazzi, R; Gambini, V; Garulli, C; Hysi, A; Iezzi, M; Kalogris, C; Marchini, C; Orlando, F; Pietrella, L; Provinciali, M; Tilio, M; Wang, J | 1 |
| Bisagni, G; Conte, P; Dieci, MV; Ficarra, G; Generali, DG; Guarneri, V; Paré, L; Piacentini, F; Prat, A; Tagliafico, E | 1 |
| Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH | 1 |
| Gonçalves, A | 1 |
| Apicella, M; Capelôa, T; Cargnelutti, M; Casorzo, L; Cassoni, P; Comoglio, PM; Corso, S; De Simone, M; Degiuli, M; Giordano, S; Marsoni, S; Menegon, S; Migliore, C; Sapino, A; Sarotto, I; Sottile, A | 1 |
| Griffith, N; Kolli, S; Li, Q; Liu, Z; Poi, MJ; Wetz, K | 1 |
| Bae, YH; Kang, JH; Le, QA | 1 |
| Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL | 1 |
| Blohmer, JU; Darb-Esfahani, S; Denkert, C; Dietel, M; Endris, V; Jackisch, C; Klare, P; Kümmel, S; Loi, S; Loibl, S; Möbs, M; Nekljudova, V; Reimer, T; Salat, C; Schem, C; Schmitt, W; Sinn, B; Sinn, P; Stenzinger, A; Tesch, H; Untch, M; von Minckwitz, G; Weichert, W | 1 |
| Kakudo, K; Nozaki, M; Ohnishi, Y; Yasui, H | 1 |
| Liu, P; Xu, B; Zhang, C | 1 |
| Bonizzi, G; Pruneri, G; Vingiani, A | 1 |
| Chen, TM; Chen, YJ; Chien, PH; Huang, WC; Hung, CM; Lin, YM; Pan, HL; Wei, CT | 1 |
| Azadi, S; Habibi-Anbouhi, M; Moradi, L; Omidvar, R; Tafazzoli-Shadpour, M | 1 |
| Ma, L; Qian, J; Shu, Y; Wang, Q; Wang, S; Xu, T; Yang, F; Zhou, J; Zhu, W | 1 |
| Afenjar, K; Bang, YJ; Chu, MP; Chua, N; Hecht, JR; Hiller, JP; Hoff, PM; Houe, V; Huang, YJ; Khan-Wasti, S; King, K; Koski, S; Mulder, K; Qin, S; Sawyer, MB; Scarfe, A; Slamon, D; Sobrero, A; Spratlin, J; Wainberg, ZA | 1 |
| Cho, BJ; Choi, EJ; Kim, DH; Kim, IA; Park, JM; Yu, T | 1 |
| Chen, N; Huang, P; Lin, Z; Liu, L; Peng, P; Tang, C; Wang, Z | 1 |
| Chiba, Y; Haratani, K; Hayashi, H; Kawakami, H; Nakagawa, K; Nonagase, Y; Takahama, T; Takeda, M; Takegawa, N; Tamura, T; Tanizaki, J; Tsurutani, J; Ueda, H; Watanabe, S; Yonesaka, K; Yoshida, T | 1 |
| Li, D; Marchenko, ND | 1 |
| Dehghankelishadi, P; Dorkoosh, FA; Gholami, M; Pordeli, M; Ravar, F; Saadat, E; Safavi, M | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Ellis, CE; Estrada, MC; Gagnon, RC; Grob, TJ; Hecht, JR; Jeziorski, K; Liang, Z; Ma, Y; Park, JO; Press, MF; Qin, SK; Robinson, DM; Sauter, G; Scherer, SJ; Slamon, DJ; Villalobos, I; Wu, S; Xu, J | 1 |
| Akhand, SS; Brown, WS; Wendt, MK | 1 |
| Borges, F; Costanzi, S; Hripcsak, G; Quezada, E; Uriarte, E; Vilar, S; Viña, D | 1 |
| Bando, H; Fujisawa, F; Hara, H; Homma, M; Kaburagi, T; Kojima, H; Mitsuhashi, S; Naito, K; Ohgami, M; Suzuki, Y; Takei, K; Uchiumi, K; Yamada, M; Yamada, Y | 1 |
| Chen, Y; Chen, ZS; Huang, JR; Jiang, QW; Li, Y; Qin, WM; Qiu, JG; Shi, Z; Wang, K; Wang, YJ; Wei, MN; Yang, DH; Yang, Y; Zhang, WJ; Zheng, DW | 1 |
| Behera, R; Guyett, PJ; Mensa-Wilmot, K; Ogata, Y; Pollastri, M | 1 |
| Guo, WW; Huang, Q; Jiang, G; Tian, Y; Xin, Y; Zhang, LZ; Zhang, P | 1 |
| Alexander, PB; Chen, R; Ding, Y; Gong, C; Jasper, JS; Markowitz, GJ; McDonnell, DP; Song, E; Wang, XF; Xu, X; Yang, P; Yuan, L | 1 |
| Kannan, N; Katiyar, S; Ruan, Z | 1 |
| Chan, EC; Chan, JC; Lim, P; Ong, PS; Teng, PX | 1 |
| Faulkner, L; Meng, X; Naisbitt, DJ; Park, BK; Spraggs, CF | 1 |
| Diao, Y; Gao, N; Jiang, W; Jin, G; Jin, Z; Li, W; Liu, Y; Wang, X; Wang, Z; Zhong, J | 1 |
| Abbasi Asbagh, L; Barber, PR; Bosch-Vilaró, A; Jacobs, B; Kim, P; Kirkland, R; Liu, X; Michel, J; Ng, T; Pomella, V; Singh, S; Tejpar, S; Vojnovic, B; Weitsman, G | 1 |
| Ackerman, C; Beresford, M; Berney, D; Chester, J; Chowdhury, S; Crabb, S; Elliott, T; Frew, JA; Hilman, S; Huddart, RA; Hughes, S; Hussain, S; Jagdev, S; Jones, R; Macdonald, G; Powles, T; Santhanam, S; Sarker, SJ; Stockdale, A | 1 |
| Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W | 1 |
| Aurisicchio, L; Bedogni, B; Cappelletti, M; Lu, J; Pavoni, E; Roscilli, G; Thakur, V; White, WL | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Yamamoto, C; Yamamoto, D; Yamamoto, M | 1 |
| Breslin, S; Lowry, MC; O'Driscoll, L | 1 |
| Jensen, RT; Mantey, SA; Moody, TW; Moreno, P; Ramos-Alvarez, I; Ridnour, L; Wink, D | 1 |
| Asano, H; Cui, X; Kanzaki, H; Kitamura, Y; Miyoshi, S; Murali, R; Namba, K; Sato, H; Sendo, T; Shien, K; Soh, J; Suzawa, K; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H; Yoshioka, T | 1 |
| Harbeck, N; Wuerstlein, R | 1 |
| Armour, A; Baselga, J; Chia, S; Eidtmann, H; Harbeck, N; Hatzis, C; Holmes, E; Jiang, T; Loi, S; Nuciforo, P; Peña, L; Piccart-Gebhart, M; Pusztai, L; Rimm, DL; Rosa, DD; Rossari, J; Shi, W; Sotiriou, C; Ueno, T; Wardley, A | 1 |
| Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Kotecha, R; Miller, JA; Mohammadi, AM; Murphy, ES; Peereboom, DM; Suh, JH; Vogelbaum, MA | 1 |
| Bai, Y; Black, J; Carvajal-Hausdorf, DE; Rimm, DL; Santin, AD; Schalper, KA | 1 |
| Gao, B; Guo, L; Hao, S; Hu, C; Jiang, Y; Luo, D; Tian, W; Yan, J; Zhang, G; Zhang, S; Zhang, X; Zhao, J | 1 |
| Berkers, CR; Kuster, B; Lemeer, S; Ruprecht, B; Wu, W; Zaal, EA; Zecha, J | 1 |
| Bermejo, B; Cortés, J; de la Peña, L; Galván, P; Llombart-Cussac, A; López, R; Martínez, N; Morales, S; Muñoz, M; Nuciforo, P; Oliveira, M; Paré, L; Peláez, A; Pernas, S; Prat, A; Vidal, M | 1 |
| Chen, L; Li, B; Liu, J; Wang, W; Zhang, Y; Zhao, L | 1 |
| Aklillu, E; Makonnen, E; Petros, Z | 1 |
| Karimi, M; Mobasseri, R; Naderi-Manesh, H; Ramakrishna, S; Tian, L | 1 |
| Baltazar, F; Barbosa, AM; Cardoso-Carneiro, D; Cury, FP; de Paula, FE; Evangelista, AF; Granja, S; Longatto-Filho, A; Marques, F; Martinho, O; Miranda-Gonçalves, V; Moreira, MA; Reis, RM; Scapulatempo-Neto, C; Silva-Oliveira, R; Zanon, M | 1 |
| Abahussain, AO; Alzoman, NZ; Maher, HM; Shehata, SM | 1 |
| Buskens, E; de Bock, GH; Greuter, MJW; Koleva-Kolarova, RG; Oktora, MP; Reyners, AKL; Robijn, AL | 1 |
| Gao, L; Gao, X; Li, N; Liu, PJ; Tie, XJ; Xu, ZQ; Zhang, Y | 1 |
| Banna, G; Berardi, R; Bisagni, G; Cagossi, K; Cavanna, L; Conte, P; Dieci, MV; Ficarra, G; Frassoldati, A; Generali, D; Goubar, A; Griguolo, G; Guarneri, V; Michelotti, A; Piacentini, F; Puglisi, F | 1 |
| Amadori, D; Andreis, D; Cecconetto, L; Donati, C; Fabbri, F; Faedi, M; Fedeli, A; Maltoni, R; Melegari, E; Monti, M; Nanni, O; Passardi, A; Pietri, E; Rocca, A; Sarti, S; Schirone, A | 1 |
| Chang, MS; Choi, Y; Jang, BG; Kim, MA; Kim, Y; Ko, YS; Lee, BL; Lee, JS; Park, J; Park, JW; Pyo, JS | 1 |
| Aiyappa, R; Alexander, A; Ce, A; Correa, M; Desai, K; Kalamdani, A; Kaluve, RS; Korlimarla, A; Lawrence, PV; Manjunath, S; Nair, MG; Patil, S; Prabhu, JS; Prasad, M; Sridhar, TS; Srinath, BS | 1 |
| Jeong, J; Kim, LK; Kim, W; VanHouten, J; Wysolmerski, JJ | 1 |
| Agbor-Tarh, D; Andersson, M; Azim, HA; Bradbury, I; Cufer, T; de Azambuja, E; Di Cosimo, S; Fumagalli, D; Gralow, J; Harris, L; Keane, M; Kroep, J; Moreno-Aspitia, A; Piccart-Gebhart, M; Salman, P; Sarp, S; Simon, SD; Sonnenblick, A; Toi, M; Wolff, AC | 1 |
| Anne Zujewski, J; Azim, HA; De Azambuja, E; Gingras, I; Gnant, M; Gralow, JR; Harris, L; Holmes, E; Inbar, M; Izquierdo, M; Moreno-Aspitia, A; Naume, B; Nguyen, DH; Piccart, MJ; Tomasello, G; Wolff, AC | 1 |
| Chen, Z; Huang, Y; Zhang, L; Zhu, B; Zhu, Y; Zhuo, W | 1 |
| Ci, X; Dong, JT; Fu, L; King, JL; Luo, A; Ma, G; Nahta, R; Qi, L; Wu, Q; Zhang, B; Zhang, S | 1 |
| Chen, L; Cheng, L; Jin, Y; Liu, M; Ruan, M | 1 |
| Bradbury, P; Chia, SK; Eisenhauer, E; Ellard, SL; Gelmon, K; Goodwin, R; Hagerman, L; Kumar, V; Lohrisch, C; Mates, M; Mihalcioiu, C; Miller, WH; Sakashita, S; Taylor, S; Tsao, MS; Wang, T; Welch, S | 1 |
| Arima, N; Hasegawa, S; Kai, Y; Katayama, K; Koga, T; Kurashita, K; Mitsuyama, S; Nishimura, R; Ohi, Y; Okumura, Y; Saimura, M; Saito, T; Shimada, K; Tamura, K; Tanaka, M; Tanaka, T; Teraoka, M; Todoroki, H; Toh, U; Toyoshima, S | 1 |
| Conlon, N; Crown, J; Kolch, W; O'Connor, R; O'Donovan, N; Roche, S; Santra, T | 1 |
| Ali, SM; Aparicio, S; Carney, WP; Chapman, JW; Crescnzo, RJ; Ellis, CE; Gelmon, KA; Ho, D; Huang, J; Leitzel, K; Lipton, A; Nomikos, D; Parulekar, WR; Shepherd, L; Virk, S; Zhu, L | 1 |
| Alladin, A; Burwinkel, B; Garcia, M; Gibson, TJ; Havas, KM; Jechlinger, M; Kafkia, E; Klaus, B; Milchevskaya, V; Patil, KR; Pruneri, G; Radic, K; Rotmensz, N; Schneeweiss, A; Sotillo, R; Stolte, J | 1 |
| Ben-Shlomo, A; Cooper, O | 1 |
| Buisseret, L; Ceppi, M; de Azambuja, E; Fumagalli, D; Garaud, S; Ignatiadis, M; Lambertini, M; Salgado, R; Scartozzi, M; Solinas, C; Sotiriou, C; Willard-Gallo, K | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Badovinac-Crnjevic, T; Ferrero, JM; Hoersch, S; Kim, SB; Krop, IE; LoRusso, PM; Martin, AG; Smitt, M; Wildiers, H | 1 |
| Eriksson, P; Liedberg, F; Sjödahl, G | 1 |
| Ackerman, C; Gómez de Liaño, A; Powles, T | 1 |
| Aogi, K; Bando, H; Homma, M; Ishiguro, H; Kurosawa, A; Masuda, N; Mitsuhashi, S; Ohgami, M; Toi, M; Toriguchi, N; Tsuda, M | 1 |
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Patra, PK; Sahu, A; Varma, M; Yadav, MK | 1 |
| De Angelis, C; Osborne, CK; Pascual, T; Prat, A; Reis-Filho, JS; Rimawi, MF; Schiff, R; Veeraraghavan, J | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K | 1 |
| Chacko, AR; Hilkens, J; Piyush, T; Rhodes, JM; Sindrewicz, P; Yu, LG | 1 |
| Abbadi, S; Blakeley, JO; Bonne, N; Brem, H; Giovannini, M; Itzoe, M; Paldor, I; Rodriguez, FJ; Rowshanshad, D; Tyler, BM; Vigilar, V; Ye, X | 1 |
| Collins, DM; Crown, J; Davies, A; Edwards, C; Gately, K; Hughes, C; Madden, SF; O'Byrne, KJ; O'Donovan, N | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Breathnach, O; Carr, A; Crown, J; Duke, D; Eustace, AJ; Fay, J; Gallagher, W; Grogan, L; Gullo, G; Hambly, N; Hennessy, BT; Hill, AD; Kay, EW; Kelly, C; Kennedy, MJ; Madden, SF; Milewska, M; Moulton, B; O'Donovan, N; Power, C; Sheehan, KM; Teiserskiene, A; Toomey, S; Walshe, J | 1 |
| Band, H; Band, V; Mirza, S; Mohibi, S; Srivastava, S | 1 |
| Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR | 1 |
| Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E | 1 |
| Chander, H; Kaur, RP; Kumar, V; Ludhiadch, A; Munshi, A; Singla, H | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghidini, M; Ghilardi, M; Lonati, V; Petrelli, F; Tomasello, G | 1 |
| Chang, MJ; Choi, HD | 1 |
| Blankstein, AR; Chen, Y; Choquette, TR; Dielschneider, RF; Gibson, SB; Henson, ES; Ma, S; Xiao, W | 1 |
| Bejjanki, H; Bishnoi, R; Reisman, D | 1 |
| Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P | 1 |
| Li, B; Li, Y; Liu, Z; Shu, T; Wu, X | 1 |
| Gray, J; Jokela, T; LaBarge, MA; Lin, CH | 1 |
| Arteaga, CL; Dugger, TC; Estrada, MV; Formisano, L; Gonzalez Ericsson, PI; Guerrero-Zotano, A; Horak, ID; Hutchinson, KE; Kragh, M; Lantto, J; Pedersen, MW; Red-Brewer, M; Rexer, BN; Sanders, ME; Schwarz, LJ; Young, CD | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Arya, N; Beelen, AP; Coker, SA; Dees, EC; Gainer, SD; Koch, KM; Lewis, LD; Reddy, NJ | 1 |
| Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU | 1 |
| Choi, MR; Clare, SE; Goodman, AM; Halas, NJ; Henderson, L; Neumann, O; Nørregaard, K | 1 |
| Burke, KA; Chang, JC; Contreras, A; De Angelis, C; Forero, A; Fuqua, SAW; Geyer, FC; Goetz, MP; Gutierrez, C; Herrera, S; Hilsenbeck, SG; Kent Osborne, C; Krop, IE; Li, MM; Mayer, IA; Nanda, R; Pareja, F; Pavlick, AC; Reis-Filho, JS; Rimawi, MF; Schiff, R; Wang, T; Weigelt, B; Wolff, AC | 1 |
| Abe, T; Hayashida, T; Kikuchi, M; Kitagawa, Y; Maeda, H; Nagayama, A; Nakashoji, A; Seki, T; Takahashi, M; Toyota, T; Watanuki, R; Yokoe, T | 1 |
| Chen, M; Gan, L; Li, L; Liu, B; Liu, L; Shan, Z; Xiao, C; Xu, T; Yao, S; Zhao, Y; Zhong, L | 1 |
| Azim, HA; Baselga, J; Bregni, G; Campbell, C; Colleoni, M; Criscitiello, C; Curigliano, G; de Azambuja, E; de la Pena, L; Di Cosimo, S; Fein, L; Ferro, A; Fumagalli, D; Galli, G; Huober, J; Izquierdo, M; Naume, BJ; Ng, WMJ; Patel, A; Piccart-Gebhart, MJ; Vinholes, J | 1 |
| Bagheri, N; Kosari, S; Madden, R; Peterson, GM; Thomas, J | 1 |
| Hannouf, MB; Nixon, NA; Verma, S | 1 |
| Bai, M; Che, X; Liu, Y; Qu, X; Song, N; Wang, X | 1 |
| Haeno, H; Michor, F; Stein, S; Vivanco, I; Zhao, R | 1 |
| Gligorov, J; Pivot, X; Richard, S | 1 |
| Chang, DY; Chao, TY; Chen, TW; Cheng, AL; Chow, LW; Consortium, TBC; Hsieh, YY; Huang, SM; Lin, CH; Lu, YS; Yeh, DC | 1 |
| Hirata, M; Nezasa, KI; Shinonome, S; Tanaka, H; Tanaka, Y; Torii, M | 1 |
| Bello, M; Correa-Basurto, J; García, B; Saldaña-Rivero, L; Sánchez-Espinosa, VA | 1 |
| Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J | 1 |
| Abe, K; Ando, O; Imaoka, T; Karibe, T | 1 |
| Goyal, S; Grover, A; Jamal, S; Kumari, A; Singh, A; Verma, S | 1 |
| Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR | 1 |
| Bando, H; Inoue, K; Iwata, H; Kasai, H; Kuroi, K; Masuda, N; Morita, S; Ohno, S; Ohtani, S; Sakurai, T; Takano, T; Toi, M; Yamamoto, N; Yanagita, Y | 1 |
| Ding, C; Jiao, XD; Yu, G; Zang, YS | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Klupczynska, A; Kokot, ZJ; Moch, M; Plewa, S; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Bucher, E; Chin, K; Dane, M; Gray, JW; Heiser, LM; Jonas, O; Kilburn, D; Korkola, JE; Liby, T; Liu, M; Mills, GB; Nederlof, M; Smith, R; Sudar, D; Tatarova, Z; Thompson, W; Watson, SS; Whitman, M | 1 |
| Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE | 1 |
| Ci, B; Fernández, ÁF; Kim, M; Levine, B; Vega-Rubín-de-Celis, S; Xiao, G; Xie, Y; Zou, Z | 1 |
| Arumí, M; Bellet, M; Escrivá-de-Romaní, S; Saura, C | 1 |
| Chang, Y; Dong, X; Jiang, T; Tang, Y; Wang, J; Yu, R; Zhang, L; Zhang, M; Zhang, R | 1 |
| Aogi, K; Fukuoka, J; Ito, Y; Kawabata, H; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Saeki, T; Sakai, K; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tsurutani, J; Yamanaka, T | 1 |
| Brandão, M; El-Hachem, G; Piccart, M; Pondé, N; Werbrouck, E | 1 |
| Duchnowska, R; Jassem, J; Loibl, S | 1 |
| Liu, H; Song, Q; Yang, Y; Yu, X; Yu, Y | 1 |
| Hayashida, T; Jinno, H; Kitagawa, Y; Matsumoto, A; Takahashi, M | 1 |
| Chu, E | 1 |
| Allen, JC; Hagiwara, M; Hu, J; Karajannis, MA; Mitchell, C; Osorio, DS; Stanek, J | 1 |
| Huang, MQ; Kocan, GP; Li, F; Pai, S | 1 |
| Ju, Y; Li, C; Qiao, R; Wu, J; Yuan, X; Zhang, G; Zhao, L | 1 |
| Bachovchin, KA; Bag, S; Buskes, MJ; Ferrins, L; Jalani, HB; Klug, DM; Mehta, N; Mensa-Wilmot, K; Momper, JD; Pollastri, MP; Rodriguez, A; Schneider, KM; Sciotti, RJ; Sharma, A; Singh, B; Tanghe, S | 1 |
| Brunton, VG; Creedon, H; Culley, J; Kemp, AJ; Klinowska, T; Muir, M; Tracey, N | 1 |
| Hong, R; Jiang, K; Lee, K; Li, Y; Liao, H; Lu, Q; Qin, G; Wang, S; Xia, W; Xu, F; Yuan, H; Zhai, Q; Zhang, J; Zhang, K; Zheng, Q | 1 |
| Gangemi, E; Greco, C; Ippolito, E; La Cesa, A; Matteucci, P; Ramella, S; Santini, D; Santo, B; Silipigni, S | 1 |
| Cao, Y; Gong, LY; Guo, CX; Hua, Y; Huang, J; Kuang, Y; Pei, Q; Wang, MN; Yang, GP | 1 |
| Bighin, C; Blondeaux, E; Cardinali, B; Del Mastro, L; Ferreira, AR; Fontana, A; Fregatti, P; Lai, A; Lambertini, M; Minuti, G; Montemurro, F; Mura, S; Poggio, F; Poletto, E; Puglisi, F; Sini, V; Sottotetti, F | 1 |
| Gelmon, KA; Tesch, ME | 1 |
| Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X | 1 |
| Ballman, KV; Chen, B; De Silva, C; Dueck, AC; Goetz, MP; Haddad, TC; Haluska, P; He, J; Hopkins, JO; Linden, H; Northfelt, D; O'Sullivan, CC; Perez, EA; Sparano, JA; Tenner, KS | 1 |
| Brugge, JS; Dering, J; Hurvitz, SA; Press, MF; Selfors, LM; Slamon, DJ; Zoeller, JJ | 1 |
| Austin, E; Kalomeris, T; Larimer, B; Mahmood, U; Nesti, S; Sinevici, N; Wehrenberg-Klee, E | 1 |
| Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y | 1 |
| Gorski, JW; Kolesar, JM; Lin, N; Liu, J; McCorkle, JR; McDowell, AB; Riggs, MB; Ueland, FR; Wang, C | 1 |
| Badiee, A; Jafari, MR; Karimi, M; Mansouri, A; Mehrabian, A; Nikpoor, AR; Sadri, K; Shokooh Saremi, S | 1 |
| Kang, W; Kwon, JY; Lee, C; Lee, H; Maher, L; Michaud, M; Ning, G; Silva, M; Suh, YS; Zhang, C; Zhu, Q | 1 |
| Ansari, K; Bhan, A; Chen, MY; Jandial, R | 1 |
| Arribas, J; Chandarlapaty, S; de Stanchina, E; Ferraro, E; Kulick, A; Lahuerta, EJA; Li, Q; Morales, CB; Razavi, P; Reis-Filho, J; Rosen, N; Ross, D; Safonov, A; Smith, AE; Solit, DB | 1 |
| Bindhya, S; Ganesan, TS; Joshua, T; Krishnapriya, S; Manasa, P; Murhekar, K; Nagare, RP; Shabna, A; Sidhanth, C; Sneha, S | 1 |
| Bachelot, T; Bailleux, C; Darlix, A; Jacot, W | 1 |
| Armstrong, A; Bliss, JM; Brunt, AM; Bundred, N; Cameron, DA; Cramer, A; Cutress, RI; Dodwell, D; Emson, MA; Evans, A; Hanby, A; Hartup, SM; Horgan, K; McIntosh, SA; Miller, SE; Morden, JP; Naik, J; Narayanan, S; Ooi, J; Porta, N; Rakha, EA; Shaaban, AM; Skene, AI | 1 |
| Ai, L; He, Q; Jiang, L; Luo, P; Xu, Z; Yan, H; Yang, B; Yang, X; Zeng, Y | 1 |
| Drover, S; Wiede, LL | 1 |
| Bowen, J; Ibahim, MJ; Khan, J; Muhamad, M; Raja Sharin, RNFS; Wan Mohamad Zain, WNI | 1 |
| Abbas, SE; Abdelrasheed Allam, H; Farouk, AKBAW; George, RF; Rashwan, E | 1 |
| Buccinnà, B; Piccinini, M; Ramondetti, C | 1 |
| Cho, KR; Jung, SP; Kim, CY; Kim, JW; Lee, JH; Lee, NK; Lim, AR; Park, KH; Song, SE; You, JY | 1 |
| Beaumont, H; Chamorey, E; Faye, N; Hsieh, CY; Iannessi, A; Klifa, C | 1 |
| Badwe, R; Bajpai, J; Bhargava, P; Budrukkar, A; Desai, S; Ghosh, J; Gulia, S; Gupta, S; Joshi, S; Kannan, S; Nair, N; Pathak, R; Patil, A; Popat, P; Rath, S; Rathnasamy, N; Sarin, R; Shenoy, R; Shet, T; Wadasadawala, T | 1 |
| Alba, E; Antolin, S; Barnadas, A; Bonfill, X; Lluch, A; Martin, M; Rodriguez-Lescure, A; Ruiz-Borrego, M; Sanchez-Rovira, P; Servitja, S; Sola, I; Urrutia, G; Vazquez, JC | 1 |
| Chen, X; Fu, H; Gao, Z; He, Q; Jin, Y; Luo, P; Pan, Z; Wang, X; Xu, B; Xu, Z; Yan, H; Yang, B; Yang, X; Zeng, Y; Zhang, X; Zhang, Y | 1 |
| Aure, MR; Engebraaten, O; Haugen, MH; Hongisto, V; Kristensen, VN; Leivonen, SK; Mælandsmo, GM; Normann, LS; Sahlberg, KK; Tahiri, A | 1 |
| Antao, V; Lamarre, N; Montemurro, F; Peña-Murillo, C; Sanglier, T; Shim, J | 1 |
| Aydiner, A; Dogan, I; Ibis, K; Kizildag, I; Özkurt, S; Saip, P; Vatansever, S | 1 |
| Chandrasekar, MJN; Naik, MR; Patnaik, SK; Selvaraj, J; Swaroop, AK | 1 |
| Gulmez, A | 1 |
| Chen, W; Jiang, Q; Li, D; Li, G; Li, P; Liu, Q; Qiu, J; Shan, G | 1 |
| Ding, H; Fang, L; Kong, S; Song, Y; Tong, Y; Xu, G; Yang, D; Zhu, J | 1 |
| Hou, R; Li, S; Liu, D; Ma, W; Meng, B; Ren, T; Shi, M; Wang, X; Xu, Z; Zhao, X; Zheng, J | 1 |
274 review(s) available for quinazolines and lapatinib
| Article | Year |
|---|---|
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Drugs, Investigational; ErbB Receptors; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2004 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Antitumor activity of HER-2 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2005 |
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PubMed; Quinazolines | 2006 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
Topics: Animals; Drug Design; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Molecular Structure; Neoplasms; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship | 2006 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
Topics: Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.
Topics: Animals; Breast Neoplasms; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2006 |
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
Topics: Animals; Antineoplastic Agents; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
HER-2-positive breast cancer: hope beyond trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
Molecular targeted therapies in breast cancer: where are we now?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; ErbB Receptors; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Receptors, Estrogen; Tamoxifen; Trastuzumab | 2007 |
HER2-positive breast cancer: current and future treatment strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2007 |
Her signaling in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Lapatinib in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic | 2007 |
Issues and controversies in the treatment of HER2 positive metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Lapatinib; Medical Oncology; Models, Biological; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Lapatinib-associated toxicity and practical management recommendations.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2 | 2007 |
[Breast cancer and Her-2].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2007 |
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachytherapy; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Genes, erbB-2; Humans; Lapatinib; Male; Mastectomy; Pharmacogenetics; Quinazolines; Radiation Dosage; Tamoxifen; Trastuzumab; Treatment Outcome | 2007 |
Targeted therapies in breast cancer: challenging questions from oncology nurses.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Delivery Systems; Drug Monitoring; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Nurse's Role; Oncology Nursing; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2007 |
Dissecting kinase signaling pathways.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Lapatinib (Tykerb) for advanced breast cancer.
Topics: Breast Neoplasms; Drug Therapy, Combination; Drugs, Investigational; Female; Humans; Lapatinib; Quinazolines | 2007 |
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab | 2007 |
Lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
Lapatinib in the treatment of breast cancer.
Topics: Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines | 2007 |
HER2 targeted therapy in breast cancer...beyond Herceptin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lapatinib; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2008 |
Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Heart Diseases; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
[Targeting ErbB receptors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
Food effects on oral agents.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Food-Drug Interactions; Humans; Lapatinib; Neoplasms; Quinazolines | 2007 |
Overcoming treatment challenges in advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2007 |
Choosing the appropriate breast cancer therapy for today's breast cancer patient.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Mastectomy; Patient Care Planning; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Trastuzumab | 2007 |
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
[Metastatic breast cancer--new methods of treatment].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Histocytochemistry; Humans; Lapatinib; Neoplasm Metastasis; Osteonecrosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Trastuzumab | 2008 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
The emerging role of lapatinib in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
[The new generation of breast cancer clinical trials: the right drug for the right target].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; International Cooperation; Lapatinib; Microarray Analysis; Multicenter Studies as Topic; Organizational Objectives; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2008 |
Lapatinib: a sword with two edges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Lapatinib; Neoplasm Staging; Quinazolines; Trastuzumab; Treatment Outcome | 2007 |
[Combined chemotherapy with molecular-targeted agent for breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Lapatinib; Quinazolines; Trastuzumab | 2008 |
[Oncology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Molecularly targeted therapy in breast cancer: the new generation.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Design; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Estrogen; Sunitinib | 2008 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Targeting Her-2/neu in breast cancer: as easy as this!
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Food-Drug Interactions; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Novel targeting therapy concept for breast cancer treatment.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Targeting; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Trastuzumab | 2008 |
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytochrome P-450 Enzyme System; Drug Interactions; Half-Life; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor, ErbB-2 | 2008 |
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epothilones; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2009 |
Unraveling the biologic and clinical complexities of HER2.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2008 |
[Advances in research on treatment of breast cancer with lapatinib].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2008 |
Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Humans; Lapatinib; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2008 |
Integrating biologically targeted therapy in head and neck squamous cell carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Lapatinib; Quinazolines | 2009 |
Jumping higher: is it still possible? The ALTTO trial challenge.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Trastuzumab | 2008 |
Acute paronychia caused by lapatinib therapy.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Paronychia; Quinazolines | 2009 |
[Stem cell-targeted therapy--a new strategy for cancer treatment].
Topics: Adenosine; Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Differentiation; Diketopiperazines; Heterocyclic Compounds, 4 or More Rings; Humans; Lapatinib; Neoplasms; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidinones; Quinazolines; Signal Transduction; Triazines; Wnt Proteins | 2008 |
Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cytological Techniques; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Genes, erbB-2; Genetic Techniques; Guidelines as Topic; Humans; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Evidence-Based Medicine; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Lapatinib; Neoplasm Staging; Polymerase Chain Reaction; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Sirolimus; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Up-Regulation | 2009 |
An overview of HER-targeted therapy with lapatinib in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2009 |
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Signal Transduction; Treatment Outcome | 2009 |
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
Topics: Adjuvants, Immunologic; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Heart Failure; Humans; Lapatinib; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Ventricular Outflow Obstruction | 2009 |
Medicinal chemistry strategies in follow-on drug discovery.
Topics: Animals; Atorvastatin; Bendamustine Hydrochloride; Benzazepines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Delivery Systems; Drug Discovery; gamma-Aminobutyric Acid; Heptanoic Acids; Humans; Lapatinib; Nitrogen Mustard Compounds; Pregabalin; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides | 2009 |
Lapatinib as a chemotherapeutic drug.
Topics: Clinical Trials as Topic; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases | 2009 |
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Metformin; Models, Biological; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2009 |
Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2009 |
Costs of adjuvant breast cancer treatments.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Health Care Costs; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab | 2009 |
Trastuzumab versus lapatinib: the cardiac side of the story.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Heart Diseases; Humans; Lapatinib; Quinazolines; Trastuzumab | 2009 |
Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Treatment of brain metastases in patients with HER2+ breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Incidence; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2009 |
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Morpholines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Trastuzumab; Up-Regulation | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Lapatinib: a competitor or companion to trastuzumab?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Female; Humans; Lapatinib; Quinazolines; Trastuzumab | 2009 |
Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Expression; Humans; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2009 |
[Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Resistance; ErbB Receptors; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factors | 2009 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab | 2009 |
Small-molecule inhibitors of the human epidermal receptor family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2010 |
Molecular predictors of response to trastuzumab and lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome | 2009 |
Lapatinib.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2010 |
Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Topics: Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2010 |
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
Does lapatinib work against HER2-negative breast cancers?
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen | 2010 |
Role of anti-Her-2 therapy in bladder carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Models, Biological; Prognosis; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Urinary Bladder Neoplasms | 2010 |
HER2 as a target for breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2010 |
Systemic treatment in breast-cancer patients with brain metastasis.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Biological Products; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lapatinib; Quinazolines | 2010 |
Lapatinib side-effect management.
Topics: Antineoplastic Agents; Diarrhea; Humans; Lapatinib; Paronychia; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2010 |
Targeted therapy in breast cancer: current status and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Forecasting; Genes, BRCA1; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Trastuzumab; Treatment Failure | 2010 |
HER2-positive breast cancer: beyond trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2010 |
[Novel targeted drug therapies in breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bevacizumab; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab | 2010 |
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Use of molecular markers for predicting therapy response in cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cytochrome P-450 CYP2D6; ErbB Receptors; Female; Genotype; Humans; Lapatinib; Mutation; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2011 |
Lapatinib and breast cancer: current indications and outlook for the future.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Female; Forecasting; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2010 |
Prevention and management of major side effects of targeted agents in breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast; Breast Neoplasms; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Skin Diseases; Trastuzumab | 2012 |
Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, IgG; Signal Transduction; Trastuzumab | 2011 |
[Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].
Topics: Antineoplastic Agents; Breast Neoplasms; Gene Expression; Humans; Lapatinib; Quinazolines; Receptor Cross-Talk; Signal Transduction; Tumor Cells, Cultured | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antinematodal Agents; Breast; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2012 |
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphatidylinositol 3-Kinase; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2010 |
[Principles and method of action of targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Vascular Endothelial Growth Factor A | 2010 |
Lapatinib for breast cancer: a review of the current literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoadjuvant Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Lapatinib in breast cancer: clinical experiences and future perspectives.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Forecasting; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Topics: Antineoplastic Agents; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Genes, erbB-2; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Predictive Value of Tests; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome | 2010 |
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
Topics: Angiogenesis Modulating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Design; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Breast Neoplasms; Disease Models, Animal; Female; Humans; Lapatinib; Meningeal Carcinomatosis; Meningeal Neoplasms; Primates; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2011 |
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
[Her2 positive breast cancer: practices].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Heart; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antigens, Neoplasm; Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Dendritic Cells; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Immunotherapy; Integrin alpha6; Isoenzymes; Lapatinib; Membrane Proteins; Models, Biological; Mucin-1; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Retinal Dehydrogenase; Signal Transduction | 2011 |
[Tykerb for breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lapatinib; Quinazolines; Trastuzumab | 2011 |
Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Cardiac Imaging Techniques; Cardiotoxins; Clinical Trials as Topic; Drug Monitoring; Humans; Lapatinib; Neoplasms; Outcome and Process Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Trastuzumab; Ventricular Dysfunction, Left | 2011 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Esophageal Neoplasms; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Early Detection of Cancer; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Treatment Outcome | 2011 |
Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Belgium; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab | 2011 |
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidence; Lapatinib; Nail Diseases; Nails; Panitumumab; Quinazolines; Risk Factors | 2012 |
Treatment of HER2-positive breast cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Disease Progression; Female; Gene Amplification; Genes, erbB-2; Heat-Shock Proteins; Humans; Lapatinib; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, IGF Type 1; Trastuzumab | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2011 |
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Belgium; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Cholangiocarcinoma; Cluster Analysis; ErbB Receptors; Female; Gene Expression Profiling; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Laser Capture Microdissection; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; Precision Medicine; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Queensland; Quinazolines; ras Proteins; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Tumor Microenvironment; United States | 2012 |
Role of chemotherapy on brain metastasis.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Novel target therapies used in breast cancer management].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; RANK Ligand; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2011 |
Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Lapatinib; Patents as Topic; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Target therapy in elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Advances in medical therapies for Cushing's syndrome.
Topics: Animals; Bexarotene; Cushing Syndrome; Etomidate; Humans; Ketoconazole; Lapatinib; Metyrapone; Mifepristone; Mitotane; Quinazolines; Somatostatin; Tetrahydronaphthalenes | 2012 |
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
The adjuvant treatment of HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cardiotoxins; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Genes, erbB-2; Heart; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Lapatinib for advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinase; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab | 2012 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Targeted therapy for gastric cancer--current status.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drugs, Investigational; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
Targeted therapies in breast cancer: are heart and vessels also being targeted?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Heart Failure; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab; Ventricular Dysfunction, Left | 2012 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Dual blockade of HER2 - twice as good or twice as toxic?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Targeted therapy in brain metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Humans; Ipilimumab; Lapatinib; Molecular Targeted Therapy; Neovascularization, Pathologic; Quinazolines | 2012 |
Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Neoadjuvant Therapy; Preoperative Period; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Lapatinib and renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Humans; Kidney Neoplasms; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Receptors, Estrogen; Treatment Outcome | 2013 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
Topics: Afatinib; Aminoquinolines; Angiogenesis Inhibitors; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2013 |
Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
Topics: Aged; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
Topics: Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Gilbert Disease; Glucuronosyltransferase; Humans; Indazoles; Lapatinib; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
HER2-positive gastric cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2014 |
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
Topics: Antibodies, Monoclonal, Humanized; Antigen-Presenting Cells; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Immunotherapy, Active; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Heart Diseases; Humans; Lapatinib; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2013 |
Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Topics: Alleles; Allopurinol; Amoxicillin-Potassium Clavulanate Combination; Azetidines; Benzylamines; Carbamazepine; Chemical and Drug Induced Liver Injury; Diclofenac; Dideoxynucleosides; Drug Hypersensitivity; Floxacillin; Genetic Markers; HLA Antigens; HLA-A Antigens; HLA-B Antigens; HLA-DQ alpha-Chains; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Skin; Stevens-Johnson Syndrome; Ticlopidine | 2013 |
Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Treatment Outcome | 2013 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Signal Transduction; Translational Research, Biomedical; Trastuzumab | 2013 |
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
A systematic review of dual targeting in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Up-Regulation | 2014 |
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride | 2014 |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Biological therapies in breast cancer: common toxicities and management strategies.
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Humans; Immunosuppressive Agents; Lapatinib; Maytansine; Quinazolines; Sirolimus; Trastuzumab | 2013 |
Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Diarrhea; Humans; Incidence; Lapatinib; Publication Bias; Quinazolines; Receptor, ErbB-2; Risk; Trastuzumab | 2014 |
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2014 |
New HER2-positive targeting agents in clinical practice.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
[Clinical evaluation of lapatinib therapy in metastatic breast cancer using the Bayes meta-analysis].
Topics: Antineoplastic Agents; Bayes Theorem; Breast Neoplasms; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2014 |
Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Systemic therapy in neurofibromatosis type 2.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Neurofibromatosis 2; Quinazolines; Signal Transduction | 2014 |
Trastuzumab-containing regimens for metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatigue; Humans; Lapatinib; Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2014 |
P95 HER2 fragments and breast cancer outcome.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Survival; Trastuzumab | 2014 |
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2014 |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2014 |
Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biomarkers, Tumor; Breast Neoplasms; Comparative Effectiveness Research; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
[New targeted therapies in breast cancer].
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab | 2014 |
[Systemic treatments of inflammatory breast cancer: an overview].
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Trastuzumab | 2014 |
Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease Management; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neural Stem Cells; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2015 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Triazoles | 2015 |
[Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Small Molecule Libraries; Trastuzumab | 2015 |
Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.
Topics: Animals; Cytochrome P-450 CYP3A; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2015 |
[Systemic treatment of brain metastases from breast cancer].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Genes, erbB-2; Humans; Lapatinib; Medicine; Molecular Targeted Therapy; Patient Care Team; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Hand-Foot Syndrome; Humans; Lapatinib; Neoplasms; Pruritus; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Lymph Nodes; Molecular Targeted Therapy; Neoadjuvant Therapy; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
HER2-positive metastatic breast cancer: a changing scenario.
Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sorafenib; Thymus Neoplasms; TOR Serine-Threonine Kinases; Young Adult | 2015 |
Dual HER2 blockade: preclinical and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Mechanisms of lapatinib resistance in HER2-driven breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lapatinib; Mutation; Phosphotransferases; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen | 2015 |
[PI3K and mTOR pathway and molecular targeted agents].
Topics: Animals; Antibodies, Monoclonal, Humanized; Class I Phosphatidylinositol 3-Kinases; Drug Discovery; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2015 |
Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Topics: Antibodies, Monoclonal, Humanized; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Delivery Systems; Female; Humans; Immunoconjugates; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Lapatinib; Oligonucleotide Array Sequence Analysis; Protein Interaction Maps; Quinazolines | 2016 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Lapatinib; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab | 2015 |
Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Probe Techniques; Nucleic Acid Amplification Techniques; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Update on cardiotoxicity of anti-cancer treatments.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids | 2016 |
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2016 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk | 2016 |
Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cancer Vaccines; Female; Humans; Immunotherapy; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Applications of cardiotoxicity in breast cancer: a meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Female; Humans; Lapatinib; Odds Ratio; Quinazolines; Risk; Trastuzumab; Ventricular Function, Left | 2017 |
Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Discovery; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
[Not Available].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Neoadjuvant Therapy; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2016 |
Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2016 |
Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Odds Ratio; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Neoadjuvant Therapy for HER2-positive Breast Cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome; Withholding Treatment | 2017 |
Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Lapatinib; Life Expectancy; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2017 |
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Mice; Mice, Transgenic; Pituitary Neoplasms; Prolactinoma; Protein Kinase Inhibitors; Quinazolines; Translational Research, Biomedical | 2017 |
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2017 |
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Oncogene Addiction; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab; Tumor Microenvironment | 2017 |
Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.
Topics: Animals; Antineoplastic Agents, Immunological; Breast; Breast Neoplasms; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; ErbB Receptors; Female; Heart; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bayes Theorem; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Network Meta-Analysis; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Treatment Outcome | 2018 |
A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
HER2-positive breast cancer: Current and new therapeutic strategies.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Treatment of advanced HER2-positive breast cancer: 2018 and beyond.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2018 |
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2 | 2018 |
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2021 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2021 |
Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.
Topics: Antineoplastic Agents; Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2022 |
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
254 trial(s) available for quinazolines and lapatinib
| Article | Year |
|---|---|
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cross-Over Studies; Double-Blind Method; ErbB Receptors; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety | 2005 |
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Cell Survival; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Lapatinib; Male; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2005 |
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Quinazolines; Receptor, ErbB-2; Safety; Treatment Outcome | 2005 |
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lapatinib; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Quinazolines | 2007 |
Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2007 |
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Disease-Free Survival; Epidermal Growth Factor; Female; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Salivary Gland Neoplasms; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab | 2008 |
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2008 |
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Humans; Immunohistochemistry; Kidney Neoplasms; Lapatinib; Male; Megestrol Acetate; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tamoxifen | 2008 |
Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2008 |
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab; Treatment Outcome | 2008 |
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Quinazolines; Treatment Outcome; Triazoles | 2008 |
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Taxoids | 2008 |
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Research Design; Trastuzumab | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult | 2008 |
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Placebos; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2008 |
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Asian People; ErbB Receptors; Humans; Japan; Lapatinib; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires | 2009 |
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Humans; Lapatinib; Liver Neoplasms; Quinazolines; Survival Analysis | 2009 |
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure; Treatment Outcome | 2009 |
Effects of food on the relative bioavailability of lapatinib in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Quinazolines; Solubility | 2009 |
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Receptor, ErbB-2; Reference Values; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Antifungal Agents; Antineoplastic Agents; Area Under Curve; Carbamazepine; Cross-Over Studies; Drug Interactions; Female; Half-Life; Humans; Ketoconazole; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2009 |
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Recurrence; Skin Diseases; Treatment Outcome | 2009 |
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Transitional Cell; Disease Progression; Female; Humans; Lapatinib; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cytochrome P-450 CYP3A; Enzyme Induction; ErbB Receptors; Female; Glioblastoma; Humans; Lapatinib; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2 | 2010 |
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2009 |
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Topics: Administration, Oral; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Injections, Intravenous; Lapatinib; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2009 |
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2009 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Female; Humans; Japan; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Young Adult | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2010 |
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Lapatinib; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2010 |
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Function, Left | 2010 |
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Synergism; Female; Humans; Lapatinib; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2010 |
Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Pain; Quality of Life; Quinazolines | 2010 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Filgrastim; Follow-Up Studies; Gene Amplification; Granulocyte Colony-Stimulating Factor; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Survival Rate; Trastuzumab; Treatment Outcome | 2010 |
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Inflammation; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines | 2010 |
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms | 2010 |
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diarrhea; ErbB Receptors; Exanthema; Fatigue; Female; Humans; Infant; Lapatinib; Male; Maximum Tolerated Dose; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Steroids; Treatment Outcome; United States; Young Adult | 2010 |
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Ventricular Function, Left | 2010 |
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quality of Life; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome; United States | 2012 |
A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Latvia; Middle Aged; Paclitaxel; Poland; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Romania; Russia; Up-Regulation | 2010 |
A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bayes Theorem; Biomarkers; Carcinoma, Squamous Cell; Contrast Media; Endpoint Determination; Head and Neck Neoplasms; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2011 |
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Carcinoma; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Stroke Volume; Trastuzumab; Troponin I | 2011 |
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Castration; ErbB Receptors; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate | 2013 |
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires; Trastuzumab; Treatment Outcome | 2011 |
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2011 |
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan | 2011 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction | 2011 |
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Europe; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines | 2011 |
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Female; Humans; Hyperplasia; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Lapatinib; Middle Aged; Placebos; Prevalence; Quinazolines; Receptor, ErbB-2; Time Factors | 2011 |
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Confidence Intervals; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Models, Economic; Probability; Quality-Adjusted Life Years; Quinazolines; State Medicine; Trastuzumab; United Kingdom; Women's Health | 2012 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2013 |
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Disease Progression; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Placebos; Quinazolines; Single-Blind Method; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2011 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Survival Rate; Triazoles | 2011 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines | 2012 |
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Count; Cohort Studies; Dasatinib; Female; Hemangioblasts; Hematopoietic Stem Cells; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Thiazoles; Trastuzumab; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2012 |
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Young Adult | 2012 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lapatinib; Liver; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
Topics: Aged; Antibody Formation; Demography; Epitopes; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; T-Lymphocytes; Treatment Outcome; Vaccination | 2012 |
Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.
Topics: Alanine Transaminase; Chemical and Drug Induced Liver Injury; Genotype; Gilbert Disease; Glucuronosyltransferase; HLA-DQ alpha-Chains; HLA-DRB1 Chains; Humans; Incidence; Lapatinib; Quinazolines | 2012 |
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2012 |
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Odds Ratio; Prognosis; Proportional Hazards Models; Quality of Life; Quinazolines; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome | 2012 |
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2012 |
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Lapatinib; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Prognosis; Prospective Studies; Quinazolines; Survival Rate; Tissue Distribution; Young Adult | 2012 |
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab | 2012 |
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Drug Administration Schedule; Endometrial Neoplasms; Female; Genes, erbB-1; Genetic Markers; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Predictive Value of Tests; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Translational Research, Biomedical; Trastuzumab; Treatment Outcome | 2012 |
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Lapatinib; Laryngeal Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids | 2013 |
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cohort Studies; ErbB Receptors; Female; Humans; Immunohistochemistry; Lapatinib; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2012 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides; Young Adult | 2013 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2013 |
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Nausea; Paclitaxel; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).
Topics: Adult; Aged; Biopsy; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Estrogen | 2013 |
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Lymph Nodes; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Female; Humans; Indazoles; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm Staging; Papillomaviridae; Quinazolines; Radiotherapy Dosage; Treatment Outcome | 2013 |
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Humans; Indazoles; Lapatinib; Middle Aged; Neoplasm Staging; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide | 2013 |
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; International Cooperation; Lapatinib; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Trastuzumab | 2013 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2013 |
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Up-Regulation | 2013 |
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Phase II study on lapatinib in advanced EGFR-positive chordoma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Chordoma; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Quinazolines; Sacrum; Skull Base; Treatment Outcome | 2013 |
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Decision Making; Female; Humans; Lapatinib; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Grading; Nitriles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
Topics: Adult; Aged; Breast Neoplasms; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2 | 2013 |
Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Diarrhea; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Stomatitis; Treatment Outcome | 2015 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Inflammation; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Leukocyte Count; Male; Megestrol Acetate; Middle Aged; Platelet Count; Prognosis; Quinazolines; Serum Albumin; Tamoxifen; Young Adult | 2013 |
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Topics: Adolescent; Antineoplastic Agents; Blotting, Western; Central Nervous System Neoplasms; Child; Child, Preschool; Ependymoma; ErbB Receptors; Female; Glioma; Humans; Infant; Lapatinib; Male; Medulloblastoma; Neoplasm Grading; Quinazolines; Treatment Outcome; Young Adult | 2013 |
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Young Adult | 2013 |
[HER2-positive breast cancer: standard and double targeted therapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting | 2013 |
Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Time Factors; Turkey; Vinblastine; Vinorelbine | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2013 |
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Failure; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Everolimus; Female; Humans; Incidence; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; United States; Young Adult | 2013 |
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2013 |
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Transcriptome; Trastuzumab; Treatment Outcome | 2014 |
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2013 |
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Lapatinib; Logistic Models; Mastectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Puerto Rico; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome; United States | 2013 |
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Trastuzumab; Treatment Outcome | 2013 |
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Lapatinib; Maytansine; Medication Adherence; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Self Report; Surveys and Questionnaires; Time Factors; Trastuzumab; Treatment Outcome | 2014 |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Female; Humans; Incidence; Lapatinib; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2013 |
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lapatinib; Male; Middle Aged; Pilot Projects; Pituitary Neoplasms; Prolactinoma; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT5 Transcription Factor; Trastuzumab | 2013 |
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Dietary Fats; Food-Drug Interactions; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2014 |
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Breast Neoplasms; Early Detection of Cancer; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Italy; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2014 |
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lapatinib; Male; Middle Aged; Neoplasms; Pyrimidines; Quinazolines; Sulfonamides | 2014 |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2014 |
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Ki-67 Antigen; Lapatinib; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2014 |
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2014 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Odds Ratio; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome | 2014 |
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2014 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.
Topics: Adult; Aged; Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; ErbB Receptors; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prognosis; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms | 2014 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome | 2014 |
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Hormones; Humans; Lapatinib; Middle Aged; Postmenopause; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; Vinblastine; Vinorelbine | 2014 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2015 |
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Proliferation; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Preoperative Period; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2015 |
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Lapatinib; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome; Uterine Cervical Neoplasms | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Thymidylate Synthase; Treatment Outcome | 2015 |
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires | 2015 |
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Female; Follow-Up Studies; Humans; International Cooperation; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Patient Selection; Quality of Life; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 10; Female; Follow-Up Studies; Gene Deletion; Humans; Immunoenzyme Techniques; Lapatinib; Neoadjuvant Therapy; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2015 |
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Child; Child, Preschool; Drug Resistance, Neoplasm; Ependymoma; Female; Follow-Up Studies; Humans; Lapatinib; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate; Tissue Distribution; Young Adult | 2015 |
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate | 2015 |
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Topics: Alanine Transaminase; Alleles; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Genome-Wide Association Study; HLA-DRB1 Chains; Humans; Hyperbilirubinemia; INDEL Mutation; Lapatinib; Polymorphism, Single Nucleotide; Quinazolines; Risk | 2016 |
Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Count; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Postmenopause; Premenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2015 |
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Indazoles; Lapatinib; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides | 2015 |
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Mutation; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Topics: Animals; Female; Heterografts; Humans; Imidazoles; Lapatinib; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Phenotype; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Colorectal Neoplasms; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Patient Selection; Quinazolines; Receptor, ErbB-2; ROC Curve; Trastuzumab | 2015 |
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2016 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Lapatinib; Male; MAP Kinase Signaling System; Middle Aged; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2015 |
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2015 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Double-Blind Method; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; International Cooperation; Kaplan-Meier Estimate; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Molecular Targeted Therapy; Odds Ratio; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
Topics: Administration, Oral; Adult; Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Dosage Calculations; ErbB Receptors; Female; Half-Life; Humans; Immunohistochemistry; Lapatinib; Mice; Mice, SCID; Phosphorylation; Quinazolines; ROC Curve; Tandem Mass Spectrometry; Transplantation, Heterologous | 2015 |
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr
Topics: Adult; Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Canada; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2015 |
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Patient Selection; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Trastuzumab | 2016 |
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Precision Medicine; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Time Factors; Treatment Outcome | 2016 |
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2016 |
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Breast Neoplasms, Male; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2016 |
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2016 |
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2016 |
Effect of lapatinib on oral digoxin absorption in patients.
Topics: Administration, Oral; Adult; Alberta; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cardiotonic Agents; Cross-Over Studies; Digoxin; Drug Interactions; Female; Gastrointestinal Absorption; Half-Life; Humans; Lapatinib; Metabolic Clearance Rate; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Seoul | 2015 |
Ongoing Clinical Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Peptide Fragments; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2016 |
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Topics: Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Lapatinib; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2016 |
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Disease Progression; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Neoplasm Staging; Polymorphism, Single Nucleotide; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Treatment Outcome | 2016 |
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Topics: Adult; Aged; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Lapatinib; Lymphocytes, Tumor-Infiltrating; Microarray Analysis; Middle Aged; Neoadjuvant Therapy; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2016 |
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Letrozole; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nitriles; Positron-Emission Tomography; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2016 |
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Interactions; Esophageal Neoplasms; Female; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proton Pump Inhibitors; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2017 |
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome; Young Adult | 2017 |
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Urinary Bladder Neoplasms | 2017 |
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; DNA, Neoplasm; Exome Sequencing; Female; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; rhoA GTP-Binding Protein; Trastuzumab | 2017 |
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab | 2017 |
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Female; Humans; Lapatinib; Liposomes; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2017 |
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Hypoglycemic Agents; Insulin; Lapatinib; Metformin; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
Topics: Antineoplastic Agents; Axilla; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lapatinib; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab; Tumor Burden | 2017 |
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Topics: Adult; Aged; Antigens, Neoplasm; Breast Neoplasms; Carbonic Anhydrase IX; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Early Termination of Clinical Trials; Female; Hemorrhage; Humans; Lapatinib; Male; Maytansine; Middle Aged; Neoplasm Metastasis; Neutropenia; Practice Patterns, Physicians'; Quinazolines; Receptor, ErbB-2; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2017 |
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Taxoids; Trastuzumab | 2017 |
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2017 |
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Demography; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Vinblastine; Vinorelbine | 2018 |
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre,
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2018 |
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2018 |
Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Topics: Adult; Antineoplastic Agents; Female; Humans; Imaging, Three-Dimensional; Lapatinib; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Retrospective Studies; Young Adult | 2018 |
Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Female; Humans; Lapatinib; Prospective Studies; Quinazolines; Receptor, ErbB-2 | 2020 |
First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.
Topics: Adolescent; Adult; Aniline Compounds; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Double-Blind Method; ErbB Receptors; Female; Healthy Volunteers; Humans; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Therapeutic Equivalency; Young Adult | 2020 |
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2021 |
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Lapatinib; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab; United Kingdom | 2022 |
870 other study(ies) available for quinazolines and lapatinib
| Article | Year |
|---|---|
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2002 |
Targeting HER2 in brain metastases from breast cancer.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Rats; Rats, Nude; Receptor, ErbB-2 | 2003 |
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
Topics: Breast Neoplasms; Cell Line, Tumor; Dimerization; Enzyme Inhibitors; Humans; Lapatinib; Neuregulin-1; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2004 |
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Neoplasm Proteins; Phosphorylation; Quinazolines; Radiation Tolerance; Receptor, ErbB-2; Signal Transduction; Tumor Stem Cell Assay | 2004 |
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Topics: Amino Acid Sequence; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Lapatinib; Models, Molecular; Molecular Sequence Data; Oncogene Proteins v-erbB; Protein Conformation; Protein Structure, Secondary; Quinazolines; Substrate Specificity | 2004 |
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen | 2005 |
Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2004 |
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic | 2005 |
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Topics: Antibiotics, Antineoplastic; Butadienes; Cell Cycle; Chromones; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mesothelioma; Mitogen-Activated Protein Kinase 3; Morpholines; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pleural Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Sirolimus; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Topics: Antibodies, Monoclonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2005 |
GlaxoSmithKline cancer drug threatens Herceptin market.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Lapatinib; Marketing; Neoplasms; Quinazolines; Trastuzumab; United States | 2005 |
Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
Topics: Child; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Drug Stability; Humans; Lapatinib; Quinazolines; Spectrometry, Mass, Electrospray Ionization | 2006 |
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |
Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays | 2006 |
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Interactions; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mice; Mice, SCID; Oncogene Protein v-akt; Phosphorylation; Quinazolines; raf Kinases; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Microtubule-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Survivin | 2006 |
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Small Interfering; Signal Transduction | 2006 |
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
Topics: Cell Line, Tumor; ErbB Receptors; Furans; Humans; Inhibitory Concentration 50; Lapatinib; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
Two targets, one drug for new EGFR inhibitors.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lapatinib; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor | 2006 |
Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase; Trastuzumab | 2006 |
Three new drugs available to fight kidney cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lapatinib; Multicenter Studies as Topic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
New hope for RCC patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lapatinib; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2006 |
Delivery of a healthy baby after first-trimester maternal exposure to lapatinib.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Infant, Newborn; Lapatinib; Live Birth; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines | 2006 |
Targeted therapy for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Lapatinib; Nitriles; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2007 |
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2007 |
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoblotting; Immunoprecipitation; Insulin-Like Growth Factor I; Lapatinib; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Trastuzumab | 2007 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Research Design; Trastuzumab; United States | 2007 |
The EGF receptor Hokey-Cokey.
Topics: Antineoplastic Agents; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
TEACH: Tykerb evaluation after chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2007 |
relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.
Topics: Cell Cycle; Cell Proliferation; Cells, Cultured; Lapatinib; Models, Statistical; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2 | 2007 |
Lapatinib plus capecitabine in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2007 |
Closing in on a cure.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; United States | 2006 |
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Cloning, Molecular; DNA, Complementary; Female; Genes, erbB-2; Genetic Vectors; Humans; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Sequence Deletion; Signal Transduction; Transfection; Transplantation, Heterologous; Trastuzumab | 2007 |
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lapatinib; Models, Biological; Oligonucleotide Array Sequence Analysis; Proteomics; Quinazolines; Time Factors | 2007 |
Lapatinib shows promise for inflammatory breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Inflammation; Lapatinib; Multicenter Studies as Topic; Quinazolines | 2007 |
Lapatinib.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2007 |
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Transformed; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; Models, Statistical; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
The value meal: how to save $1,700 per month or more on lapatinib.
Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Labeling; Drug Packaging; Eating; Economics, Medical; Humans; Lapatinib; Quinazolines; Time Factors | 2007 |
Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts.
Topics: Apoptosis; Arthritis, Rheumatoid; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Epidermal Growth Factor; Fibroblasts; Gene Expression Regulation; Humans; Inflammation Mediators; Lapatinib; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Synovial Membrane | 2008 |
Why are promising new drugs for dying patients still out of reach?
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Drug Approval; Female; Health Services Accessibility; Humans; Lapatinib; Quinazolines; Terminal Care; United States; United States Food and Drug Administration | 2007 |
The value of label recommendations: how to dose lapatinib.
Topics: Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Drug Labeling; Food-Drug Interactions; Humans; Lapatinib; Quinazolines | 2007 |
Effect of food on lapatinib pharmacokinetics.
Topics: Antineoplastic Agents; Biological Availability; Food-Drug Interactions; Humans; Lapatinib; Quinazolines | 2007 |
The value meal: effect of food on lapatinib bioavailability.
Topics: Antineoplastic Agents; Biological Availability; Food-Drug Interactions; Humans; Lapatinib; Quinazolines | 2007 |
Controversies in using lapatinib at reduced dosage with food.
Topics: Antineoplastic Agents; Food; Humans; Lapatinib; Quinazolines | 2007 |
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colorimetry; Drug Synergism; Flow Cytometry; Humans; Indicators and Reagents; Lapatinib; Mutation; Oncogene Protein v-akt; Piperidines; Prenylation; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2008 |
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutant Proteins; Phosphorylation; Polymorphism, Single Nucleotide; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2008 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.
Topics: Animals; Biological Transport; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Humans; Lapatinib; Male; Membrane Transport Proteins; Mice; Mice, Mutant Strains; Organic Anion Transporters; Quinazolines; Rats; Rats, Wistar; Tissue Distribution | 2008 |
Development of new targeted therapies for breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Female; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2008 |
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Proteome; Proteomics; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2008 |
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Topics: Animals; Cells, Cultured; Conserved Sequence; Enzyme Activation; ErbB Receptors; Humans; Lapatinib; Models, Biological; Models, Molecular; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Quaternary; Protein Structure, Secondary; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Spodoptera | 2008 |
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Endometrial Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2008 |
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Chlorocebus aethiops; COS Cells; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Mutation; Quinazolines | 2008 |
Advances in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lapatinib; Lung Neoplasms; Mastectomy, Modified Radical; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Trastuzumab | 2008 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |
Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cerebellar Ataxia; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.
Topics: Antineoplastic Agents; Cell Proliferation; Gene Dosage; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Lapatinib; Models, Molecular; Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; ROC Curve; Tumor Cells, Cultured | 2008 |
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Topics: Antineoplastic Agents; Cell Survival; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Humans; Lapatinib; Mutation; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
FDA approves new drug for specific type of advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Approval; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; United States; United States Food and Drug Administration | 2007 |
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Research Design | 2008 |
Mathematics in the realm of lapatinib: 500 + 500 = 1,500?
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2008 |
Ten years of HER2-directed therapy: still questions after all these years.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Forecasting; Humans; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2009 |
Lapatinib study supports cancer stem cell hypothesis, encourages industry research.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; CD24 Antigen; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Up-Regulation | 2008 |
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stroke Volume; Ventricular Dysfunction, Left | 2008 |
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
Topics: bcl-2 Homologous Antagonist-Killer Protein; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; HCT116 Cells; Humans; Lapatinib; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2008 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
Topics: Animals; Cell Line; Cell Proliferation; Cell Survival; Drug Combinations; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Immunoblotting; Immunoprecipitation; Interleukin-3; Lapatinib; Mice; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lignans; Magnolia; Medicine, Chinese Traditional; Quinazolines; Signal Transduction; Sirolimus; Time Factors | 2008 |
Focus on ERBB2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Genetic Predisposition to Disease; Humans; Lapatinib; Polymorphism, Genetic; Protein Binding; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
[New treatment approaches in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2008 |
Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Female; Folliculitis; Granuloma, Pyogenic; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2008 |
As metastasis yields its biological secrets, researchers hope to apply findings.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab | 2008 |
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Immunochemistry; Lapatinib; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2008 |
Drug development in the targeted therapy era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disclosure; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Quinazolines; Receptor, ErbB-2 | 2008 |
Promising newer molecular-targeted therapies in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
Dual targeting of EGFR and HER-2 in colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; ErbB Receptors; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Paclitaxel; Quinazolines; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Are volumetric changes of brain metastases the best evaluation of efficacy?
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cranial Irradiation; Endpoint Determination; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Treatment Outcome | 2008 |
Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Breast Neoplasms; Disease Progression; Epithelial Cells; Female; Gene Amplification; Humans; Lapatinib; Monitoring, Physiologic; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2009 |
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2008 |
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carrier Proteins; Cell Line, Tumor; Drug Resistance; Female; Humans; Imidazoles; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2008 |
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Laboratories, Hospital; Lapatinib; Medical Laboratory Personnel; Pathology, Clinical; Physicians; Quinazolines; Receptor, ErbB-2; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2008 |
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Insulin-Like Growth Factor I; Lapatinib; Leptin; Neoplasm Invasiveness; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptors, Leptin; Signal Transduction; Transcriptional Activation | 2008 |
An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}meth
Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Breast Neoplasms; Central Nervous System; Cricetinae; Disease Models, Animal; Drug Synergism; Female; Humans; Lapatinib; Male; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution | 2009 |
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Remission Induction; Signal Transduction; Trastuzumab | 2009 |
How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Taxoids | 2009 |
tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
Topics: Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flavonoids; Humans; Lapatinib; Leupeptins; Lignans; Olive Oil; Phenols; Phosphorylation; Plant Oils; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Trastuzumab | 2008 |
Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Expression Profiling; Humans; Lapatinib; Multicenter Studies as Topic; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Inhibitory Concentration 50; Lapatinib; Models, Chemical; Molecular Conformation; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2009 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclin D1; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Precancerous Conditions; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2009 |
Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell-Free System; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Glioma; Glutathione S-Transferase pi; Humans; Lapatinib; Mice; Mice, Nude; Models, Molecular; Molecular Sequence Data; Neoplasm Transplantation; Phosphorylation; Protein Conformation; Quinazolines; Recombinant Proteins; RNA, Small Interfering; Signal Transduction; Static Electricity; Transplantation, Heterologous; Tyrosine | 2009 |
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Quinazolines | 2009 |
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
Topics: Antineoplastic Agents; Humans; Lapatinib; Likelihood Functions; Quinazolines; Randomized Controlled Trials as Topic; Research Design | 2010 |
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Humans; Lapatinib; Mice; Quinazolines; Receptor, ErbB-2; Receptor, Notch1; RNA, Messenger; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
microRNA-205 regulates HER3 in human breast cancer.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Gefitinib; Genes, Tumor Suppressor; Genetic Therapy; Humans; Lapatinib; MicroRNAs; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-3; Transfection | 2009 |
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Humans; Inhibitory Concentration 50; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
[Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Hungary; Immunohistochemistry; Insurance, Health, Reimbursement; Lapatinib; Medical Oncology; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Societies, Medical; Up-Regulation | 2009 |
Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
The "win-win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Trastuzumab | 2009 |
No cure in sight for the world's drug problem.
Topics: Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Utilization; Female; Humans; Lapatinib; Quinazolines; United Kingdom | 2009 |
Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Blotting, Western; Digoxin; Everolimus; Female; Intestinal Mucosa; Intestines; Lapatinib; Mice; Mice, Knockout; Quinazolines; Sirolimus; Substrate Specificity; Tissue Distribution | 2009 |
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lapatinib; Male; Mice; Middle Aged; Mitogen-Activated Protein Kinase 7; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Movement; ErbB Receptors; Female; Gefitinib; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays | 2009 |
Lapatinib for inflammatory breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Humans; Inflammation; Lapatinib; Quinazolines | 2009 |
Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2009 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Humans; Indazoles; Lapatinib; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Transgenic; Middle Aged; Paraffin Embedding; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Messenger; Signal Transduction; Transcription, Genetic; Transfection; Up-Regulation | 2009 |
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
Topics: Amino Acid Sequence; Cell Line; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Lapatinib; Molecular Sequence Data; Mutant Proteins; Phosphopeptides; Phosphorylation; Phosphotyrosine; Quinazolines; Time Factors | 2009 |
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
Topics: Active Transport, Cell Nucleus; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Genes, erbB-2; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
Effects of food on bioavailability of lapatinib: useful data, wrong conclusion.
Topics: Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Lapatinib; Male; Neoplasms; Quinazolines; Reference Values; Risk Assessment | 2009 |
Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Calreticulin; Cell Line, Tumor; Cell Nucleus; Cetuximab; Endoplasmic Reticulum; ErbB Receptors; Green Fluorescent Proteins; Humans; Lapatinib; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Recombinant Fusion Proteins; SEC Translocation Channels; Signal Transduction; Transfection | 2009 |
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioma; Humans; Indoles; Lapatinib; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Quinazolines; Sunitinib | 2010 |
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mucin-1; Quinazolines; Receptor, ErbB-2; Thrombocytopenia; Trastuzumab | 2009 |
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Clone Cells; Drug Antagonism; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Lapatinib; Oncogene Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Estrogen; RNA, Small Interfering; Trastuzumab | 2009 |
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Culture Techniques; Cell Division; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Matrix; Female; Gels; Humans; Integrin beta1; Laminin; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2010 |
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; ErbB Receptors; Humans; Lapatinib; Melanoma; Mice; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-4; RNA Interference; Skin Neoplasms | 2009 |
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line; Drug Resistance, Multiple; Erlotinib Hydrochloride; Humans; Lapatinib; Multidrug Resistance-Associated Proteins; Quinazolines | 2010 |
Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Indazoles; Lapatinib; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Liposomes; Neoplasm Proteins; Quinazolines; RNA, Small Interfering | 2009 |
Gastric cancer: trastuzumab trial results spur search for other targets.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Everolimus; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Receptor, ErbB-2; Sirolimus; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2009 |
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Nitriles; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Survival Analysis; Time Factors; Trastuzumab; Triazoles | 2009 |
Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Eruptions; ErbB Receptors; Female; Humans; Lapatinib; Mammaplasty; Middle Aged; Quinazolines; Surgical Flaps | 2009 |
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Cell Death; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Indoles; Lapatinib; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines | 2009 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Topics: Anthracenes; Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-raf; Quinazolines; Radiation Tolerance; Receptor, ErbB-2; Tumor Cells, Cultured | 2009 |
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dasatinib; Humans; Lapatinib; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sensitivity and Specificity; Thiazoles | 2009 |
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Topics: Adenoviridae; Animals; Blotting, Western; Breast Neoplasms; Cancer Vaccines; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Genetic Therapy; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Information for patients. HER2: what you need to know.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genetic Techniques; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression; Gene Expression Profiling; Humans; Lapatinib; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quinazolines; Sensitivity and Specificity; Signal Transduction; Urinary Bladder Neoplasms | 2009 |
Autophagy can contribute to cell death when combining targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Death; Colonic Neoplasms; HCT116 Cells; Humans; Indoles; Lapatinib; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines | 2009 |
Targeting breast cancer stem cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Isoenzymes; Lapatinib; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Retinal Dehydrogenase; Signal Transduction | 2009 |
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Tegafur; Xenograft Model Antitumor Assays | 2010 |
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Retinoblastoma-Like Protein p130; RNA Interference; RNA, Messenger; Signal Transduction; Time Factors; Trastuzumab | 2010 |
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Fatty Acids; Gene Knockdown Techniques; Glioblastoma; Humans; Hydrolysis; Lapatinib; Lipogenesis; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Sterol Regulatory Element Binding Protein 1 | 2009 |
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical | 2009 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Ras-induced resistance to lapatinib is overcome by MEK inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, ras; Humans; Immunoblotting; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Mutation; Nitriles; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Female; Genes, ras; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Nelfinavir; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
[New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
Topics: Apoptosis; Biopsy; Breast Neoplasms; Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Humans; Immunohistochemistry; Lapatinib; NF-kappa B; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Transcription Factor RelA | 2010 |
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Topics: Adaptation, Physiological; Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; GRB7 Adaptor Protein; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transplantation, Heterologous; Up-Regulation | 2010 |
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome | 2010 |
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Mice; Mice, Nude; Mice, SCID; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2010 |
Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression; Gene Expression Profiling; Humans; Lapatinib; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Triazoles; United States; United States Food and Drug Administration; Women's Health | 2010 |
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lapatinib; Mutation; Neuregulin-1; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Trastuzumab | 2010 |
Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin alpha3beta1; Integrin alpha6beta4; Kalinin; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tetraspanin 24; Trastuzumab | 2010 |
HER2 as a cancer stem-cell target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Lapatinib; Mice; Paclitaxel; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2010 |
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lapatinib; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.
Topics: Adenylate Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Breast Neoplasms; Calcium; Cell Line, Tumor; Elongation Factor 2 Kinase; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Lapatinib; Quinazolines; Signal Transduction; Trastuzumab | 2010 |
Reporting of studies on new medicines in major medical journals: a case study in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Paclitaxel; Periodicals as Topic; Quinazolines; United States; United States Food and Drug Administration | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lapatinib; Mice; Mitogen-Activated Protein Kinases; Neoplasms; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2010 |
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzenesulfonates; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; Cytosol; DNA Primers; Endoplasmic Reticulum; Flow Cytometry; Gefitinib; Humans; Lapatinib; Membrane Potentials; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2010 |
Updates on therapeutic approaches in HER2-positive disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization.
Topics: Action Potentials; Animals; Antineoplastic Agents; Cell Line; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Heart Conduction System; Humans; Ion Channels; KCNQ1 Potassium Channel; Kidney; Lapatinib; Muscle Proteins; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Potassium Channels, Voltage-Gated; Purkinje Fibers; Quinazolines; Rabbits; Sodium Channels; Transfection | 2010 |
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Combinations; Drug Delivery Systems; Drug Synergism; Fluorouracil; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
Topics: Animals; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Mice; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Transplantation, Heterologous | 2010 |
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Endothelial Cells; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stem Cells; Time Factors; Xenograft Model Antitumor Assays | 2010 |
Targeting alternative pathways in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2010 |
Novel targeted therapies in inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2010 |
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; ErbB Receptors; Humans; Immunohistochemistry; Lapatinib; Mitogen-Activated Protein Kinases; Neuroma, Acoustic; Protein Array Analysis; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |
Trastuzumab in gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Forecasting; Genes, erbB-2; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2010 |
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; ErbB Receptors; Europe; Evidence-Based Medicine; Female; Humans; Lapatinib; Neoplasm Staging; Neoplasms, Hormone-Dependent; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.
Topics: Anoikis; Antineoplastic Agents; Carcinoma; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lapatinib; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2011 |
Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.
Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Line, Tumor; Computational Biology; Computer Simulation; Female; G1 Phase; Humans; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Mutant Proteins; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Resting Phase, Cell Cycle; Signal Transduction | 2010 |
Modulation of P-gp expression by lapatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins | 2010 |
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Everolimus; Female; Humans; Lapatinib; Quinazolines; Sirolimus | 2011 |
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Lapatinib; Microsomes, Liver; Quinazolines | 2010 |
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Decoupling of receptor and downstream signals in the Akt pathway by its low-pass filter characteristics.
Topics: Animals; Epidermal Growth Factor; ErbB Receptors; Immunoblotting; Lapatinib; Models, Biological; PC12 Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Ribosomal Protein S6; Signal Transduction | 2010 |
Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Centromere; Chromosomes, Human, Pair 17; Clinical Trials as Topic; False Negative Reactions; False Positive Reactions; Female; Humans; Immunohistochemistry; Lapatinib; Practice Guidelines as Topic; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, ErbB-2 | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Immunotoxins; Lapatinib; Maytansine; Mice; Mice, Nude; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult | 2010 |
[HER2 ASCO guidelines. The answer to everything?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Delivery Systems; Female; Formaldehyde; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Practice Guidelines as Topic; Predictive Value of Tests; Prognosis; Quinazolines; Receptor, ErbB-2; Tissue Fixation; Trastuzumab; Treatment Outcome | 2010 |
Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2010 |
A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Cycle; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Humans; Indazoles; Intracellular Space; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2010 |
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Logistic Models; Middle Aged; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Transforming Growth Factor alpha; Treatment Outcome; Up-Regulation | 2011 |
[Therapeutic targets and molecular mechanisms].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Lung Neoplasms; Lymphangioleiomyomatosis; Middle Aged; Neoplasms, Second Primary; Oxygen Inhalation Therapy; Pneumothorax; Quinazolines; Trastuzumab | 2010 |
Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Topics: Acetylation; Acrylamides; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Histone Deacetylase Inhibitors; Histones; Humans; Isoenzymes; Lapatinib; Quinazolines; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship | 2010 |
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Topics: 4-Butyrolactone; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Fatty Acid Synthases; Female; Fluorescent Antibody Technique; Gene Expression; Humans; Lapatinib; Mass Spectrometry; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuregulin-1; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2010 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lapatinib; Mice; Mice, SCID; Pentacyclic Triterpenes; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lactotrophs; Lapatinib; Molecular Targeted Therapy; Prolactin; Prolactinoma; Quinazolines; Rats; Receptor, ErbB-2; RNA, Messenger; Signal Transduction | 2011 |
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase II as Topic; Docetaxel; Enzyme Activation; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Taxoids; Transfection; Trastuzumab | 2011 |
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cancer Vaccines; Clinical Trials as Topic; Humans; Immunotherapy; Lapatinib; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; T-Lymphocytes; Trastuzumab | 2011 |
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2011 |
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Sorafenib; Survivin; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chromosomes, Human, Pair 17; Female; Gene Amplification; Humans; Lapatinib; Neoplasm Metastasis; Polyploidy; Prognosis; Quinazolines; Receptor, ErbB-2 | 2010 |
Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy.
Topics: Animals; Female; Genes, erbB; Lapatinib; Mice; Mice, Inbred C57BL; Neuregulin-1; Phosphorylation; Pregnancy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Sprague-Dawley; Ventricular Function, Left; Ventricular Remodeling | 2011 |
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Focal Adhesion Kinase 1; Glioblastoma; Humans; Indoles; Integrin beta1; Integrin beta3; Integrins; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Genes, erbB-2; Humans; Lapatinib; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2011 |
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
[Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; HLA-DQ alpha-Chains; HLA-DQ Antigens; Humans; Lapatinib; Liver; Liver Diseases; Liver Function Tests; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Topics: Anilides; Antibodies, Monoclonal; Apoptosis; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunoprecipitation; Lapatinib; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2011 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Humans; Lapatinib; Mice; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptors, Fibroblast Growth Factor | 2011 |
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; Disease Progression; Female; Gefitinib; Humans; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT1 Transcription Factor; Transplantation, Heterologous | 2011 |
Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure | 2010 |
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cells, Cultured; Female; Gene Expression; Gene Expression Profiling; Humans; Immunoblotting; Immunoprecipitation; Lapatinib; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Mastectomy; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Skin Neoplasms | 2011 |
Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab.
Topics: Abdominal Pain; Adenocarcinoma, Papillary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Immunohistochemistry; Lapatinib; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2011 |
Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.
Topics: Breast Neoplasms; Disease Progression; Female; Humans; Immediate-Early Proteins; Lapatinib; Quinazolines; Tumor Suppressor Proteins | 2011 |
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Activation; Escherichia coli; Ferricyanides; Humans; Lapatinib; Mass Spectrometry; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Protein Binding; Quinazolines | 2011 |
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Salvage Therapy; Treatment Failure | 2011 |
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Topics: Animals; Breast Neoplasms; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Transcription, Genetic; Transplantation, Heterologous; Up-Regulation | 2011 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Quinazolines; Receptor, ErbB-2; RNA Interference; Survivin; Trastuzumab | 2011 |
Hints of future progress for HER-2 breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Off-Label Use; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2011 |
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Child; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Embryo, Mammalian; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Pyrimidines; Pyrroles; Quail; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA Interference; Tumor Burden; Tumor Cells, Cultured; Young Adult | 2011 |
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Panobinostat; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2011 |
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Staining and Labeling; Treatment Outcome | 2011 |
Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Lapatinib; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2011 |
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; MAP Kinase Kinase Kinases; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin | 2011 |
A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network.
Topics: Amino Acid Sequence; Antineoplastic Agents; Computer Simulation; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Intracellular Signaling Peptides and Proteins; Lapatinib; Models, Biological; Molecular Dynamics Simulation; Molecular Sequence Data; Principal Component Analysis; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-3; Signal Transduction; Structural Homology, Protein | 2011 |
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maytansine; Mice; Mice, SCID; Mitosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Models, Biological; Quinazolines; Vinblastine; Vinorelbine | 2011 |
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Trastuzumab; Young Adult | 2012 |
Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
Topics: Antineoplastic Agents; Autophagy; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2011 |
[Breast cancer therapy with combination of endocrine and target drugs].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Sirolimus; Trastuzumab | 2011 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Survivors; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Lapatinib-induced hepatitis: a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Jaundice; Lapatinib; Middle Aged; Quinazolines | 2011 |
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Electrophoresis, Polyacrylamide Gel; HCT116 Cells; HT29 Cells; Humans; Immunohistochemistry; Lapatinib; Mice; Mice, Nude; Microscopy, Fluorescence; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.
Topics: Benzothiazoles; Cell Cycle; Cell Proliferation; Epidermal Growth Factor; Humans; Lapatinib; Neuroma, Acoustic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2011 |
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Trastuzumab | 2011 |
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of NRC-AN-019 in a pre-clinical breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Predictive Value of Tests; Prognosis; Quinazolines; Trastuzumab | 2011 |
HER2-targeted therapies: how far we've come--and where we're headed.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Delivery Systems; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2011 |
Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Female; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Threonine; Trastuzumab; Tyrosine | 2012 |
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Female; Humans; Lapatinib; Neuregulin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.
Topics: Animals; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lapatinib; Mammary Neoplasms, Animal; Models, Chemical; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2011 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cyclic S-Oxides; Drug Resistance, Neoplasm; Female; Gene Targeting; Genes, erbB; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Recurrence; Signal Transduction; Thiadiazoles; Trastuzumab | 2011 |
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase 2; Humans; Lapatinib; Quinazolines; Vascular Endothelial Growth Factor A | 2012 |
Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Blotting, Western; Drug Synergism; Female; Flow Cytometry; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Quinazolines; Trastuzumab; Up-Regulation | 2011 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Humans; Integrin beta1; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Trastuzumab; Up-Regulation | 2011 |
Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.
Topics: Binding Sites; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Biological; Pharmaceutical Preparations; Phosphorylation; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tumor Cells, Cultured | 2011 |
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Claudin-4; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2011 |
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heart; Humans; Lapatinib; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Razoxane; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Humans; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Thymidine Kinase | 2011 |
Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Dimerization; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Immunoprecipitation; Lapatinib; Plasmids; Protein Conformation; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2012 |
Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.
Topics: Administration, Oral; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2012 |
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cetuximab; DNA; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Reporter; Green Fluorescent Proteins; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Lapatinib; Molecular Sequence Data; Neoplasm Metastasis; Quinazolines; Transcription, Genetic | 2011 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms | 2011 |
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Injections, Intravenous; Lapatinib; Mice; Quinazolines; Receptor, ErbB-2; Up-Regulation | 2012 |
Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2 | 2011 |
hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cetuximab; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Ovarian Neoplasms; Prognosis; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2011 |
The role of lapatinib in the preoperative therapy of breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Neoplasm Proteins; Preoperative Care; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Failure | 2012 |
Surrogate markers for targeted therapy-based treatment activity and efficacy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Trastuzumab; Treatment Outcome; Validation Studies as Topic | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab | 2012 |
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2011 |
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Amplification; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Smad3 Protein; Transcription, Genetic; Transcriptome; Transforming Growth Factor beta; Tretinoin | 2012 |
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Death; Cholesterol; ErbB Receptors; Glioblastoma; HeLa Cells; Humans; Lapatinib; Liver X Receptors; Mice; Mice, SCID; Orphan Nuclear Receptors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2011 |
Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Caspase 7; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cyclin B1; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lapatinib; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Poly(ADP-ribose) Polymerases; Protein Kinases; Proto-Oncogene Proteins c-akt; Quercetin; Quinazolines; Signal Transduction | 2013 |
Hepatotoxicity associated with lapatinib in an experimental rat model.
Topics: Alanine Transaminase; Albumins; Analysis of Variance; Animals; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Lapatinib; Lipoproteins, VLDL; Liver; Liver Function Tests; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triglycerides | 2012 |
Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colloids; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Nanocapsules; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2012 |
Mechanistic insights into the activation of oncogenic forms of EGF receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Epidermal Growth Factor; ErbB Receptors; HEK293 Cells; Humans; Kinetics; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Quinazolines; Tumor Suppressor Proteins | 2011 |
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Estrogen; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
[A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines | 2011 |
Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Cell Differentiation; Flow Cytometry; Humans; K562 Cells; Lapatinib; Megakaryocytes; Protein Kinase Inhibitors; Quinazolines | 2011 |
Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
Topics: Antineoplastic Agents; Autophagy; Cell Death; Cell Line, Tumor; Genes, erbB-2; Humans; Indoles; Lapatinib; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines | 2012 |
A time-series DDP for functional proteomics profiles.
Topics: Bayes Theorem; Biomarkers, Tumor; Biometry; Cell Line, Tumor; Data Interpretation, Statistical; ErbB Receptors; Female; Humans; Lapatinib; Linear Models; Markov Chains; Models, Statistical; Monte Carlo Method; Multivariate Analysis; Ovarian Neoplasms; Protein Array Analysis; Proteomics; Quinazolines; Signal Transduction; Statistics, Nonparametric | 2012 |
Treatment of vestibular schwannoma cells with ErbB inhibitors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Ear Neoplasms; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lapatinib; Neuroma, Acoustic; Oncogene Proteins v-erbB; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Vestibular Nerve | 2012 |
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Stomach Neoplasms; Sulfones | 2012 |
Don't pick the loser: lessons from the GeparQuinto trial.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2012 |
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Female; Fertility Preservation; Humans; Lapatinib; Lymphoma; Molecular Targeted Therapy; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Receptor, ErbB-2; Rituximab; Trastuzumab; Vinblastine; Vincristine | 2011 |
Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
Topics: Amino Acid Sequence; Binding Sites; Drug Design; Drug Resistance; ErbB Receptors; Humans; Lapatinib; Molecular Dynamics Simulation; Molecular Sequence Data; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Sequence Homology, Amino Acid; Solvents; Substrate Specificity; Thermodynamics; Water | 2012 |
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Topics: Antineoplastic Agents; Autophagy; bcl-X Protein; Cell Line, Tumor; ErbB Receptors; Humans; Indoles; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytochrome P-450 CYP3A; Dexamethasone; Drug Interactions; Female; Hepatocytes; Humans; Lapatinib; Mice; Middle Aged; Quinazolines; Retrospective Studies; Risk Factors | 2012 |
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship | 2012 |
HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Line, Tumor; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Small Cell Lung Carcinoma; Transfection; Up-Regulation | 2012 |
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzoxazoles; Blotting, Western; Breast Neoplasms; Cell Cycle; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Transcription Factors; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Sensitivity control through attenuation of signal transfer efficiency by negative regulation of cellular signalling.
Topics: 3T3 Cells; Animals; Cell Line; Cell Line, Tumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; HeLa Cells; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction | 2012 |
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; Gene Amplification; Humans; Lapatinib; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Transcription, Genetic; Trastuzumab; Up-Regulation | 2012 |
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Humans; Lapatinib; M Phase Cell Cycle Checkpoints; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Colorectal Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Mice; Mice, Nude; Mutation; Quinazolines; ras Proteins; Sirolimus; Xenograft Model Antitumor Assays | 2013 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Liver Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Scalp; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Interaction of lapatinib with cytochrome P450 3A5.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dealkylation; Humans; Hydroxylation; Lapatinib; Midazolam; NADP; Protein Kinase Inhibitors; Quinazolines; Testosterone | 2012 |
[Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Janus Kinase 2; Lapatinib; Mutation; Myeloproliferative Disorders; Protein Kinase Inhibitors; Quinazolines | 2012 |
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells | 2012 |
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
Topics: Amino Acid Sequence; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Humans; Lapatinib; Molecular Dynamics Simulation; Molecular Sequence Data; Neoplasms; Point Mutation; Protein Folding; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines; Sequence Alignment; Signal Transduction | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lapatinib; Membrane Microdomains; Quinazolines; rho GTP-Binding Proteins; Signal Transduction; Skin Neoplasms | 2012 |
Die and let live: harnessing BikDD to combat breast cancer stem cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; CD24 Antigen; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; MCF-7 Cells; Neuregulin-1; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2012 |
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gene Expression; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Mucin-4; Oligonucleotide Array Sequence Analysis; Phenotype; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Statistics, Nonparametric; Tamoxifen; Transcriptome; Trastuzumab; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Female; Humans; Lapatinib; MAP Kinase Signaling System; Myoblasts, Cardiac; Myocytes, Cardiac; Protein Binding; Proto-Oncogene Mas; Quinazolines; Rats; Receptor, ErbB-2; Receptor, ErbB-4; Trastuzumab | 2012 |
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
HER2 testing in patients with breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Immunohistochemistry; Lapatinib; Maytansine; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Trigeminal nerve injury ErbB3/ErbB2 promotes mechanical hypersensitivity.
Topics: Animals; Blotting, Western; Disease Models, Animal; Hyperalgesia; Lapatinib; Male; Neuralgia; Pain Threshold; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred F344; Receptor, ErbB-2; Receptor, ErbB-3; Trigeminal Nerve Injuries; Vibrissae | 2012 |
Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Transcription Factors | 2012 |
Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Heart; Heart Diseases; Humans; Incidence; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2012 |
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Inhibitory Concentration 50; Lapatinib; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Quinazolinones; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab | 2012 |
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Ligands; Melanoma; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Vemurafenib | 2012 |
[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Hydrocephalus; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Ventriculoperitoneal Shunt | 2012 |
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Leucovorin; Oligodeoxyribonucleotides; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Thionucleotides | 2012 |
Metabolic rewiring drives resistance to targeted cancer therapy.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Lapatinib; Quinazolines; Signal Transduction | 2012 |
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Turkey | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Topics: ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Doxorubicin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Ovarian Neoplasms; Ovary; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2012 |
Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Lapatinib; Quinazolines | 2012 |
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Genomics; Glucose; Humans; Hypoglycemic Agents; Lapatinib; Macrolides; Metformin; Models, Biological; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Quinazolines; RNA Interference; Signal Transduction; Tyrphostins; Xenograft Model Antitumor Assays | 2012 |
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; RNA, Messenger; RNA, Untranslated; Signal Transduction; Tamoxifen | 2012 |
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; Lapatinib; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases | 2012 |
Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.
Topics: Animals; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Cell Survival; Electrophysiological Phenomena; Gene Expression; Isoproterenol; Lapatinib; Male; Mice; Mice, Transgenic; Myocytes, Cardiac; Organ Size; Organ Specificity; Protein Biosynthesis; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction | 2012 |
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2012 |
The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
Topics: Animals; Animals, Newborn; Cells, Cultured; Dose-Response Relationship, Drug; Doxorubicin; Drug Delivery Systems; Drug Synergism; ErbB Receptors; Lapatinib; Myocytes, Cardiac; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2 | 2013 |
Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis.
Topics: Animals; Butadienes; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; Female; Focal Adhesion Kinase 1; Humans; Integrin alpha6beta4; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tetraspanin 24; Transendothelial and Transepithelial Migration | 2012 |
Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations.
Topics: Adenosine Triphosphate; Binding Sites; Drug Design; ErbB Receptors; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Lapatinib; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines; Static Electricity; Structure-Activity Relationship; Thermodynamics | 2013 |
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cystadenocarcinoma, Mucinous; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.
Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Trastuzumab | 2012 |
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Breast Neoplasms; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Stress; Female; HSP70 Heat-Shock Proteins; Humans; Indoles; Lapatinib; Membrane Proteins; Mice; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; p38 Mitogen-Activated Protein Kinases; Pyrroles; Quinazolines; Reactive Oxygen Species | 2012 |
OSU-03012 interacts with lapatinib to kill brain cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Benzoquinones; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Genes, erbB-1; Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Lipids; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2012 |
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms | 2012 |
Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Genes, erbB-1; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Immunoglobulin Fab Fragments; Lactams, Macrocyclic; Lapatinib; Male; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin | 2012 |
EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Humans; Lapatinib; MCF-7 Cells; Neoplastic Stem Cells; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; STAT3 Transcription Factor | 2013 |
Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Guideline Adherence; Humans; Lapatinib; Practice Guidelines as Topic; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United Kingdom; Up-Regulation | 2012 |
Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Coumarins; Endocytosis; Fluorescent Antibody Technique; Glioma; Humans; Imaging, Three-Dimensional; In Situ Nick-End Labeling; Lapatinib; Lipoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Nanoparticles; Osteonectin; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Xenograft Model Antitumor Assays | 2012 |
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Death; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Female; Gene Amplification; Humans; Killer Cells, Natural; Lapatinib; Mice; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Breaks, Double-Stranded; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Transport; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinational DNA Repair; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
EGFR and HER2 inhibition in pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Mutation; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteins; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2012 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Skin Neoplasms; Skin Ulcer | 2012 |
Primary systemic treatment of breast-cancer brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Female; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Expression; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2012 |
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2012 |
Novel dithiocarbamic acid esters derived from 6-aminomethyl-4-anilinoquinazolines and 6-aminomethyl-4-anilino-3-cyanoquinolines as potent EGFR inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Esters; Female; HCT116 Cells; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship | 2013 |
Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Tumor Cells, Cultured | 2013 |
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prevalence; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Turkey | 2012 |
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Kidney Neoplasms; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Immune System; Lapatinib; Models, Genetic; Oligonucleotide Array Sequence Analysis; Polymorphism, Genetic; Quinazolines; Trastuzumab | 2012 |
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Sequence Data; Mutation; NIH 3T3 Cells; Protein Structure, Tertiary; Quinazolines; Quinolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Transplantation, Heterologous | 2013 |
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; I-kappa B Proteins; Lapatinib; Morpholines; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Time Factors | 2013 |
Lapatinib in early breast cancer--questions to be resolved.
Topics: Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2013 |
[Lapatinib is useful for metastatic breast cancer patients who cannot be treated with trastuzumab-report of a case].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Liver Neoplasms; Mastectomy; Neoplasm Staging; Quinazolines; Trastuzumab | 2012 |
Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Cytological Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer - authors' reply.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Carcinoma, Embryonal; Cell Survival; Cetuximab; Choriocarcinoma; Endodermal Sinus Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Lapatinib; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neoplasms, Germ Cell and Embryonal; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptor, ErbB-3; Teratocarcinoma; Testicular Neoplasms; Transplantation, Heterologous | 2013 |
Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2013 |
Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Imatinib radiosensitizes bladder cancer by targeting homologous recombination.
Topics: Antigens, Nuclear; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homologous Recombination; Humans; Imatinib Mesylate; Ku Autoantigen; Lapatinib; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Urinary Bladder Neoplasms | 2013 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Female; Humans; Lapatinib; Liver; Mice; Models, Biological; Neoplasms; Quinazolines; Tissue Distribution | 2013 |
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Exons; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2013 |
TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tissue Inhibitor of Metalloproteinase-1; Trastuzumab; Tumor Cells, Cultured | 2013 |
[Supports for the toxicity of the molecular target medicine].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab | 2012 |
Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; ErbB Receptors; Female; Gene Expression Regulation, Enzymologic; Humans; Lapatinib; Mice; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Severe Combined Immunodeficiency; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Lapatinib inhibits meiotic maturation of porcine oocyte-cumulus complexes cultured in vitro in gonadotropin-supplemented medium.
Topics: Animals; Cell Differentiation; Cells, Cultured; Cumulus Cells; Female; Follicle Stimulating Hormone; Growth Inhibitors; Lapatinib; Meiosis; Oocytes; Quinazolines; Swine | 2013 |
Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cells, Cultured; Central Nervous System Neoplasms; Child; ErbB Receptors; Female; Humans; Infant; Lapatinib; Male; Mice; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Rhabdoid Tumor; Signal Transduction | 2013 |
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Psoriasis aggravation due to lapatinib.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Psoriasis; Quinazolines | 2013 |
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.
Topics: Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Humans; Lapatinib; Mass Spectrometry; Microsomes, Liver; Nitrogen Oxides; Oximes; Quinazolines | 2013 |
Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
Topics: Cadherins; Cell Communication; Cell Line, Tumor; Cytoskeleton; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction | 2013 |
For breast cancer patients with brain mets, new drug combo may be option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Treatment Outcome | 2012 |
Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Chromatography, Affinity; ErbB Receptors; HeLa Cells; Humans; Lapatinib; Ligands; Models, Molecular; Molecular Sequence Data; Molecular Targeted Therapy; Morpholines; NAD; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Purines; Quinazolines; Structural Homology, Protein; Trypanosoma brucei brucei | 2013 |
Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Y-Box-Binding Protein 1 | 2013 |
Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Lipoproteins; Mice; Nanoparticles; Quinazolines; Solubility; Xenograft Model Antitumor Assays | 2013 |
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Dosage; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Regression Analysis; ROC Curve | 2013 |
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genes, erbB-2; High-Throughput Screening Assays; Humans; Lapatinib; Quinazolines; RNA Interference; RNA, Small Interfering | 2014 |
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.
Topics: Adenosine Triphosphate; Binding, Competitive; Cell Cycle Proteins; Chaperonins; HSP90 Heat-Shock Proteins; Indoles; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2013 |
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast; Breast Neoplasms; Cell Line, Tumor; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2013 |
PUMA and BIM are required for oncogene inactivation-induced apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Chromatin Immunoprecipitation; ErbB Receptors; Female; Flow Cytometry; Gene Silencing; Humans; Immunoblotting; Immunohistochemistry; Lapatinib; MAP Kinase Signaling System; Membrane Proteins; Mice; Nitrophenols; Oncogenes; Piperazines; Plasmids; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2013 |
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
Topics: Cell Survival; Enzyme Inhibitors; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Lapatinib; MAP Kinase Kinase Kinases; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Quinazolines; raf Kinases; Receptor, ErbB-3; Signal Transduction; Skin Neoplasms; Sulfonamides; Transcription, Genetic | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib.
Topics: Brain Neoplasms; Female; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Coloring Agents; Drug Design; Drug Discovery; ErbB Receptors; Humans; Indicators and Reagents; Lapatinib; Morpholines; Neglected Diseases; Phosphotransferases; Quinazolines; Structure-Activity Relationship; Tetrazolium Salts; Thiazoles; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2013 |
Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans of the rat liver.
Topics: Animals; Antineoplastic Agents; Biomarkers; Contrast Media; Gadolinium DTPA; Gene Expression Regulation, Neoplastic; Image Enhancement; Lapatinib; Liver; Magnetic Resonance Imaging; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Cation Transport Proteins; Quinazolines; Rats | 2013 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Receptor, ErbB-2; Signal Transduction; Substrate Specificity | 2013 |
Inhibitory activity against epidermal growth factor receptor (EGFR) based on single point mutations of active site residues.
Topics: Catalytic Domain; ErbB Receptors; Humans; Lapatinib; Molecular Structure; Point Mutation; Protein Engineering; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Structure-Activity Relationship; Thiazoles | 2014 |
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Gene Expression; Humans; Hyperplasia; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Transcriptome; Tumor Burden | 2013 |
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
Topics: Antineoplastic Agents; Biological Transport; Calorimetry, Differential Scanning; Cell Membrane; Cold Temperature; Dimyristoylphosphatidylcholine; Docetaxel; Drug Delivery Systems; Hot Temperature; Injections; Lapatinib; Liposomes; Membranes, Artificial; Neoplasms; Phospholipids; Quinazolines; Tamoxifen; Taxoids | 2013 |
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Immunoblotting; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Phosphoprotein Phosphatases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Quinazolines; Receptor, ErbB-2; RNA Interference; Signal Transduction; Substrate Specificity; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2013 |
Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; High-Throughput Screening Assays; Humans; Inflammatory Breast Neoplasms; Lapatinib; Quinazolines; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Interaction between Her2 and Beclin-1 proteins underlies a new mechanism of reciprocal regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Humans; Jurkat Cells; Lapatinib; MCF-7 Cells; Membrane Proteins; Mice; Microscopy, Electron, Transmission; Phagosomes; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA Interference | 2013 |
Identifying the challenges of biomarkers that predict response to HER2-directed therapies.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Dosage; Genes, erbB-1; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Immunoprecipitation; Lapatinib; Oncogene Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection | 2013 |
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Lapatinib; Male; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; Random Allocation; Receptor, ErbB-2; Transcriptome; Xenograft Model Antitumor Assays | 2013 |
Predicting drug responsiveness in human cancers using genetically engineered mice.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment | 2013 |
Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslipidemias; Female; Fluorouracil; Humans; Hypertriglyceridemia; Israel; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Risk Factors | 2013 |
Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Topics: Adenine; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
RON confers lapatinib resistance in HER2-positive breast cancer cells.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Lapatinib; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2013 |
A gene expression profile indicative of early stage HER2 targeted therapy response.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Time Factors | 2013 |
Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Humans; Intracranial Hypertension; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Quinazolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2013 |
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.
Topics: Animals; Antigens, Neoplasm; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Movement; Cells, Cultured; Chemotaxis; Disease Models, Animal; Doxorubicin; ErbB Receptors; Female; Humans; In Vitro Techniques; Interferon-gamma; Lapatinib; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; STAT1 Transcription Factor | 2013 |
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm, Residual; Quinazolines; Receptor, ErbB-2; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab; Vascular Endothelial Growth Factor A | 2014 |
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2013 |
Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Topics: beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; G1 Phase; Humans; Lapatinib; Proteoglycans; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Transcription, Genetic; Up-Regulation | 2014 |
Personalised cancer management: closer, but not here yet.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Lapatinib induces p27(Kip1)-dependent G₁ arrest through both transcriptional and post-translational mechanisms.
Topics: Blotting, Western; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA Primers; Dyrk Kinases; ErbB Receptors; Flow Cytometry; Forkhead Box Protein O3; Forkhead Transcription Factors; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Humans; Lapatinib; Models, Biological; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference | 2013 |
[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Up-Regulation | 2013 |
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Mucin-1; Peptides; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Blotting, Western; Brain; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cells, Cultured; Electric Impedance; Endothelium, Vascular; ErbB Receptors; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2013 |
Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.
Topics: Animals; Benzamides; Bleomycin; Cell Line; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Feedback, Physiological; Imatinib Mesylate; Lapatinib; Lung; Mice; Myofibroblasts; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pulmonary Gas Exchange; Pyrimidines; Quinazolines; Receptor, ErbB-2; Receptors, Platelet-Derived Growth Factor; Transforming Growth Factor beta; Up-Regulation | 2013 |
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Immunoblotting; Immunoprecipitation; Lapatinib; Mice; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Survival Rate; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Intestine, Small; Lapatinib; Membrane Transport Modulators; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Quinazolines; Taxoids; Tissue Distribution; Topoisomerase II Inhibitors; Tubulin Modulators | 2013 |
Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay.
Topics: Breast Neoplasms; Cell Line, Tumor; Electrophoresis, Capillary; Female; Humans; Immunoassay; Isoenzymes; Lapatinib; Metabolic Networks and Pathways; Microfluidic Analytical Techniques; Nanotechnology; Oxadiazoles; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines | 2013 |
In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lapatinib; Pancreatic Neoplasms; Quinazolines; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma.
Topics: Acetonitriles; Administration, Oral; Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Lapatinib; Limit of Detection; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib; Spectrophotometry, Ultraviolet | 2013 |
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Computer Simulation; Feedback, Physiological; Female; Lapatinib; MAP Kinase Signaling System; Mice; Models, Biological; Neuregulin-1; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2013 |
Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Mucin-4; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2014 |
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.
Topics: Adult; Exome; Female; Humans; Lapatinib; Li-Fraumeni Syndrome; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2013 |
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Lapatinib; Mice; Neoplasm Proteins; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Quinazolines | 2013 |
LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Topics: Acinar Cells; Amino Acid Oxidoreductases; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Morphogenesis; Neoplasm Metastasis; Phenotype; Prognosis; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Signal Transduction | 2013 |
[Chinese expert consensus on the molecular-targeted therapy for HER-2-positive advanced gastric cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Consensus; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2013 |
Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Hyaluronan Receptors; Integrin beta1; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Trastuzumab | 2013 |
Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis.
Topics: Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Drug Evaluation, Preclinical; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression; Humans; Imidazoles; Lapatinib; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; RNA, Messenger; Signal Transduction; Smad Proteins; Snail Family Transcription Factors; Transcription Factors; Transforming Growth Factor beta1; Up-Regulation | 2014 |
Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Luciferases; Multienzyme Complexes; Neuregulin-1; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2013 |
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Topics: Autocrine Communication; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Gene Knockdown Techniques; Humans; Lapatinib; Neuregulin-1; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; src-Family Kinases; TOR Serine-Threonine Kinases | 2013 |
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2013 |
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Lapatinib; Male; Purines; Quinazolines; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazines; Urinary Bladder Neoplasms | 2014 |
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridones; Quinazolines; Sulfonamides | 2013 |
Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Cell Survival; Cells, Cultured; Coronary Vessels; Doxorubicin; Fibrosis; Heart Diseases; Humans; Lapatinib; Male; Mice; Mice, Inbred C57BL; Microvessels; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Pericardium; Quinazolines; Radiation Injuries, Experimental; Receptor, ErbB-2; Trastuzumab; Ventricular Function, Left | 2013 |
Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2013 |
Dual HER2 targeting for early breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.
Topics: Amino Acid Substitution; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; MAP Kinase Signaling System; Mutation, Missense; Neuregulin-1; Protein Multimerization; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4 | 2013 |
Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; Lapatinib; Neuregulin-1; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2013 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Neoplasms, Experimental; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Solubility; Structure-Activity Relationship | 2013 |
Unsuspected allies: chemotherapy teams up with immunity to fight cancer.
Topics: Animals; Breast Neoplasms; CD8-Positive T-Lymphocytes; Doxorubicin; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; STAT1 Transcription Factor | 2013 |
[Effects of mammalian-target-of-rapamycin pathway on lapatinib resistance in breast cancer MDA-MB-231 cells].
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; TOR Serine-Threonine Kinases | 2013 |
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Addition of amino acid moieties to lapatinib increases the anti-cancer effect via amino acid transporters.
Topics: Amino Acid Transport Systems; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dogs; Glutamine; Humans; Lapatinib; Madin Darby Canine Kidney Cells; Protein Kinase Inhibitors; Quinazolines; Tyrosine; Valine | 2014 |
Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
Topics: Antineoplastic Agents; Articulation Disorders; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Insulin-Like Growth Factor Binding Protein 2; Lapatinib; Lymphocytes, Tumor-Infiltrating; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Neoplasm Invasiveness; Precancerous Conditions; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; T-Lymphocytes; Tetrahydronaphthalenes; Tumor Cells, Cultured; Vaccines, Subunit | 2013 |
Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fatty Acid Synthase, Type I; Humans; Lapatinib; Neoplasm Invasiveness; Osteosarcoma; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.
Topics: Antineoplastic Agents; Chromatography, Liquid; Humans; Lapatinib; Limit of Detection; Neoplasms; Quinazolines; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry | 2013 |
Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
Topics: Biotransformation; Cell Line, Tumor; Cell Survival; Cysteine; Cytochrome P-450 CYP3A; Dexamethasone; Glutathione; Hepatocytes; Humans; Lapatinib; Liver; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rifampin | 2014 |
Differences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutants.
Topics: Adenosine Triphosphate; Drug Resistance; ErbB Receptors; Gene Components; Lapatinib; Models, Molecular; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2014 |
Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, CXCR4; Signal Transduction; src-Family Kinases | 2014 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2013 |
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
Topics: Androstadienes; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; HLA-A Antigens; Humans; Lapatinib; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Wortmannin | 2013 |
Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; Cell Proliferation; Female; Humans; In Vitro Techniques; Lapatinib; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2 | 2014 |
Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2013 |
Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship.
Topics: Animals; Animals, Newborn; Cells, Cultured; Desmoglein 1; Desmoglein 3; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratinocytes; Lapatinib; Mice; Mice, Inbred C57BL; Mice, Knockout; Nonlinear Dynamics; Pemphigus; Quinazolines | 2014 |
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2014 |
Tosylate salts of the anticancer drug lapatinib.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Hydrogen Bonding; Lapatinib; Quinazolines; Salts; Tosyl Compounds | 2013 |
NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Growth Processes; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; NF-kappa B; Quinazolines; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Managing breast cancers with low estrogen receptor and HER2 by drugging both.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.
Topics: Annexin A6; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Lysosomes; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proteolysis; Quinazolines | 2013 |
Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
Topics: Antineoplastic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Lapatinib; Metabolic Clearance Rate; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Reproducibility of Results; Sorafenib; Spectrophotometry, Ultraviolet | 2014 |
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Chordoma; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasm Recurrence, Local; Quinazolines; Sacrum; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug.
Topics: Animals; Area Under Curve; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endocytosis; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Osteonectin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Solubility; Survival Rate; Time Factors | 2014 |
Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Heart; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; L-Lactate Dehydrogenase; Lapatinib; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Fluorescence; Nanomedicine; Nanotechnology; Neoplasm Transplantation; Particle Size; Polyethylene Glycols; Polypropylenes; Quinazolines | 2014 |
Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2014 |
In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Glioma; Injections, Intravenous; Lapatinib; Lethal Dose 50; Lipids; Male; Mice, Inbred ICR; Nanoparticles; Organ Specificity; Particle Size; Quinazolines; Rats, Sprague-Dawley; Solubility; Surface Properties; Tablets; Tissue Distribution | 2014 |
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
Topics: Apoptosis; Cell Line, Tumor; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Signaling System; MCF-7 Cells; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2014 |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Genes, p53; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Mice; Mice, SCID; Mutation; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transcription Factor RelA | 2014 |
Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Spectrum Analysis, Raman | 2014 |
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2014 |
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult | 2014 |
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Cell Nucleus; Cross-Linking Reagents; Drug Resistance, Neoplasm; Female; Ficusin; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; PUVA Therapy; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Ultraviolet Rays | 2014 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Topics: Anoikis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MicroRNAs; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, IGF Type 1 | 2014 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Biomimetics; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Extracellular Matrix; Female; Humans; Immunohistochemistry; Lapatinib; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Scanning; Neoplasm Transplantation; Quinazolines; Regeneration; Tissue Engineering; Tissue Scaffolds | 2014 |
p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.
Topics: Apoptosis; Cell Line, Tumor; ErbB Receptors; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2014 |
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
[Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: experience of use].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2014 |
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Lapatinib; Mice; Mice, Transgenic; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Tumor Cells, Cultured | 2014 |
Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Topics: Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Neuregulin-1; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Stability; RNA, Messenger; Signal Transduction; Time Factors; Transcription, Genetic | 2014 |
Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Lapatinib; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Triple Negative Breast Neoplasms | 2014 |
[A case of trastuzumab-resistant breast cancer responding to lapatinib/capecitabine therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Trastuzumab | 2014 |
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Topics: Animals; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endometrial Neoplasms; Endometrium; ErbB Receptors; Female; Humans; Lapatinib; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factor AP-1; Up-Regulation | 2014 |
Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Drug Interactions; Lapatinib; Male; Mass Spectrometry; Pyridines; Quinazolines; Rats; Rats, Sprague-Dawley | 2014 |
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Humans; Lapatinib; Oncogene Protein v-akt; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Lapatinib; Ligands; Mice; Myelin Proteins; Neoplasms; Nogo Receptor 1; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Cell Surface; Transcription, Genetic; Transcriptional Activation; Triple Negative Breast Neoplasms | 2014 |
Two dimensions in targeting HER2.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2014 |
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transplantation, Heterologous | 2014 |
Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; ErbB Receptors; Female; Humans; Lapatinib; Lipoproteins; Mice; Mice, SCID; Nanoparticles; Quinazolines; Receptor, ErbB-2 | 2014 |
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Breast Neoplasms; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; HEK293 Cells; Humans; Lapatinib; Mitogen-Activated Protein Kinases; Open Reading Frames; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response | 2015 |
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma.
Topics: Animals; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Immunoblotting; Lapatinib; Liver Neoplasms; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Mitochondria; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2014 |
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Elongation Factor 2 Kinase; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphorylation; Protein Phosphatase 2; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2014 |
Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2014 |
Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Topics: Antigens, CD; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Middle Aged; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Stomach Neoplasms | 2014 |
Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Health Care Costs; Health Resources; Health Services Research; Humans; Kaplan-Meier Estimate; Lapatinib; Medicare; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Risk Factors; SEER Program; Trastuzumab; United States | 2014 |
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines | 2015 |
Assay of lapatinib in murine models of cigarette smoke carcinogenesis.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; DNA Adducts; DNA Damage; Erythrocytes; Gene Expression Regulation; Lapatinib; Lung; Lung Neoplasms; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Tobacco Smoke Pollution; Toxicity Tests, Subchronic | 2014 |
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; ErbB Receptors; Goblet Cells; Intestinal Mucosa; Intestines; Lapatinib; Male; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2 | 2014 |
Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Topics: Antibodies, Monoclonal, Humanized; Cell Differentiation; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Doxorubicin; Gene Expression Regulation, Developmental; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Neuregulin-1; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA Interference; Signal Transduction; Time Factors; Transfection; Trastuzumab | 2014 |
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Metastasis; Odds Ratio; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Screening and identification of small molecule inhibitors of ErbB2-induced invasion.
Topics: Antineoplastic Agents; Cathepsin L; Female; Humans; Lapatinib; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Female; Follow-Up Studies; Humans; Lapatinib; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Translational Research, Biomedical; Trastuzumab | 2014 |
Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; NIH 3T3 Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Tumor Burden; Vincristine | 2014 |
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles | 2014 |
Dual targeting of HER2 with lapatinib and trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Trastuzumab | 2014 |
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genetic Vectors; Humans; Lapatinib; Lentivirus; Molecular Targeted Therapy; Mutagenesis, Insertional; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Exons; Female; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; MCF-7 Cells; Mutagenesis, Site-Directed; Mutation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factors | 2014 |
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Metformin; Middle Aged; Neoplasm Invasiveness; Neurotensin; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Live cell off-target identification of lapatinib using ligand-directed tosyl chemistry.
Topics: Cell Line, Tumor; Cell Survival; Humans; Lapatinib; Ligands; Molecular Structure; Protein Disulfide-Isomerases; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Tosyl Compounds | 2014 |
Lapatinib ameliorates experimental arthritis in rats.
Topics: Animals; Arthritis, Experimental; Female; Inflammation Mediators; Lapatinib; Quinazolines; Random Allocation; Rats; Rats, Wistar | 2015 |
Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Tumor Burden; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Survival; Computer Simulation; Female; Humans; Lapatinib; Models, Biological; Molecular Targeted Therapy; Protein Array Analysis; Quinazolines; Transcription Factors; Transcriptional Activation | 2014 |
Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; ErbB Receptors; Flow Cytometry; Humans; In Vitro Techniques; Lapatinib; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2014 |
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors.
Topics: Anoikis; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diffusion Chambers, Culture; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2015 |
HER2 activation results in β-catenin-dependent changes in pulmonary epithelial permeability.
Topics: Adherens Junctions; beta Catenin; Cell Adhesion; Cell Line; Electric Impedance; Enzyme Activation; Humans; Lapatinib; Lung; Neuregulin-1; Permeability; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Respiratory Mucosa; RNA Interference; RNA, Small Interfering; Signal Transduction; Tight Junctions | 2015 |
Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Mastectomy; Medicare; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome; United States | 2014 |
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; Stomach Neoplasms | 2014 |
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.
Topics: Animals; Antineoplastic Agents; Enhancer Elements, Genetic; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Transgenic; Pituitary Neoplasms; Prolactinoma; Promoter Regions, Genetic; Quinazolines | 2015 |
A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Combinations; Drug Compounding; Endocytosis; Female; Humans; Lactic Acid; Lapatinib; Micelles; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Quinazolines; Receptor, ErbB-2; Solubility; Surface Properties | 2015 |
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mice, Nude; Mutant Proteins; Mutation; Phenotype; Phosphorylation; Prognosis; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2015 |
Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Situ Hybridization; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Organotechnetium Compounds; Quinazolines; Radionuclide Imaging; Receptor, ErbB-2; Tissue Distribution | 2014 |
Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells.
Topics: 4-Butyrolactone; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fatty Acid Synthases; Female; Humans; Lapatinib; Lichens; Molecular Structure; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Female; Gene Expression; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; DNA Copy Number Variations; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2015 |
Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, p53; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products.
Topics: Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Ions; Lapatinib; Limit of Detection; Linear Models; Mass Spectrometry; Quinazolines; Reproducibility of Results | 2015 |
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Connective Tissue Growth Factor; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hippo Signaling Pathway; Humans; Lapatinib; Mechanotransduction, Cellular; Neuregulin-1; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-4; Transcription Factors | 2014 |
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Autophagy; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Neoplasms, Animal; Molecular Targeted Therapy; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2015 |
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Lapatinib; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2015 |
miR-1470 mediates lapatinib induced p27 upregulation by targeting c-jun.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Lapatinib; MicroRNAs; Proliferating Cell Nuclear Antigen; Quinazolines; Receptor, ErbB-2; Signal Transduction; Up-Regulation | 2015 |
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Proliferation; Central Nervous System; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2 | 2015 |
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.
Topics: Aged; Aged, 80 and over; Bronchoscopy; Crizotinib; Electromagnetic Phenomena; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Phosphotransferases; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2014 |
Investigation of drug-excipient interactions in lapatinib amorphous solid dispersions using solid-state NMR spectroscopy.
Topics: Biological Availability; Biopharmaceutics; Crystallization; Drug Carriers; Drug Stability; Excipients; Humans; Hydrogen Bonding; Lapatinib; Magnetic Resonance Spectroscopy; Methylcellulose; Polyethylene Glycols; Polyvinyls; Povidone; Quinazolines; Solubility | 2015 |
Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2014 |
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Lapatinib; Mice; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Trastuzumab | 2015 |
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Topics: Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 2; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Kaplan-Meier Estimate; Lapatinib; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction | 2015 |
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2015 |
Identifying differentially expressed genes and screening small molecule drugs for lapatinib-resistance of breast cancer by a bioinformatics strategy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Computational Biology; Databases, Genetic; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Small Molecule Libraries | 2014 |
Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2015 |
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Gene Knockdown Techniques; Glucuronidase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Corneal Neovascularization; Corneal Stroma; Disease Models, Animal; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; Injections, Intraperitoneal; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Trastuzumab; Vascular Endothelial Growth Factor A | 2015 |
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neuregulin-1; Quinazolines; Random Allocation; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2015 |
The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Quinazolines; Serum Albumin; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Hypopituitarism; Lapatinib; Pituitary Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lapatinib; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2015 |
Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib.
Topics: Binding Sites; Fluorescence; Humans; Lapatinib; MCF-7 Cells; Microscopy, Confocal; Molecular Structure; Protein Kinase Inhibitors; Quantum Theory; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured | 2015 |
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mass Spectrometry; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Y-Box-Binding Protein 1 | 2015 |
The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Androgens; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Androgen; RNA-Binding Proteins; Signal Transduction | 2015 |
Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Connexin 43; Drug Delivery Systems; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2015 |
The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fibroblast Growth Factors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lapatinib; Molecular Sequence Data; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor | 2015 |
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured | 2015 |
Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.
Topics: Acyltransferases; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Gene Amplification; Hedgehog Proteins; Humans; Lapatinib; Protein Transport; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tamoxifen | 2015 |
Pharmacokinetic interaction study combining lapatinib with vorinostat in rats.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Hydroxamic Acids; Lapatinib; Male; Quinazolines; Rats, Sprague-Dawley; Vorinostat | 2015 |
Disentangling multidimensional spatio-temporal data into their common and aberrant responses.
Topics: Algorithms; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lapatinib; Mutation; Neural Networks, Computer; Principal Component Analysis; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab | 2015 |
MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Female; Humans; Lapatinib; MicroRNAs; Phosphoinositide Phospholipase C; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2015 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Retreatment; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2015 |
The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Doxorubicin; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lapatinib; Paclitaxel; Polychlorinated Dibenzodioxins; Quinazolines; Receptors, Aryl Hydrocarbon; RNA, Messenger; RNA, Small Interfering; Transcription Factor RelB; Ultraviolet Rays | 2015 |
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lapatinib; Mice; Molecular Targeted Therapy; Neoadjuvant Therapy; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Interactions; Female; Hepatocytes; Humans; Immunohistochemistry; Lapatinib; Mice; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Cell Line, Tumor; DNA Damage; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; Lapatinib; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Transfection | 2015 |
Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters.
Topics: ATP-Binding Cassette Transporters; Biological Transport; Cell Death; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Quinazolines; Signal Transduction; Spheroids, Cellular | 2015 |
Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Multidrug Resistance-Associated Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Dosage; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2015 |
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Membrane Proteins; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01.
Topics: Chemical and Drug Induced Liver Injury; HLA-DRB1 Chains; Humans; Lapatinib; Models, Molecular; Molecular Dynamics Simulation; Quinazolines; Tetanus Toxoid | 2015 |
Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; United States; Women's Health | 2015 |
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Catechin; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acid Synthase, Type I; Female; Gallic Acid; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Naphthalenes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus; Trastuzumab | 2015 |
Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Young Adult | 2015 |
The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; ErbB Receptors; Hyperglycemia; Lapatinib; Male; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2015 |
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Canada; Capecitabine; Delivery of Health Care; Female; Health Care Costs; Humans; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Epigenesis, Genetic; ErbB Receptors; Gefitinib; Human papillomavirus 16; Humans; Lapatinib; Matrix Metalloproteinase 9; Quinazolines; Vimentin | 2015 |
Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Lapatinib; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates; TOR Serine-Threonine Kinases | 2015 |
Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Humans; Lactic Acid; Lapatinib; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mononuclear Phagocyte System; Nanoparticles; Phagocytosis; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Tumor Burden; Vitamin E; Xenograft Model Antitumor Assays | 2015 |
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MicroRNAs; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Transcription Factors; Trastuzumab; Tumor Suppressor Proteins | 2015 |
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diamines; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Mutation; Oxadiazoles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6; Signal Transduction | 2015 |
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2015 |
miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Base Sequence; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Gene Expression; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lapatinib; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Proto-Oncogene Proteins c-ets; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Tumor Burden | 2015 |
Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Salvage Therapy; Trastuzumab | 2015 |
Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Fatal Outcome; Female; Furans; Humans; Ketones; Lapatinib; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab | 2015 |
Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Proteomics; Quinazolines; Quinolines; Receptor, ErbB-2 | 2015 |
Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dietary Supplements; Female; Lapatinib; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Transgenic; MicroRNAs; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Time Factors; Transfection; Trastuzumab; Tumor Burden | 2015 |
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.
Topics: Alleles; Antineoplastic Agents; DNA; Drug Eruptions; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; HLA Antigens; Humans; Lapatinib; Polymorphism, Genetic; Quinazolines | 2015 |
Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Compounding; Drug Delivery Systems; Lapatinib; Liposomes; Mice; Paclitaxel; Particle Size; Quinazolines; Structure-Activity Relationship; Surface Properties | 2016 |
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gastrointestinal Neoplasms; Gene Amplification; Gene Expression; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Lobular; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Long Noncoding | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Letrozole; Molecular Imaging; Neoadjuvant Therapy; Nitriles; Precision Medicine; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triazoles | 2015 |
Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Knockout; Mice, Nude; Nuclear Proteins; Porphyrins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Transcription Factors; Tumor Microenvironment; Verteporfin; Xenograft Model Antitumor Assays | 2015 |
Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Transfection | 2016 |
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Israel; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2015 |
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Mass Spectrometry; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2016 |
Preparation of Antibodies and Development of an Enzyme-Linked Immunosorbent Assay for the Tyrosine Kinase Inhibitors Lapatinib and Nilotinib.
Topics: Animals; Antibodies; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Horseradish Peroxidase; Humans; Lapatinib; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rabbits; Rats, Wistar | 2015 |
t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
HER2 as a novel therapeutic target for cervical cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; HeLa Cells; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Middle Aged; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Zinc pyrithione inhibits caspase-3 activity, promotes ErbB1-ErbB2 heterodimerization and suppresses ErbB2 downregulation in cardiomyocytes subjected to ischemia/reperfusion.
Topics: Amino Acid Chloromethyl Ketones; Animals; Benzothiazoles; Cardiotonic Agents; Caspase 3; Caspase Inhibitors; Cell Hypoxia; Chlorides; Down-Regulation; ErbB Receptors; Lapatinib; Leupeptins; Myocytes, Cardiac; Organometallic Compounds; Phosphorylation; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Multimerization; Pyridines; Quinazolines; Rats; Receptor, ErbB-2; RNA, Messenger; Thiones; Tyrphostins; Zinc Compounds | 2015 |
A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; ErbB Receptors; G1 Phase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Resting Phase, Cell Cycle; Signal Transduction; Stomach Neoplasms | 2015 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis.
Topics: Animals; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Survival; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Compounding; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Hydrogels; Injections, Intralesional; Injections, Intravenous; Lapatinib; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanotechnology; Paclitaxel; Poloxamer; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Solubility; Technology, Pharmaceutical; Temperature; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cadherins; Capecitabine; Carcinoma, Lobular; Female; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation, Missense; Quinazolines; Radiography; Receptor, ErbB-2; Treatment Outcome | 2016 |
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice, Knockout; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Imaging of drug and metabolite distribution by MS: case studies.
Topics: Animals; Autoradiography; Dogs; Fluoroquinolones; Lapatinib; Liver; Lung; Mice; Moxifloxacin; Pharmaceutical Preparations; Quinazolines; Rabbits; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Terfenadine; Tissue Distribution; Whole Body Imaging | 2015 |
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Flow Cytometry; Gene Targeting; HEK293 Cells; Humans; Immunoblotting; Lapatinib; Mutation, Missense; Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Thiazoles | 2015 |
Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
Topics: Antineoplastic Agents; Blotting, Western; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Immunoprecipitation; Interleukin-6; Lapatinib; MicroRNAs; Mitogen-Activated Protein Kinase 1; Phosphorylation; Proto-Oncogene Proteins c-raf; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2015 |
Phenol 8% solution for the treatment of epidermal growth factor receptor inhibitor-induced periungual pyogenic granulomas.
Topics: Administration, Topical; Antineoplastic Agents; Breast Neoplasms; Caustics; Cautery; ErbB Receptors; Female; Granuloma, Pyogenic; Humans; Lapatinib; Middle Aged; Nail Diseases; Neoplasm Proteins; Phenol; Protein Kinase Inhibitors; Quinazolines; Toes | 2015 |
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Indoles; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lapatinib; Nanoparticles; Powder Diffraction; Quinazolines; Receptor, ErbB-2; Serum Albumin; Spectrum Analysis, Raman | 2015 |
Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA).
Topics: Animals; Binding Sites; Cattle; Circular Dichroism; Fluorescence Resonance Energy Transfer; Gefitinib; Indoles; Lapatinib; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrroles; Quinazolines; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sunitinib; Thermodynamics | 2015 |
POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Medicine: Eyes on the target.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Precision Medicine; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2015 |
Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.
Topics: Animals; Breast Neoplasms; Collagen; ErbB Receptors; Female; Lapatinib; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Stromal Cells; Tenascin; Up-Regulation; Wnt1 Protein | 2015 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay | 2016 |
HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatitis B virus; Humans; Lapatinib; Liver Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Trans-Activators; Up-Regulation; Viral Regulatory and Accessory Proteins | 2016 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2016 |
The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Insulin-Like Growth Factor I; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1; Signal Transduction; Trastuzumab | 2016 |
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cyclin E; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Mitogen-Activated Protein Kinases; Outcome Assessment, Health Care; Phosphorylation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Ribosomal Protein S6 Kinases, 70-kDa; Young Adult | 2016 |
Lapatinib Induced Suicidal Death of Human Erythrocytes.
Topics: Antineoplastic Agents; Cell Death; Erythrocytes; Humans; Lapatinib; Quinazolines; Reactive Oxygen Species | 2015 |
Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.
Topics: Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Glucuronosyltransferase; Humans; Inhibitory Concentration 50; Kinetics; Lapatinib; Microsomes, Liver; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Indoles; Lapatinib; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides | 2016 |
S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.
Topics: Animals; Antineoplastic Agents; Biomarkers; Catalase; Glutathione; Heart Failure; Lapatinib; Male; Malondialdehyde; Myocardium; Neoplasms; Oxidative Stress; Quinazolines; Rats, Wistar; S100 Proteins; Superoxide Dismutase; Trastuzumab | 2015 |
[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance].
Topics: Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Lapatinib; Neoplasm Metastasis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
[Combination of lapatinib with chlorogenic acid inhibits breast cancer metastasis by suppressing macrophage M2 polarization].
Topics: Animals; Chlorogenic Acid; Female; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Quinazolines | 2015 |
Acid-Base Interactions of Polystyrene Sulfonic Acid in Amorphous Solid Dispersions Using a Combined UV/FTIR/XPS/ssNMR Study.
Topics: Acid-Base Equilibrium; Antineoplastic Agents; Calorimetry, Differential Scanning; Crystallization; Drug Carriers; Drug Compounding; Drug Stability; Excipients; Gefitinib; Lapatinib; Magnetic Resonance Spectroscopy; Photoelectron Spectroscopy; Polystyrenes; Quinazolines; Solubility; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2016 |
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Lapatinib; MAP Kinase Signaling System; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; STAT5 Transcription Factor | 2016 |
Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma.
Topics: Animals; Carcinoma; Cell Line, Tumor; Humans; Lapatinib; Male; Maxillary Sinus Neoplasms; Mice; Mice, Nude; Polymorphism, Single Nucleotide; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2016 |
Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Lapatinib; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Quinazolines; Uncertainty | 2016 |
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2016 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Lapatinib; Molecular Targeted Therapy; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2016 |
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Evaluation of Lapatinib and Trastuzumab for Ototoxic Effects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ear Diseases; In Situ Nick-End Labeling; Lapatinib; Male; Organ of Corti; Otoacoustic Emissions, Spontaneous; Quinazolines; Random Allocation; Spiral Ganglion; Trastuzumab | 2015 |
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
Topics: Animals; Brain Neoplasms; Carbazoles; DNA-Binding Proteins; Glioblastoma; High Mobility Group Proteins; Humans; Lapatinib; Mice; Quinazolines; Transcriptional Elongation Factors | 2016 |
Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Female; Humans; Lapatinib; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutagenesis, Insertional; Protein Binding; Protein Structure, Secondary; Quinazolines; Receptor, ErbB-2 | 2016 |
P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2.
Topics: Adenosine Triphosphate; Alkylation; Antineoplastic Agents; Catalysis; Cell Line, Tumor; Cytochrome P-450 CYP3A; Humans; Lapatinib; Mitochondria, Liver; NF-E2-Related Factor 2; Quinazolines; RNA, Messenger | 2016 |
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2016 |
The role of tyrosine kinase inhibitor "Lapatinib" in pulmonary hypertension.
Topics: Aged; Antineoplastic Agents; Cardiac Catheterization; Echocardiography; Humans; Hypertension, Pulmonary; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors | 2016 |
[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemical and Drug Induced Liver Injury; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2016 |
Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.
Topics: Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Lapatinib; Ligands; Mutagenesis, Site-Directed; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Spectrometry, Fluorescence | 2016 |
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Cell Cycle; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Cystadenoma, Serous; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Microarray Analysis; MicroRNAs; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; RNA, Long Noncoding; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays | 2016 |
Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer.
Topics: Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Lapatinib; MAP Kinase Kinase 4; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2016 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Drug Carriers; Drug Compounding; Drug Stability; Female; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Phosphatidylcholines; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Tissue Distribution; Triple Negative Breast Neoplasms | 2016 |
Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diarrhea; Female; Humans; Lapatinib; Liver Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Doxazosin; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Lapatinib; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Tumor Suppressor Protein p53 | 2016 |
Characterization of the binding of an anticancer drug, lapatinib to human serum albumin.
Topics: Antineoplastic Agents; Binding Sites; Circular Dichroism; Humans; Hydrogen Bonding; Kinetics; Lapatinib; Metals; Molecular Docking Simulation; Protein Binding; Protein Stability; Protein Structure, Tertiary; Quinazolines; Serum Albumin; Spectrometry, Fluorescence; Temperature; Thermodynamics | 2016 |
Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Isothiocyanates; Lapatinib; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates | 2017 |
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclins; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lapatinib; Male; Mice; MicroRNAs; Models, Biological; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA-Binding Proteins; Stomach Neoplasms; Trastuzumab | 2016 |
Colorectal Cancer Yields to Dual HER2 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Humans; Lapatinib; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Italy; Lapatinib; Logistic Models; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult | 2016 |
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Epidermal Growth Factor; Female; Gene Expression; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Neuregulin-1; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2016 |
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dioxins; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triazoles | 2016 |
Porous Matrix Stiffness Modulates Response to Targeted Therapy in Breast Carcinoma.
Topics: Acrylic Resins; Breast Neoplasms; Cell Line, Tumor; Extracellular Matrix; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Integrin beta4; Lapatinib; Molecular Targeted Therapy; Porosity; Quinazolines; Receptor, ErbB-2 | 2016 |
Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer.
Topics: Acetanilides; Area Under Curve; Binding Sites; Biological Products; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Half-Life; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; ROC Curve; Thiazolidinediones | 2016 |
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Gene Frequency; Genotype; Humans; Lapatinib; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, IgG; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2016 |
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ERRalpha Estrogen-Related Receptor; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; MCF-7 Cells; Mice; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retroviridae Infections; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Virus Infections | 2016 |
Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.
Topics: Calibration; Chromatography, Liquid; Drug Monitoring; Humans; Imatinib Mesylate; Lapatinib; Plasma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2016 |
Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Berberine; Breast Neoplasms; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; NF-E2-Related Factor 2; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Signal Transduction | 2016 |
Suppression of breast cancer cell growth by Her2-reduced AR serine 81 phosphorylation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Lapatinib; Metribolone; Molecular Targeted Therapy; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptors, Androgen | 2016 |
Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells.
Topics: Antineoplastic Agents; Cation Transport Proteins; Cell Death; Cell Line, Tumor; Cyclohexylamines; Deferoxamine; Drug Synergism; Female; Ferritins; Gene Expression Regulation; Humans; Imidazoles; Indoles; Iron; Iron Chelating Agents; Lapatinib; Lysosomes; MCF-7 Cells; Phenylenediamines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Receptors, Transferrin; Signal Transduction; Spiro Compounds; Transcription Factors; Transferrin | 2016 |
Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
Topics: Alkylation; Biocatalysis; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Glutathione; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Tandem Mass Spectrometry | 2016 |
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies.
Topics: Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Least-Squares Analysis; Linear Models; MAP Kinase Signaling System; Quinazolines; Receptor, ErbB-2 | 2016 |
Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1(G93A) ALS mice and after partial muscle denervation.
Topics: Amyotrophic Lateral Sclerosis; Animals; Axons; Cell Survival; Disease Models, Animal; Lapatinib; Mice, Transgenic; Motor Neurons; Muscle Denervation; Neuregulin-1; Neurogenesis; Neuromuscular Junction; Quinazolines; Superoxide Dismutase-1 | 2016 |
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Topics: Alternative Splicing; Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Humans; Inhibitory Concentration 50; Lapatinib; Mammary Neoplasms, Experimental; Mice, Transgenic; Phenotype; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptor, ErbB-2; Signal Transduction; Time Factors | 2016 |
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lapatinib; Quinazolines; Suspensions | 2016 |
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Humans; Lapatinib; Markov Chains; Maytansine; Middle Aged; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United States | 2016 |
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin D2; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Mouth Neoplasms; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2016 |
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-6; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Up-Regulation | 2016 |
Epidermal growth factor receptor targeting alters gene expression and restores the adhesion function of cancerous cells as measured by single cell force spectroscopy.
Topics: Breast Neoplasms; Cell Adhesion; Cetuximab; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Microscopy, Atomic Force; Neoplasm Proteins; Quinazolines | 2016 |
JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Membrane Transport Proteins; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2016 |
Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Activated Protein Kinase; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MCF-7 Cells; Nuclear Proteins; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2 | 2016 |
Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.
Topics: Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Elongation Factor 2 Kinase; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; Lapatinib; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; src-Family Kinases | 2016 |
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Topics: Ado-Trastuzumab Emtansine; Aged; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Male; Maytansine; Middle Aged; Neuregulin-1; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms; Survivin; Trastuzumab | 2016 |
ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mutation; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Receptor, ErbB-2; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
In vitro and in vivo evaluation of paclitaxel-lapatinib-loaded F127 pluronic micelles.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Hemolysis; Lapatinib; Male; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Poloxamer; Quinazolines; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Fibroblast Growth Factor 2; Humans; Hyaluronan Receptors; Lapatinib; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nuclear Proteins; Phenotype; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Time Factors; Transforming Growth Factor beta; Twist-Related Protein 1; Xenograft Model Antitumor Assays | 2016 |
Computational Drug Target Screening through Protein Interaction Profiles.
Topics: Binding Sites; Computational Biology; Cyclooxygenase 1; Drug Evaluation, Preclinical; Humans; Imidazoles; Indoles; Lapatinib; Molecular Conformation; Molecular Docking Simulation; Monoamine Oxidase; Oximes; Protein Interaction Maps; Pyridines; Quinazolines | 2016 |
A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma.
Topics: Acetonitriles; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Lapatinib; Plasma; Quinazolines; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2016 |
Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Novel Effects of Lapatinib Revealed in the African Trypanosome by Using Hypothesis-Generating Proteomics and Chemical Biology Strategies.
Topics: Chromatography, Affinity; Endocytosis; ErbB Receptors; Humans; Lapatinib; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Peptides; Phosphorylation; Proteomics; Protozoan Proteins; Quinazolines; Signal Transduction; Tandem Mass Spectrometry; Trypanosoma brucei brucei; Trypanosomiasis, African | 2017 |
Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2017 |
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines | 2017 |
Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
Topics: Activation, Metabolic; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen | 2017 |
No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; HLA-DRB1 Chains; Humans; Lapatinib; Lymphocyte Activation; Quinazolines; T-Lymphocytes | 2016 |
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.
Topics: Adenine; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line; Dendritic Cells; Female; Immunotherapy; Indoles; Lapatinib; Lymphocytes; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Spleen; Succinates; Sunitinib; Toll-Like Receptor 7 | 2016 |
Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Feedback, Physiological; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Up-Regulation | 2017 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan | 2017 |
The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Melanoma; Mice; Mice, SCID; New Zealand; Polysaccharides; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Transcription Factor RelA; Undaria | 2017 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Lung Diseases, Interstitial; Nitriles; Quinazolines; Triazoles | 2016 |
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cytochrome P-450 CYP3A; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2017 |
Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Receptor, Endothelin B; Receptor, ErbB-2; Transcriptional Activation | 2017 |
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Proto-Oncogene Mas; Proto-Oncogene Proteins c-yes; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Trastuzumab | 2017 |
Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; ErbB Receptors; Female; Humans; Lapatinib; Metastasectomy; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2017 |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Extracellular Space; Female; Fluorescent Antibody Technique; Humans; Intracellular Space; Lapatinib; Maytansine; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Protein Domains; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Tissue Array Analysis; Trastuzumab; Uterine Neoplasms | 2017 |
Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cellular Reprogramming; Drug Resistance, Neoplasm; Female; Glycolysis; Humans; Lapatinib; Phosphorylation; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2017 |
Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2017 |
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.
Topics: Amoxicillin-Potassium Clavulanate Combination; Cell Adhesion Molecules; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; Genome-Wide Association Study; Genotype; HLA-B Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Lapatinib; Liver; Proteins; Quinazolines | 2017 |
Hydrophobic lapatinib encapsulated dextran-chitosan nanoparticles using a toxic solvent free method: fabrication, release property & in vitro anti-cancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Dextrans; Drug Carriers; Drug Liberation; Dynamic Light Scattering; Humans; Hydrophobic and Hydrophilic Interactions; Lapatinib; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Quinazolines; Spectroscopy, Fourier Transform Infrared | 2017 |
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Topics: Acrylamides; Adenocarcinoma; Antimetabolites; Antineoplastic Agents; Biomarkers, Tumor; Diagnostic Tests, Routine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glucose; Humans; Lapatinib; Quinazolines; Theranostic Nanomedicine; Therapeutic Uses; Uterine Cervical Neoplasms | 2017 |
UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Herb-Drug Interactions; Lapatinib; Limit of Detection; Linear Models; Plant Extracts; Quinazolines; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tea | 2017 |
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Letrozole; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Cell Surface; Treatment Outcome; Triazoles | 2017 |
FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Humans; Lapatinib; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Transfection; Up-Regulation | 2018 |
HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Topics: Aged; Antigens, Neoplasm; Biomarkers, Tumor; Breast Neoplasms; Cadherins; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Integrins; Kaplan-Meier Estimate; Lapatinib; Matrix Metalloproteinase 9; MCF-7 Cells; Middle Aged; Quinazolines; Receptor, ErbB-2; Snail Family Transcription Factors; Transforming Growth Factor beta1 | 2017 |
HER2 signaling regulates HER2 localization and membrane retention.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Membrane; Cell Proliferation; ErbB Receptors; Gene Knockdown Techniques; Humans; Intracellular Space; Lapatinib; Plasma Membrane Calcium-Transporting ATPases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Small Interfering; Ubiquitination | 2017 |
Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Ontology; Humans; Lapatinib; Protein Interaction Mapping; Quinazolines; Transcriptome | 2017 |
ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Survival Analysis; Xenograft Model Antitumor Assays | 2017 |
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Topics: Benzimidazoles; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Imidazoles; Inhibitory Concentration 50; Lapatinib; MAP Kinase Kinase 1; Microscopy, Fluorescence; Mutation, Missense; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms | 2017 |
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines | 2017 |
Metabolic shifts in residual breast cancer drive tumor recurrence.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lipid Metabolism; Metabolic Networks and Pathways; Mice; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxidative Stress; Progesterone; Quinazolines; Reactive Oxygen Species; Transcriptome; Xenograft Model Antitumor Assays | 2017 |
Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Meta
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2017 |
Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-lin
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2017 |
Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy.
Topics: Amino Acid Sequence; Binding Sites; Breast Neoplasms; Female; Humans; Lapatinib; Ligands; Molecular Conformation; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-4; Sequence Alignment | 2017 |
Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.
Topics: Blood Proteins; Cell Line, Tumor; Cell Membrane; Endocytosis; Enzyme Activation; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Galectin 3; Galectins; Humans; Lapatinib; MAP Kinase Signaling System; Mucin-1; Mutation; Neoplasms; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines | 2017 |
The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Everolimus; Lapatinib; Mice; Mice, Nude; Mice, Transgenic; Models, Statistical; Neoplasm Transplantation; Neurilemmoma; Neurofibromatosis 2; Peripheral Nervous System Neoplasms; Pyrimidines; Quinazolines; Sciatic Nerve; Time Factors | 2017 |
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; L-Lactate Dehydrogenase; Lapatinib; MCF-7 Cells; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.
Topics: Acetylation; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gene Knockdown Techniques; Humans; Lapatinib; Models, Biological; Mutation; p300-CBP Transcription Factors; Phosphorylation; Protein Stability; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factors; Ubiquitination | 2017 |
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Ferritins; Humans; Indoles; Lapatinib; Quinazolines; Reactive Oxygen Species; Spiro Compounds | 2017 |
Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Female; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Middle Aged; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2017 |
Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound.
Topics: Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Extracellular Matrix Proteins; High-Throughput Screening Assays; Humans; Lapatinib; Porphyrins; Quinazolines; Receptor, ErbB-2; Single-Cell Analysis; Small Molecule Libraries; Tumor Microenvironment; Verteporfin | 2017 |
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Maytansine; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Lapatinib; Male; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2017 |
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2017 |
Near-infrared remotely triggered drug-release strategies for cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA; Docetaxel; Drug Delivery Systems; Drug Liberation; Female; Gold; Humans; Infrared Rays; Lapatinib; Lasers; Nanoshells; Quinazolines; Serum Albumin, Human; Taxoids | 2017 |
[Mechanism underlying inhibition of proliferation and promotion of apoptosis by lapatinib in HL60 cells].
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspase 9; Cell Proliferation; Cell Survival; HL-60 Cells; Humans; Lapatinib; Leukemia, Promyelocytic, Acute; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2017 |
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Female; Humans; Lapatinib; Mammography; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2018 |
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Lapatinib; Logistic Models; Maximum Tolerated Dose; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines | 2018 |
Emilia: use cunning to survive cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2018 |
Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Dimerization; ErbB Receptors; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Neoplasms; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2018 |
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.
Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results | 2018 |
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Availability; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Curcumin; Cytochrome P-450 CYP3A; Female; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lapatinib; Macaca fascicularis; Male; Midazolam; Neoplasm Proteins; Pantoprazole; Quinazolines; Rosuvastatin Calcium; Sulfasalazine; Terfenadine | 2018 |
Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
Topics: Drug Resistance, Neoplasm; Humans; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2018 |
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes | 2017 |
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Capecitabine; Diagnostic Imaging; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Meningeal Carcinomatosis; Multimodal Imaging; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2018 |
A pharmacokinetic study on lapatinib in type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Lapatinib; Male; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2018 |
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Databases, Genetic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; High-Throughput Screening Assays; Humans; Lapatinib; MCF-7 Cells; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles | 2018 |
Increased autophagy blocks HER2-mediated breast tumorigenesis.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Female; Gene Knock-In Techniques; Humans; Lapatinib; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Peptide Fragments; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2018 |
Cytotoxic and glycosaminoglycan priming activities of novel 4-anilinequinazoline β-D-xylosides.
Topics: A549 Cells; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glycosaminoglycans; Glycosides; HCT116 Cells; Humans; Lapatinib; Molecular Structure; Quinazolines | 2018 |
miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; MicroRNAs; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms | 2018 |
Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytotoxins; E2F1 Transcription Factor; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2018 |
How I treat chemorefractory metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Neoplasm Staging; Nivolumab; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trastuzumab; Trifluridine; Uracil; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis.
Topics: Chromatography, Liquid; Drug Stability; Humans; Kidney Failure, Chronic; Lapatinib; Linear Models; Neoplasms; Quinazolines; Renal Dialysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
Topics: A549 Cells; Adenosine Triphosphate; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Female; Humans; Lapatinib; Mice, Inbred BALB C; Molecular Docking Simulation; Polyamines; Protein Domains; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2018 |
Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development.
Topics: Animals; Blood Proteins; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Half-Life; Hepatocytes; Humans; Lapatinib; Mice; Microsomes, Liver; Quinazolines; Rats; Solubility; Structure-Activity Relationship; Thermodynamics; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African; Water | 2019 |
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
Topics: Animals; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Lapatinib; Membrane Proteins; Mice; Mice, Transgenic; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2020 |
Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2020 |
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Italy; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2020 |
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Trastuzumab; Up-Regulation | 2021 |
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Liver Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tissue Distribution | 2021 |
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation | 2021 |
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Proteins; Ovarian Neoplasms; Quinazolines | 2021 |
Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx®: In vitro and in vivo evaluations.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; Lapatinib; Mice; Polyethylene Glycols; Quinazolines | 2021 |
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidines; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Carriers; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2 | 2021 |
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; MAP Kinase Signaling System; Mutation; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Tumor Escape | 2021 |
LASP-1 interacts with ErbB2 in ovarian cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Cytoskeletal Proteins; Female; HEK293 Cells; Humans; Lapatinib; LIM Domain Proteins; Middle Aged; Ovarian Neoplasms; Phosphorylation; Plasmids; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2022 |
Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; HMGB1 Protein; Humans; Lapatinib; Mice; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2022 |
Western Blot Analysis of Lapatinib-Mediated Inhibition of the Epidermal Growth Factor Receptor 2 (HER2) Pathway in Breast Cancer Cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2022 |
Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lapatinib; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Female; Humans; Lapatinib; Ligands; Neuregulin-1; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Up-Regulation | 2022 |
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Mutation; Quinazolines; Retrospective Studies; Trastuzumab | 2023 |
Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2023 |
Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Calcium; Cardiotoxicity; Endothelial Cells; Female; Heart Diseases; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2023 |
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dasatinib; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2023 |
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Trastuzumab | 2023 |
Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2.
Topics: Antineoplastic Agents; Drug Repositioning; Lapatinib; Peptides; Quinazolines | 2023 |
The unexpected effect of the combination of lapatinib and capecitabin in cranial metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2023 |
Ligand-Directed Photodegradation of Interacting Proteins: Oxidative HER2/HER3 Heterodimer Degradation with a Lapatinib-Derived Photosensitizer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Lapatinib; Ligands; Photolysis; Photosensitizing Agents; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab | 2023 |
Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study.
Topics: Animals; Chromatography, Liquid; Emulsions; Enteral Nutrition; Lapatinib; Quinazolines; Rabbits; Rats; Tandem Mass Spectrometry | 2023 |
Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; RNA, Long Noncoding; SOXB1 Transcription Factors; Stomach Neoplasms | 2023 |